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Novel Roles of Tobacco-associated Genes Underlying Disparate 
Survival in Appalachian Head and Neck Squamous Cell Carcinoma 
Brenen William Papenberg 
 
Head and neck squamous cell carcinoma (HNSCC) is an aggressive neoplasm primarily caused by tobacco 
consumption or human papillomavirus (HPV) infection. Incidence and mortality rates for HNSCC vary 
geographically. Appalachian residents consume tobacco products to a greater extent than national averages, a 
risk factor known to promote HPV-negative HNSCC through increased genomic instability. Male Appalachian 
patients display significantly worse relative survival than Appalachian females or non-Appalachian residents of 
either sex. Secondary analysis of available cancer registry outcome data from 2007-2013 indicates that white 
males with stage IV oral cavity/pharyngeal (OC/P) HNSCC are responsible for the decreased male survival 
observed within Appalachian regions. This disparity is seen in a subset of Appalachian states and is associated 
with lower relative survival in HPV-Associated subsites, suggesting a higher percentage of HPV-negative 
cancers occur in oral cavity regions typically associated with HPV infection. This increase is likely associated 
with higher smoking and smokeless tobacco usage in Appalachian states. An unbiased statistical analysis of 
gene copy number alterations (CNAs) from the Cancer Genome Atlas (TCGA)-HNSC national cohort indicates 
that smoking significantly correlates with amplification or deletions of genes found in several chromosomal 
cytobands. Of these, chromosome 11q13.3 and 11q13.4 (amplified) and chromosomes 9p21.3 and 9p24.1 
(deleted) are the only altered segments that correlate with reduced overall survival in patients that smoked, 
independent of HPV status. 11q13 amplification is the most common CNA in HNSCC and enhances tumor 
progression and poor outcome due to protein overexpression. Transcriptome analysis of HNSCC with 11q13 
amplification indicates that 13 out of 17 amplified genes are overexpressed, including the oncogenic cell gene 
CCND1 (cyclin D1). Recently, 3’UTRs of select mRNAs have been shown to function as positive regulators of 
cancer progression by sequestering tumor-suppressive microRNAs (miRNAs) as competing endogenous 
(ce)RNA. Thus, a novel mechanism of poor outcome in 11q13 amplified patients may be due to the 3’UTR 
regions of elevated 11q13 transcripts serving to titrate tumor-suppressive miRNAs, permitting increased 
oncogenic progression. The overall hypothesis of this dissertation is that HNSCC patients in Appalachia have 
lower survival due to a larger number of individuals harboring tumors with 11q13 amplification from tobacco-
induced damage, resulting in increased transcript expression that downregulates tumor-suppressive miRNA 
functions. Predictive algorithms and secondary TCGA data analysis indicate that the CCND1 3’UTR contains 
multiple miRNA response elements expected to bind known tumor-suppressive miRNAs. Patient outcome data 
indicates that CCND1-amplified patients with 3’UTR containing transcripts have poorer overall survival than 
patients with CCND1 overexpression lacking the 3’UTR. Stratification by CCND1 expression reveals several 
altered protein targets including CCNB1, TYMS, and SERPINE1, that share miRNA response elements with 
CCND1 mRNA. Identification of tumor-promoting effects from 11q13 transcripts provides alternative avenues for 
therapeutic intervention in this most aggressive form of HNSCC by identifying novel druggable transcription 
targets that can augment protein-based precision medicine strategies or by facilitating stratification of patients 
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Head and neck squamous cell carcinoma 
Head and neck squamous cell carcinoma (HNSCC) is an aggressive neoplasm that arises from squamous 
epithelial cells of the upper aerodigestive tract, encompassing the oral cavity, pharynx, and larynx(1). There are 
over 65,000 new HNSCC cases and 14,500 deaths estimated for 2020, with a five-year relative survival rate in 
the United States of 65% for all races and American Joint Committee on Cancer (AJCC) stages(2). Risk factors 
for the development of HNSCC include alcohol and tobacco use(3) and high-risk human papillomavirus (HPV) 
infection(4) (Figure 1). 
Treatment of HNSCC depends on anatomical site (surgical accessibility) and stage of disease. For early stage 
patients (AJCC stage I or II), which represent 30-40% of new diagnoses(1), HNSCC is curable with surgical 
resection or radiotherapy alone(5). For patients with locally advanced disease (AJCC stage III or IV), which 
represent over 60% of new diagnoses(1), surgical resection followed by adjuvant radiotherapy or 
 
Figure 1. Characteristics of head and neck squamous cell carcinoma. 
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chemoradiotherapy is used when surgical accessibility is 
feasible. Chemoradiotherapy alone is the curative standard of 
care when surgery is not feasible(5). Chemotherapeutic 
options for HNSCC include high dose cisplatin as the standard 
of care(5). To date, there are only two United States Food and 
Drug Administration (FDA) approved targeted therapies for 
HNSCC. The epidermal growth factor receptor (EGFR) 
inhibitor cetuximab was approved for use in 2006 to be used 
in certain circumstances, such as in cases with high EGFR 
where it was shown in clinical trials to increase 5-year survival 
when compared to radiotherapy alone(6), but platinum-based 
chemotherapy remains standard(5). However, if a patient 
tumor expresses the immune checkpoint protein programmed 
death ligand 1 (PD-L1), the patient is eligible for PD-L1 
checkpoint inhibiting drugs such as pembrolizumab or 
nivolumab(5). Pembrolizumab has been shown in clinical trials to increase 5-year survival of recurrent or 
metastatic patients when compared to radiotherapy alone as well as cetuximab and radiotherapy(7). The lack of 
additional therapeutics for HNSCC treatment underscores the persistent need for the continued development of 
new drugs against known important gene products, as well as continued identification and testing of novel targets 
for improved treatments in populations more refractory to conventional clinical approaches. Patient survival is 
largely dependent on stage of diagnosis as well as treatment regimens (Figure 2), highlighting the need for 
additional treatment options. 
Widespread next-generation sequencing of HNSCC cohorts has identified driver mutations, common tumor-
suppressor and oncogenes, and molecular subtypes(8–11), concluding that HPV-positive tumors harbor fewer 
mutations and copy-number alterations (CNAs) than HPV-negative tumors. This is in agreement with HPV-
positive patients exhibiting better overall survival and stratifies HNSCC into two distinct prognostic 
 




subtypes(12,13). HNSCC driver mutations identified in both HPV-positive and HPV-negative HNSCC are 
discussed throughout this review. 
HPV-positive HNSCC incidence has been increasing and accounts for nearly 20% of all current HNSCC 
cases(14). HPV-positivity is significantly enriched in oropharyngeal tumors, where it is responsible for 60-80% 
of all HNSCC in this region(14–16). The remainder of HNSCC cases are HPV-negative and are described later 
in this review. High-risk HPV subtypes 16 and 18 are responsible for the majority of HPV-positive HNSCC, 
predominantly diagnosed in younger people after oral sex exposure(17) and is usually due to infection of the 
reticular epithelium lining the tonsillar crypts of the oropharynx(18–20).  
HPV has a double-stranded, circular genome with genes important for early viral functions (E1-7) that mostly act 
by blocking host cell division and viral genome replication, as well as genes involved in late viral functions (L1-
2) such as capsid development(21). Early viral proteins E6 and E7 are oncoproteins that target the tumor-
suppressors retinoblastoma (pRB) and p53, respectively (Figure 3A). E6 disrupts normal cell growth inhibition 
by inhibiting p53, leading to degradation of p53 through ubiquitination by ubiquitin-protein ligase E3A (E6AP)(22). 
E7 targets pRb family members for degradation, which results in sequential activation of the transcription factor 
E2F, expression of S-phase genes and ultimately hyperproliferation. Degradation of pRb and release of E2F 
also leads to overexpression of the tumor-suppressor p16, which is used as a surrogate marker for HPV-positive 
 
Figure 3. Cellular function of HPV viral proteins E6 and E7 (left) and comparison of p16 staining between HPV-
positive and HPV-negative patient derived xenografts (PDXs)(right). 
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tumors as it is commonly overexpressed in HPV positivity tumors(23) (Figure 3B). As such, p16 
immunohistochemistry (IHC) is currently used by the National Comprehensive Cancer Network (NCCN) as a 
diagnostic step to determine treatment of oropharyngeal cancers(5).  
While treatment for HPV-positive tumors has largely remained the same as treatment of HPV-negative tumors, 
the prospect of treatment de-escalation has been proposed due to the increased chemo-radiosensitivity and 
curative rate of HPV-positive tumors(24–26). To this end, AJCC revised staging of HPV-positive tumors in AJCC-
8, effective January 1, 2017, classifying most HPV-positive tumors as a lower stage(27). This is an important 
consideration for treatment guidance(5). However, recent studies have shown that some patients are under-
treated using these guidelines, compromising patient safety(28). Prophylactic HPV vaccines have been 
approved for oropharyngeal cancer prevention, yet HPV-associated oropharyngeal incidence trends are not 
expected to reverse until after 2060(17). This expected delay is due to the vaccine being given to young 
individuals before sexual activity, the required time needed to achieve vaccine coverage in a population, and the 
time required to develop HPV-positive HNSCC(29). 
HPV-negative HNSCC has a worse prognosis compared to HPV-positive HNSCC. This is mainly due to 
carcinogen-induced genomic instability that creates tumors with high mutational load, deleterious epigenetic 
alterations, large-scale chromosomal rearrangements and high intra-tumor heterogeneity (Figure 4). The 
aggregate effect of this genotoxic stress exerts a pleiotropic molecular impact on oncogenic processes that 
increases disease aggressiveness and lowers patient survival(8,9,30,31). The most common large-scale CNAs 
in HPV-negative HNSCC include amplifications of 7p11.2 (EGFR), 11q13.3 (CCND1), 8p24.21 (MYC), and 
3p26.32 (PIK3CA) and homozygous deletion of 9p21.3 (CDKN2A). The most common somatic mutations in 
HPV-negative HNSCC include the tumor-suppressors CDKN2A and TP53. The most common CNA and somatic 
mutation in HPV-positive HNSCC is of PIK3CA(8).  
To briefly describe these alterations, EGFR is part of the erythroblastic oncogene B (ErbB) family of receptor 
tyrosine kinases (RTKs) that responds to extracellular mitogens, driving downstream signaling via epidermal 
growth factor (EGF) binding, dimerization, autophosphorylation, and recruitment of adaptor proteins. EGFR has 
been shown to activate the Ras-Raf-MEK-ERK pathway described later in this review. The PI3K-AKT-mTOR 
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pathway, which consists of phosphoinositide 3-kinases (PI3Ks) such as phosphatidylinositol-4,5-bisphosphate 
3-kinase catalytic subunit alpha (PIK3CA), protein kinase B (AKT), and mammalian target of rapamycin (mTOR) 
regulates downstream molecules that are mainly related to metabolism and cell cycle(32). Activation of the Ras-
Raf-MEK-ERK pathway can also induce Wnt (wingless/integrated) and Shh (Sonic hedgehog) signaling, which 
in turn can activate the transcription factor Myc(33). Amplification of EGFR, amplification of MYC, or mutation to 
PIK3CA lead to aberrant downstream signaling of these pathways and altered expression of various genes(34). 
Cyclin D1 (CCND1) is a cell cycle regulator that is regulated by cyclin-dependent kinase inhibitor 2A (CDKN2A). 
These proteins are discussed in-depth later in this review. Tumor protein 53 (TP53) is a tumor-suppressing 
transcription factor that regulates the cell cycle, apoptosis, and genomic stability(35).  
Combining genetic characteristics and gene expression profiles of HPV-negative HNSCC stratifies the disease 
into three distinct subtypes: basal (BA), classical (CL), and inflamed/mesenchymal subtypes (IMS)(9) (Figure 5). 
Characteristics of the BA subtype include enriched hypoxia signaling (HIF1A, CA9, and VEGF), neuregulin 
signaling (EGFR, AREG, and NRG1), and overexpression of the epithelial marker CDH3 and cytokeratins KRT1 
and KRT9. This subtype is descriptive of nearly 40% of all cases and has been shown to be preferentially 
responsive to EGFR-target therapies(36). Characteristics of the CL subtype include enrichment for polyamine 
degradation pathways, which is related to tobacco detoxification. CL is also divided by HPV status into CL-HPV 
and CL-nonHPV, which make up 8.0% and 18.2% of all cases, respectively. While these two groups have 
similarities, they are still distinct in certain pathways, including cell-cycle and cell-division regulation. The IMS 
 
Figure 4. Commonly altered pathways in HNSCC. 
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subtype features expression of genes related to T lymphocyte infiltration (CD8, ICOS, LAG3, and HLA-DRA), 
overexpression of mesenchymal markers (VIM), overexpression of matrix metalloproteinases (MMP9), and 
downregulation of the epithelial marker CDH3 and cytokeratins KRT1 and KRT9. IMS is also divided by HPV 
status into IMS-HPV and IMS-nonHPV, two distinct subtypes that share characteristics, but differ in cell-cycle 
and smoking-associated pathways. They are responsible for 12.9% and 20.9% of all cases, respectively(9). 
Patient outcome differs between all subtypes, with the HPV-related subtypes CL-HPV and IMS-HPV having 
better overall survival than tobacco-related subtypes BA, CL-nonHPV, and IMS-nonHPV(9). Although many 
driving mutations in HNSCC have been extensively studied, most are related to alteration of protein expression. 
In Study 3, we evaluated the potential contributions to tumor progression through alteration of mRNA expression. 
Cancer in Appalachia 
Currently available data from the CDC show that cancer incidence and mortality rates have varied geographically 
(Figure 6) from 2013-2017 with higher rates present in the Appalachian region. The United States Appalachian 
region has a long history of diverse factors, such as low socioeconomic status (SES) and increased tobacco 
usage that contribute to the overall allostatic load responsible for increased cancer incidence and poorer patient 
outcomes(37). High cancer incidence in Appalachia has been recognized by the Appalachian Regional 
Commission (ARC) and the National Cancer Institute (NCI) as a health disparity since 1993, with high incidence 
rates remaining high in the region since that time(37–41).  
 




The United States Appalachian region currently encompasses 205,000 square miles across 420 counties in 13 
contiguous states surrounding the Appalachian Mountains(37). The legal definition of Appalachia has changed 
multiple times since the ARC was first established in 1965 through amendments to United States Code(42). The 
demographics of the region portray a population that is over 80% white and 42% rural, with the region reporting 
higher unemployment, lower income, and higher poverty rates than most of the rest of the United States(43).  
Recently, cancer incidence in general has been shown to have disparate and increasing incidence in Appalachia 
compared to non-Appalachia, regardless of sex, race, region, or primary site(38). However, this incidence 
disparity has decreased over time for most primary sites, with the exception of HNSCC (oral cavity, pharynx, and 
larynx) and cancers of the lung, bronchus, and thyroid(38), most of which are tobacco-associated 
malignancies(38,39,44–47). Previous work evaluating oral cancer survival in Appalachia using 2004 
Surveillance, Epidemiology, and End Results (SEER) data identified higher mortality in 10 Appalachian states 
including West Virginia, Alabama, Pennsylvania, Tennessee, Kentucky, Georgia, South Carolina, Mississippi, 
 
Figure 6. Incidence (A) and Death (B) rates of U.S. by state. 
 
Figure 7. Smoking tobacco usage in United States, 1986-2010, 2011-2018. 
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North Carolina, and Ohio(48). Of the cancer risk factors endemic to Appalachia, age at diagnosis, travel distance 
to critical care centers, and a disproportionate presentation of patients at a late AJCC stage have been reported 
to have no impact on survival in Appalachian subpopulations(49,50). However, increased smoking and 
smokeless tobacco use for several decades within Appalachia have been linked to low SES and increased 
HNSCC incidence(51–53) and presumably contribute to HNSCC incidence and mortality disparities within 
Appalachia (Figure 7). A systematic evaluation within the Appalachian region to identify specific subregions or 
HNSCC sites responsible for driving disparate survival has not been conducted to date. 
Tobacco and Cancer 
There has been a presumed connection between tobacco usage and cancer development since Nazi Germany 
first investigated links between tobacco exposure and lung cancer in the late 1930s(54). The first clear evidence 
was published in 1954, which linked smoking habits to the mortality of British doctors(55). Evidence has mounted 
since then, and in 2004 the United States Surgeon General concluded that evidence is sufficient to infer a causal 
relationship between smoking tobacco usage and the development of tumors of the lung, larynx, oral cavity, 
pharynx, esophagus, pancreas, bladder, kidney, cervix, and stomach, as well as acute myeloid leukemia(56).  
Incinerated tobacco products including cigarettes or cigars contain compounds that have been attributed to this 
relationship with cancer by previous work and the World Health Organization (WHO) International Agency for 
Research on Cancer (IARC). The most extensively investigated compounds include polycyclic aromatic 
hydrocarbons (PAHs), heavy metals, aldehydes, aromatic amines, and tobacco-specific nitrosamines (TSNAs). 
These compounds can be naturally produced by the tobacco plant or can be by-products from the combustion 
process, referred to as pyrolysis. Nicotine is a tobacco-generated alkaloid which the plant uses for defense 
against herbivorous insects(57) and is the addictive, stimulating substance within tobacco products due to its 
similarity to the neurotransmitter acetylcholine(58). Although nicotine is the addictive substance that drives 
tobacco consumption and uptake of tobacco-associated compounds, it has not been shown to be 
carcinogenic(56). PAHs are formed by the incomplete combustion of biological material. The United States 
Environmental Protection Agency (EPA) has identified 16 key PAHs, including benzo[a]pyrene, that cause or 
may cause various types of cancer(59,60), all of which are found in tobacco smoke(61). PAHs have been shown 
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to likely be involved in the carcinogenesis of lung, laryngeal, oral cavity, and cervical cancers(62). Heavy metals, 
including the human carcinogen cadmium(60,63), are absorbed from the soil into the tobacco leaves(64) and 
are released into tobacco smoke when incinerated(65). Heavy metals are likely to be involved in the 
carcinogenesis of lung cancer(62). Volatile carbonyl compounds, including acetaldehyde, formaldehyde, 
acetone, and 2-butanone, are formed from heating amino acids and sugars in the tobacco leaf(66) and are 
classified as possibly carcinogenic to humans by the IARC(60,67). Aldehydes are likely to be involved in the 
carcinogenesis of lung and nasal cancers(62). Aromatic amines, including 2-naphthylamine, are found in unburnt 
tobacco and are also formed as pyrolysis products(68) and are known human bladder carcinogens(60,69). 
TSNAs are another class of chemical compounds that have been implicated in cancer development and include 
N-Nitrosonornicotine (NNN) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), which have been shown 
to be carcinogenic(60,70). TSNAs do not occur naturally within the tobacco plant and are not only a product of 
tobacco combustion, but are products of aerobic bacteria during drying and curing of tobacco(71). TSNAs are 
likely to be involved in the carcinogenesis of lung, nasal, oral cavity, esophageal, liver, pancreatic, and cervical 
cancers(62). 
Smokeless tobacco, which is a tobacco product intended to be consumed without combustion but instead by 
direct absorption through the oral mucosa in the form of chewing tobacco, snuff, or snus, has a shorter list of 
carcinogenic compounds due to the lack of combustion. Smokeless tobacco does contain PAHs 
(benzo[a]pyrene), heavy metals (cadmium), carbonylic compounds (formaldehyde), and TSNAs (NNK and 
NNN), among others(72). Although smokeless tobacco still contains similar carcinogenic compounds when 
compared to smoking tobacco, the levels of these compounds are lower in smokeless tobacco(73). Electronic 
cigarettes are an interesting area in the development of a safer form of tobacco consumption. Several studies 
have shown that electronic cigarettes deliver a lower concentration of TSNAs(74,75), but more research is 
required to determine how safe electronic cigarettes are in general or as a replacement for traditional smoking 
or smokeless tobacco(76).  
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The carcinogenic compounds within tobacco typically require metabolic activation, usually catalyzed by 
cytochrome P-450 enzymes, to convert them into a form that can covalently bind to DNA and form a DNA adduct 
(Figure 8). Differences in the efficiency of this metabolic activation or carcinogen detoxification may be able to 
explain cancer susceptibility between individuals(77). Two classes of tobacco-associated carcinogens that have 
been extensively studied concerning DNA adducts include PAHs and TSNAs. The molecular activation of 
benzo[a]pyrene (PAH) occurs through conversion to benzo[2]pyrene-7,8-diol-9,10-epoxides (BPDEs). This 
molecule forms adducts with deoxyguanosine to form BPDE-N2-deoxyguanosine(78). The molecular activation 
of NNN through α-hydroxylation creates the same intermediate as methyl hydroxylation of NNK, pyridyloxo-butyl 
(POB)-DNA adducts(79). There are several mechanisms that cells can use to remove tobacco-generated DNA 
adducts, such as alkyltransferases, nucleotide excision repair, mismatch repair, and double strand break 
repair(62,80). However, if the enzymes required for these repair mechanisms are unable to repair the DNA 
adduct, either through loss-of-function via mutation or being utilized elsewhere to repair widespread DNA 
damage, these DNA adducts can persist and be converted to genomic mutations through error-prone repair 
mechanisms or incorrect nucleotide insertion during translesion DNA synthesis(80) (Figure 9). Double stranded 
DNA breaks can also occur through oxidative damage to DNA linked to tobacco exposure(81). These double 
strand breaks can cause large chromosomal aberrations which can result in deletions and amplifications of 
genomic DNA(82). The tumor-suppressor p53 is one of the most important proteins for detecting and repairing 
DNA damage(83). Thus it is not surprising that mutations to TP53 are the most common mutations in human 
malignancies(84), preventing the cell to properly address DNA adducts, resulting in the eventual accumulation 
of mutations and chromosomal aberrations(85,86).   
 




Chromosomal Instability and Amplification of Chromosome 11q13 
Chromosomal instability is a hallmark of cancer(87) that is defined as the rate of genetic aberrations seen within 
a cell or tumor and includes small mutations, insertions, and deletions. Instability also includes larger 
chromosomal rearrangements such as translocations and amplifications, and also includes generation of 
aneuploidy through gain or loss of entire chromosomes(88). Chromosomal instability is categorized into two main 
groups. The first is numerical chromosomal instability, which depicts the gain or loss of entire chromosomes. 
The second is structural chromosomal instability, which characterizes large chromosomal fragment changes that 
include chromosomal rearrangements and CNAs. CNAs include amplifications (more than two extra copies, +2), 
gene gains (two extra copies, +1), heterozygous deletions (missing one copy, -1), or homozygous deletions 
(missing both copies, -2)(88,89). Chromosomal instability has been linked to cellular transformation, tumor 
heterogeneity, metastasis, tumoral drug resistance, and worse patient outcomes(90–93). 
CNAs that arise from chromosomal instability are important areas of research due to the multitude of lost tumor-
suppressors and gained oncogenic drivers which shape tumor progression. CNAs can range in size from focal 
alterations that include relatively few genes and comprise less than 25% of the length of a chromosome arm or 
alterations smaller than 3 Mb, to larger arm-length alterations that can encompass the length of an entire 
chromosome arm(94,95). The shorter length of focal CNAs allows more straightforward determination of driving 
alterations, which remains difficult in large scale, arm-length alterations. Pan-cancer analyses have shown that 
many CNAs are specific to cancer type, but there are common deletions and amplifications found shared 
 
Figure 9. Link between cigarette smoke and cancer through carcinogens in tobacco smoke. Adapted from U.S. 
Department of Health and Human Services. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis 
for Smoking-Attributable Disease, p.226. 
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amongst multiple cancers. The most common focal amplifications across multiple cancer types include MYC, 
CCND1, ERBB2, CDK4, NKX2-1, MDM2, EGFR, FGFR1, and KRAS- all of which are documented 
oncogenes(96,97). The most common focal deletions across multiple cancer types include those of CDKN2A, 
PTEN, and NF1 which are all tumor-suppressors(96,97).  
To briefly describe these alterations, receptor tyrosine-protein kinase erbB-2 (ERBB2/HER2), fibroblast growth 
factor receptor 1 (FGFR1), and EGFR are all RTKs that function in signaling transduction to activate the (KRAS)-
Raf-MEK-ERK pathway(34) that is regulated by neurofibromin 1 (NF1)(98), Wnt/Shh signaling which activates 
MYC(33), and the PI3K-AKT-mTOR pathway that is regulated by phosphatase and tensin homolog (PTEN)(32). 
Thyroid transcription factor 1 (TTF-1) or NK2 homeobox 1 (NKX2-1) is a transcription factor important for lineage 
survival as well as enhancing EGFR-driven tumorigenesis(99). Murine double minute (MDM2) functions an 
oncogene by inhibiting p53-mediated transactivation(100,101). CCND1 is a cyclin-dependent kinase 4 
(CDK4)/CDK6 regulator that is involved in cell cycle regulation and is regulated by CDKN2A that will be discussed 
in-depth later in this review.  
Fragile sites within normal chromosomes are sites of genomic instability during DNA replication stress. There 
are two classes of fragile sites, including rare fragile sites that are expressed (experience breakage) in less than 
5% of individuals and common fragile sites (CFSs) that are found in all individuals(102–107). Fragile sites are 
 




usually located within large genes and have been linked to secondary structures of DNA and replication fork 
stalling due to replicative stress(107) (Figure 10). During replication, DNA strands are separated to expose the 
DNA template to DNA replication machinery, which allows for single stranded DNA to form secondary structures. 
If the replication fork is stalled due to replication stress, such as by tobacco-associated DNA-adducts as 
discussed in the previous section(108), more time is allowed for these secondary structures to form. This free, 
single strand DNA is then exposed to environmental damage and strand breaks may occur. Targeted cleavage 
of DNA by structure-specific endonucleases (SSEs) attempting to resolve the stalled fork can also lead to strand 
breaks(107). If stalled forks near fragile sites do not get resolved, DNA bridges may assist during nuclear division, 
which will lead to the mechanical breakage of DNA strands(107). Loss-of-heterozygosity or homozygous 
deletions can occur if multiple stalled forks are cleaved through deletion of the DNA between replication 
forks(107). If a double stranded DNA break remains unresolved during replication, it is possible for the broken 
strand to fuse to a sister chromatid and begin a breakage-fusion-bridge (BFB) cycle (Figure 11), which can lead 
to chromosomal amplification(109–111). 
When evaluating HNSCC for chromosomal aberrations, several alterations stand out and are common in an 
appreciable number of patients(8,112,113). CNAs within HNSCC vary by HPV status(8,112,114–117), with HPV-
negative patients harboring a higher number of total CNAs, likely due to increased tobacco exposure(8,112,113). 
Figure 11. Diagrammatic representation of breakage-fusion-bridge mechanism. 
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The most common large-scale chromosomal amplification within HNSCC is the amplification of chromosome 
11q13.3-q13.4. This amplification is found in nearly a third of all HPV-negative HNSCC patients and contains 
several genes of oncogenic interest, including the potential oncogenesis-promoting genes CCND1, FADD, and 
CTTN(8,113,118,119). The mechanism of 11q13 amplification has been linked to BFB(120) and appears to 
involve fragile sites FRA11H, and FRA11F(121,122). However, other mechanisms such as amplification 
involving segmental duplications, which do not require the loss of a telomere, have also been proposed(123). 
Genes of note within the 11q13 amplicon (Figure 12) include the cell cycle regulator CCND1 which will be 
discussed in depth later in this review. Briefly, cyclin D1 functions as the regulatory subunit of CDK4/6, whose 
activity is required for cell cycle transition from G1 to S(124). Overexpression of cyclin D1 protein leads to a 
constitutively active cell cycle and can lead to tumorigenesis(125). Oral cancer overexpressed 1 
(ORAOV1/LTO1) has recently been shown to be involved in relief of reactive oxygen species (ROS)(126) and 
its overexpression has been shown to be a biomarker of progression(127). Liprin-α1 (PPFIA1) has been shown 
Figure 12. Most commonly amplified 11q13 genes from TCGA. 
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to localize LAR phosphatase to cell focal adhesions and has been shown to be involved in cell invasion, cell 
spreading, and cancer cell signaling(128–130). Anoctamin-1 (ANO1)/Transmembrane member 16A (TMEM16A) 
is a calcium-activated voltage-gated chloride channel that has been shown to play a role in inhibiting 
apoptosis(131). Fas-associated death domain (FADD) is involved in apoptosis by mediating the formation of 
death-inducing signaling complexes (DISC) during programmed cell death(132). Although FADD has been 
associated with HNSCC metastasis, its tumor-promoting functions are poorly understood(133,134). Fibroblast 
growth factor 3 (FGF3) acts as a negative regulator of bone growth through fibroblast growth factor receptor 3 
(FGFR3)(135). Amplification and overexpression of FGF3 is associated with increased invasiveness in breast 
cancer(136). Fibroblast growth factor 4 (FGF4) functions in embryonic development`(137) through an 
undetermined fibroblast growth factor receptor and is involved in human stomach cancer(138). Fibroblast growth 
factor 19 (FGF19) functions as a hormone in the regulation of bile acid synthesis and signals through fibroblast 
growth factor receptor 4 (FGFR4)(139). FGF19 amplification has been tied to autocrine signaling that promotes 
tumor growth(139). Cortactin (CTTN) is an actin-binding protein that regulates Arp2/3 and the branching of actin 
networks to facilitate cellular invasion, migration, and tumor metastasis(140–142). Myeloma overexpressed 
(MYEOV) appears to be involved in cell migration and is a prognostic marker in multiple myeloma and colon 
cancer(143,144). SH3 and multiple ankyrin repeat domains protein 2 (SHANK2) is a scaffold protein involved 




CCND1, originally referred to as parathyroid adenomatosis (PRAD1), was first identified as a candidate 
oncogene in 1991 when it was found to be part of a genomic rearrangement with parathyroid hormone (PTH) in 
parathyroid adenomas, leading to its overexpression(148,149). Shortly after, it was implicated in genomic 
translocations in B-cell lymphoma where it was referred to as B-cell lymphoma 1 (BCL1)(150). PRAD1 was then 
confirmed to be a novel cyclin. Cyclins were identified due to their cyclic accumulation and subsequent 
destruction that varied depending on stage of cell cycle through the fertilization of marine invertebrate eggs(151). 
At the time of this discovery, two types of human cyclins had been characterized: A-type, important for the early 
cell cycle, and B-type, which drove the cell into mitosis. PRAD1 was similar in sequence to all cyclins, but could 
not fit into either group, suggesting it was part of a new cyclin family and was then renamed cyclin D1 
(CCND1)(152,153). CCND1 was 
then confirmed to be a nuclear 
protein that is required during cell 
cycle progression in G1(124).  
The transcription regulation and 
cellular function of CCND1 has 
been elucidated in great detail 
(Figure 13, left). The best-studied 
activators of cyclin D1 transcription 
are mitogenic growth factors, 
which act through mitogen-
activated protein kinases (MAPKs) 
in the canonical Ras-Raf-MEK-ERK pathway(154). Briefly, small proteins that can induce a cell to begin mitosis 
through extracellular signaling are referred to as mitogens. These mitogens interact with RTKs on the cell surface 
such as EGFR, fibroblast growth factor receptor (FGFR), and vascular endometrial growth factor receptor 
(VEGFR)(155). After receptor-ligand binding, RTKs signal through adapter proteins and guanine nucleotide 
 
Figure 13. Transcriptional regulation of Cyclin D1 (left) and regulation of 
cell cycle by Cyclin D1 (right). 
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exchange factors (GEFs) such as growth factor receptor-bound protein 2 (GRB2) and son of sevenless homolog 
1 (SOS1) which lead to the activation and release of the GTPase Ras (HRAS). HRAS will then begin a 
phosphorylation cascade through the Ras-Raf-MEK-ERK pathway which includes BRAF, mitogen-activated 
protein kinase kinase (MEK) and ultimately extracellular signal-related kinases (ERKs)(155). This pathway leads 
to the dimerization of Jun and Fos to produce the activator protein 1 (AP1) transcription factor and subsequent 
transcription of CCND1(154). Once transcribed, CCND1 transcript can be regulated by both AU-rich elements 
(AREs) which stabilize the transcript and by microRNAs that can block translation or degrade the transcript(156). 
After translation, cyclin D1 protein functions as a regulatory partner with CDK4 or CDK6 (Figure 13, right). Cyclin 
D1 binds to CDK4/CDK6, allowing this complex to be activated by cdk-activating kinase (CAK)(157) where it 
enters the nucleus and then poly-phosphorylates pRB. This phosphorylation event causes a conformational 
change, allowing pRB to release pRB-bound E2F transcription factors which are responsible for the transcription 
of S phase genes(158,159). E2F target genes that are induced by this interaction include DNA polymerase alpha, 
thymidylate synthase, and ribonucleotide reductase, all of which are involved in DNA synthesis in S phase(160). 
CCND1 has been established as a human oncogene via amplification or overexpression in breast cancer, lung 
cancer, melanoma, mantle cell lymphoma, and oral cancer(161). CCND1 overexpression predominately occurs 
because CCND1 is one of the most common CNAs in human cancer(96), but overexpression in mantle cell 
lymphoma is due to the translocation of CCND1 that places it next to the immunoglobulin heavy chain locus 
(IGH)(162). The role of cyclin D1 in cancer is through increased CDK4/CDK6 activity, leading to increased pRB 
phosphorylation, hyperactivation of E2F-responsive genes and ultimately increased proliferation of tumor cells. 
However, there have been other non-canonical functions of cyclin D1 that have been suggested that can also 
contribute to its oncogenic ability. These functions fit into other hallmarks of cancer and include evading growth 
suppressors(163), activation of invasion and metastasis(164), enabling replicative immortality(165), inducing 
angiogenesis(166), and resisting cell death(167). The activity of CDK4/CDK6 is regulated by a family of tumor-
suppressor proteins referred to as inhibitors of CDK4 (INK4). This family includes p16 INK4A, p15 INK4B, p18 
INK4C, and p19 INK4D which inhibit CDK4/CDK6 by binding directly to the kinase(168,169). Therapeutic 
targeting of the proliferate functions of cyclin D1 have been an area of interest which has focused on using small 
molecule selective inhibitors of CDK4/CDK6. To date, there are three FDA approved CDK4/6 inhibitors: 
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palbociclib, abemaciclib, and ribociclib, all of which are approved for treatment of HR-positive and HER2-
negative breast cancer(170,171). While clinical trials are still underway for other cancer types, HR-positive and 
HER2-negative breast cancer remains the only approved cancer for CDK4/6 inhibitor treatment(172).   
Non-coding and Competing Endogenous RNA 
A discrepancy between annotated RNA molecules and RNA molecules found within the human transcriptome 
has been noticed for some time(173–175). Recent studies have attempted to elucidate the function of some of 
these “junk” RNA molecules and have yielded new classes of RNA with new biological functions. To date there 
are many classes of RNA with varying functions including the canonical RNA involved in protein synthesis 
(messenger RNA, mRNA; ribosomal RNA, rRNA; transfer RNA, tRNA), RNA involved in DNA replication or post-
transcriptional modification (small nucleolar RNA, snoRNA; guide RNA, gRNA) and RNA involved in regulatory 
functions (long non-coding RNA, lncRNA; microRNA, miRNA)(176), the focus of this review. Many of these RNA 
classes lack open reading frames (ORFs) and do not code for a protein product, which could solve the observed 
discrepancy. 
One group of small regulatory RNA molecules are miRNAs, which are small RNAs that range from 20 to 30 
nucleotides and do not have an ORF. The first miRNA was discovered in Caenorhabditis elegans in 1993 and 
was named small temporal RNA (stRNA) lin-4(177). It was then observed that lin-4 had complementary 
sequences to 3’ untranslated region (3’UTR) of the C. elegans gene lin-14 and was important for its temporal 
regulation during development(178). It took some time for other miRNA to be observed in C. elegans or in other 
species. The next miRNA to be observed was let-7 in C. elegans, which was again important for development. 
Excitingly, homologs for let-7 were found in humans and other animals(179). Multiple laboratories quickly found 
over 100 different small RNAs that came from a stem-loop precursor and were also evolutionarily conserved. 
However, these did not seem to be temporally expressed and were hence renamed to miRNA(180–182). To 
date, there have been thousands of miRNAs described in humans alone(183,184). 
Canonical biogenesis of miRNA begins with transcription by RNA polymerase II into pri-miRNAs(185) (Figure 
14). These are then processed into pre-miRNAs by the microprocessor complex which includes RNA binding 
protein DiGeorge Syndrome Critical Region 8 (DGCR8) and the ribonuclease III enzyme Drosha(186). These 
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pre-miRNAs are then exported into the 
cytoplasm by exportin 5 (XPO5) and are 
processed into a mature miRNA duplex by 
the RNAse III endonuclease Dicer, which 
cleaves the hairpin loop(186,187). These 
free strands of miRNA can then be loaded 
into the Argonaute (AGO) family of 
proteins(188) to form the miRNA-induced 
silencing complex (miRISC)(189) and 
miRNA-induced gene regulation can occur.  
The miRISC complex can regulate gene 
expression via multiple mechanisms. The 
majority of miRISC gene regulation occurs 
through complementary sequences 
between the miRISC-bound miRNA and 
sequences in other RNA molecules called 
miRNA response elements (MREs). The 
degree of complementary interaction between the miRNA:MRE and the AGO in the miRISC determines the 
mechanism of regulation. If the interaction is fully complementary and AGO2 is in the miRISC, this will result in 
direct AGO2-dependent endonuclease activity and degradation of the RNA(190). However, most miRNA:MRE 
interactions in animals are not fully complementary, so target degradation occurs through another mechanism. 
This begins with recruitment of trinucleotide repeat-containing gene 6A protein (TNRC6A/GW182) and poly(A)-
binding protein C (PABPC) which promotes deadenylation of the target transcript(191,192). Decapping of the 
transcript is then facilitated by decapping protein 2 (DCP2), which is then followed by target degradation by 
exonucleases(192,193). Not all miRISC interactions lead to immediate degradation of target RNAs through this 
mechanism. There is also evidence that miRISC can inhibit gene translation through blocking translation 
machinery initiating translation or inhibiting translation after it has initiated(190,194). It is also not necessary for 
 
Figure 14. Biogenesis and function of cellular microRNA. 
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this regulatory mechanism to result in degradation of target RNA, as multiple studies have shown that these 
interactions can result in a decrease in target protein without changes in target mRNA levels(195–198). Due to 
this observation, it is possible for miRNA to be sequestered or “sponged” by target mRNAs, lncRNAs, and 
circRNAs with shared MREs to mitigate their regulatory role(199). 
Regulatory RNAs that are longer than miRNAs include long non-coding RNAs (lncRNAs). lncRNAs are RNA 
molecules that are longer than 200 nucleotides and either lack an ORF or code for small peptides less than 100 
aa(200). lncRNA were first described in 1990 with the discovery of the regulatory lncRNA H19(201) and the X-
inactivation linked lncRNA Xist(202). lncRNA can exist in the genome as stand-alone RNAs that are transcribed 
and polyadenylated(203), or as antisense transcripts opposite of sense coding genes(204), or as pseudogenes 
that have lost their coding potential due to mutations(200), or as intronic sequences(205), or as other promoter-
associated and enhancing RNAs(206).  
There have been many described lncRNAs involved in a variety of functions including epigenetic and 
transcriptional decoys and regulators. The lncRNA HOTAIR functions as a recruiter for the polycomb repressive 
complex 2 (PRC2) and regulates chromatin state of genes, including HOXD which is involved in differentiation 
and limb development(207). lncRNAs can also function as molecular recruiters by recruiting epigenetic 
complexes during transcription. The DNA:RNA complementarity of lncRNAs allow them to target these 
complexes to specific genomic positions, something that is not possible with protein-driven recruitment(208). 
Some lncRNAs act as decoy RNA and compete for transcription factor binding(209) while others can directly 
inhibit RNA polymerase II(210), both resulting in a downregulation in transcription. On the other hand, lncRNAs 
can also function as coregulators to activate transcription, such as ncRNACCND1 regulation during stress(154).  
Aberrant expression levels of miRNAs and lncRNAs have been shown to be involved in cancer. In HNSCC, 
several oncogenic miRNA expression levels are altered, including miR-21 and miR-31, which are well 
documented oncogenic miRNAs that are detectable in plasma(211–215) and indicate a poor prognosis. miR-21 
is the most frequently upregulated miRNA in HNSCC and is involved in drug resistance, invasion, cell survival, 
and metastasis(216). Well known targets of miR-21 include the tumor suppressors GRHL3 and PTEN(212,216–
219). miR-31 is also significantly upregulated in HNSCC and functions by targeting factor-inhibiting-factor (HIF), 
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subsequently activating HIF and its downstream targets, ultimately contributing to the development of 
HNSCC(220,221). Other aberrant miRNA expressions have been noted, especially in the case of gene 
amplification, but their cellular targets are still under investigation. Tumor suppressing miRNA can also 
experience expression changes in HNSCC, such as the let-7 family which includes let-7a-j and miR-98 that 
regulate cell renewal, cellular motility, and EMT regulation(222). The miR-99 family normally targets the mTOR 
signaling pathway to inhibit the phosphorylation of AKT. Downregulation of these miRNA, including through gene 
deletion, can lead to the initiation of HNSCC(223–225). Hundreds of lncRNAs have been shown to be 
differentially expressed in HNSCC(226) with the most extensively studied lncRNA being MALAT1, which is 
notably located on chromosome 11q13.1. High levels of MALAT1 are associated with increased lymph node 
metastasis and poor patient prognosis(227,228).  
The presence of MREs on cellular mRNA, lncRNA, and other RNA molecules leads to the possibility that there 
is another layer of complexity involved in RNA regulation due to these molecules all competing for the same pool 
of cellular miRNA. This concept was first discussed in 2011 and is referred to as the competing endogenous 
RNA (ceRNA) hypothesis(229). Briefly, the hypothesis states that since the levels of MREs and miRNAs are in 
balance, any change to this balance, be it either from an increase in the amount of MREs through target gene 
overexpression or a decrease in miRNA due to mutation, will also alter expression of other target RNAs that 
share the same MREs(229–232) (Figure 15). This is still a controversial hypothesis as there is both ample 
evidence, such as ceRNAs that alter expression of the tumor suppressor PTEN(233) or BRAF(234) and 




   
Despite these conflicting reports, ceRNAs have been implicated in several disease states including 
cardiovascular disease with roles in atrial fibrillation, myocardial infarction, and cardiac hypertrophy(236–238); 
neurodegenerative disorders with roles in Parkinson’s and Alzheimer’s disease(239,240); and cancer(241–245). 
It remains clear that additional studies are necessary to further bridge this gap of knowledge to either support or 
reject the ceRNA hypothesis.    
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The United States Appalachian region harbors a higher cancer burden than the rest of the nation, with disparate 
incidence of head and neck squamous cell carcinomas (HNSCC), including oral cavity and pharynx (OC/P) 
cancers. Whether elevated HNSCC incidence generates survival disparities within Appalachia is unknown. To 
address this, HNSCC survival data for 259,737 tumors from the North American Association for Central Cancer 
Registries (NAACCR) 2007-2013 cohort were evaluated, with age-adjusted relative survival (RS) calculated 
based on staging, race, sex, and Appalachian residence. Tobacco use, a primary HNSCC risk factor, was 
evaluated through the Behavioral Risk Factor Surveillance System (BRFSS) from Appalachian states. 
Decreased OC/P RS was found in stage IV Appalachian white males within a subset of states. The survival 
disparity was confined to human papillomavirus (HPV)-associated oropharyngeal cancers, specifically the 
oropharynx subsite. This correlated with significantly higher smoking and male smokeless tobacco use in most 
Appalachian disparity states. Lower survival of Appalachian males with advanced-stage HPV-associated 
oropharyngeal cancers suggests pervasive tobacco consumption likely generates more aggressive tumors at 
HPV-associated oropharynx subsites than national averages. Comprehensive tobacco and HPV status should 
therefore be evaluated prior to considering treatment de-intensification regimens for HPV-associated 





HNSCC involves the epithelium of the oral cavity, pharynx and larynx. OC/P cancers are a major HNSCC subset, 
with nearly 11,000 deaths predicted in the US in 2020[1]. Risk factors include tobacco and alcohol use, and high-
risk human papillomavirus (HPV) infection[2,3]. OC/P cancers are subdivided into HPV-associated oropharynx 
(HPV-associated) and non-HPV-associated oral cavity, hypopharynx, and nasopharynx (non-HPV-associated) 
cancers[4]. These designations are supported by studies indicating that non-HPV-associated cancers are 
primarily tobacco/alcohol induced, whereas HPV-associated cancers are predominantly caused by HPV 
infection[5]. Furthermore, HPV-negative or non-HPV-associated cancers consistently have poorer outcomes 
than HPV-positive or HPV-associated cancers, segregating these cancers as distinct diseases with differential 
clinical management[6,7]. While national incidence of non-HPV-associated cancers is decreasing due to tobacco 
cessation, HPV-associated cancers are increasing due to rising infection rates[8]. Regarding race, blacks with 
HNSCC present with more advanced disease, are older and have worse survival than whites, denoting a racial 
disparity[9–11]. Increased screening for HPV coupled with subsite analysis indicates that blacks with HNSCC 
have less HPV-positive cancer than whites, explaining differences in survival[12,13]. Consistent with this, HPV-
associated cancers continue to increase in white males and in rural areas[4,14,15]. 
The Appalachian region encompasses 205,000 square miles across 420 counties in 13 contiguous states[16]. 
Forty-two percent of Appalachia is rural, with poverty rates in many counties 1.5 times above the national 
mean[16]. The region is over 80% white, with several states having higher percentages of oral and other HPV-
associated cancers, and higher smoking and smokeless tobacco use[17–19]. Aggregate risk factors experienced 
by Appalachian residents contribute to a high allostatic load capable of generating cancer disparities in a region 
with low ethnic diversity[20]. Incidence disparities within Appalachia are well recognized[21] with rates higher for 
HPV- and tobacco-related malignancies[22–24]. Elevated risk factor exposure has been suggested as the prime 
reason for disparate incidence in Appalachian male HNSCC[24,25]. However, due to gaps in data availability 
and small patient numbers at the county level, details on how increased incidence impacts HNSCC survival in 
Appalachia have not been rigorously evaluated[25]. Here we have evaluated the RS of all HNSCC in the majority 
of Appalachian states from 2007-2013 and have identified an outcome disparity in white males with oropharynx 
cancers that corresponds with elevated smoking and smokeless tobacco use in the region. 
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Materials and Methods  
HNSCC Cohort and Relative Survival Data 
All methods were carried out in accordance with relevant guidelines and regulations. Survival data were 
generated by NAACCR and provided in Surveillance, Epidemiology, and End Results (SEER)*Stat 
approved under NAACCR IRB protocol 16-14, where all patient data was obtained following informed 
consent. Patients were diagnosed from 2007-2013 with tumors of International Classification of 
Diseases for Oncology (ICD-O)-3 histology types 8050-8084, 8120-8131 (squamous and transitional 
epithelium). Selecting all primary tumors matching selection criteria, the cohort includes tumors of the 
oral cavity (n=55,620/259,737, 21.4%) including ICD-O-3 site groups of tongue (C02.0-02.3, 02.9), floor 
of mouth (C04.0-04.9), and gum and other mouth (C03.0-03.9, C05.0, C05.8-05.9, C06.0-06.9); 
oropharynx (n=81,170/259,737, 31.3%) including ICD-O-3 site groups of tongue (C01.9, C02.4, C02.8), 
gum and other mouth (C05.1-05.2), tonsil (C09.0-09.9), oropharynx (C10.0-10.9), and “other oral cavity 
and pharynx” (C14.0-14.8); “other pharynx” (n=17,731/259,737, 6.8%) including ICD-O-3 site groups 
of nasopharynx (C11.0-11.9) and hypopharynx (C12.9-13.9); and larynx (n=60,296/259,737, 23.2%) 
including ICD-O-3 site group larynx (C32.0-32.9). Remaining tumors are additional primaries of 
miscellaneous ICD-O-3 site groups (n=44,916/259,737, 17.3%). The cohort includes variables denoting 
whether or not patients were Appalachian county residents at the time of diagnosis, and county 
economic status from the Appalachian Regional Commission (ARC)[26]. Appalachian states with 
survival data fit for use through the reporting period included New York, Pennsylvania, West Virginia, 
Kentucky, North Carolina, South Carolina, Georgia, and Alabama[27]. The majority of cases were white 
(n=221,939/259,737, 85.4%), stage IV (n=84,253/259,737, 32.4%), and male (n=193,647/259,737, 
74.6%). Cases were evaluated using the Ederer II method and the “U.S. by race (W, B, AIAN, API) and 
Canada 1995-2012, Ages 0-99, State-county (modeled by varied state-county-ses)” life table. Included 
cases were microscopically confirmed for malignant behavior and followed at monthly intervals. 
Excluded cases were those that were diagnosed solely via death certificate or autopsy, and alive cases 
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with no survival time. Age-adjusted RS, defined as net survival measure representing cancer survival 
in the absence of other causes of death[28], was calculated using SEER*Stat for each patient 
stratification, with z-tests for significance testing between each group using an alpha level of 0.05. 
Cumulative (C)RS was used to compare groups with five years of available RS data and the maximum 
available follow-up RS was used to compare groups that failed to reach five years of follow-up. 
Mapping 
Maps were generated using 2014 cartographic boundary shapefiles from the United States Census Bureau[29] 
and Quantum Geographic Information System (QGIS) 3.2.2 software[30]. Appalachian state-Appalachian county 
refers to a county within Appalachia. Appalachian state-non-Appalachian county refers to a county outside of the 
Appalachian region, but within a state containing Appalachian counties. Non-Appalachian states lack 
Appalachian counties. 
TCGA Cohort and Associated Clinical Data 
Data from The Cancer Genome Atlas (TCGA) were obtained from the Broad Genomic Data Analysis Center 
(GDAC) Firehose 2016_01_28 TCGA-HNSC cohort consisting of 529 patients with tumors of the oral cavity 
(n=320/529, 60.5%), pharynx (n=92/529, 17.4%), and larynx (n=117/529, 22.1%). Clinical data and patient 
characteristics were retrieved from the level 4 TCGA clinical data file All_CDEs.txt and cBioPortal[31,32]. OC/P 
patients were stratified by HPV-associated or non-HPV-associated subsite defined by the Centers for Disease 
Control (CDC)[33] and by confirmed HPV status. All patients were evaluated for HPV in the All_CDEs.txt file, 
denoted by variable “hpv_status”. Kaplan-Meier P-values were calculated using Mantel-Cox log-rank test and 
were validated by an independent biostatistician. 
Appalachian Tobacco Use Data and Analysis 
Data for 2016 current smoker and smokeless tobacco user frequency, weighted frequency, prevalence, and 
confidence intervals for Appalachian and non-Appalachian counties were calculated and provided by BRFSS 
coordinators from Appalachian states. Current smoker status was calculated using CDC BRFSS Tobacco Use 
Question 1 and 2 from the 2016 questionnaire. Current smokeless status was calculated using CDC BRFSS 
Tobacco Use Question 3. Non-Appalachian state tobacco use data were acquired from CDC BRFSS[19]. 
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Statistical significance was determined within states and between regions using G-tests for independence 
without Yates’ correction using BRFSS frequency (N) values and an alpha value of 0.05. BRFSS recommends 
caution interpreting results with less than 50 respondents. Bonferroni correction was used where applicable to 
reduce type I error. Due to changes in sample composition and weighting methodology in 2011, data from years 
after 2011 cannot be directly compared to previous years[34].
Results 
Identification of a Survival Disparity in White Appalachian Males with Stage IV Oral Cavity and 
Pharyngeal Cancer 
The NAACCR cohort from 2007-2013 in this study contained 145,823 OC/P tumors and 57,805 laryngeal tumors 
(Table 1, Fig. 1a, Fig. S1). The eight NAACCR-reporting Appalachian states cover 67.6% of all Appalachian 
counties and 72.3% of the Appalachian population[35]. The OC/P and laryngeal cohorts reflect overall 
Appalachian demographics, with a higher percentage of white cases and lower percentage of ethnic minorities 
than non-Appalachia (Table 1). Except for lower CRS in Appalachian OC/P and laryngeal cancers, all other 
parameters were nearly identical to national averages in each disease (Table 1). The majority of OC/P and 
laryngeal cancer cases came from distressed or transitional Appalachian counties. 
RS was measured among OC/P and laryngeal cancer patients by Appalachian or non-Appalachian residency at 
time of diagnosis (Fig. 1a, Fig S1). When stratified by American Joint Committee on Cancer (AJCC)-6 stages I 
to IV, stage IV patients had the highest patient numbers and lowest CRS for each disease (OC/P; 
n=63,396/116,595, CRS=45.5%; laryngeal; n=14,963/51,362; CRS=67.1%), and were selected for further 
evaluation (Fig. 1b and Fig. S1). OC/P and laryngeal patients were stratified by sex, race, and Appalachian 
residency (Fig. 1c, 1d; Fig S1). Survival analyses indicated that white Appalachian OC/P males (n=5,014/53,696; 
CRS=44.9%) displayed a significantly lower CRS compared to white non-Appalachian males (Fig. 1c; 
n=37,843/53,696; CRS=49.2%), P=0.00001. In OC/P, there was no significant difference in CRS between white 
Appalachian females (n=1,381/53,696; CRS=43.1%) and white non-Appalachian females (n=9,458/53,696; 
CRS=43.7%) (Fig. 1c) or between black Appalachian males (n=387/7,342; CRS=35.8%) and black non-
Appalachian males (n=5,297/7,342; CRS=34.4%) (Fig. 1d). Black Appalachian females (n=116/7,342; three-
year RS=46.1%) failed to reach five-year follow-up for CRS comparison, but there was no observed significance 
60 
 
between black non-Appalachian females at the latest available follow-up year (n=1,540/7,342; three-year 
RS=34.8%) (Fig. 1d). No significant differences in CRS were observed for Appalachian laryngeal cancers 
between any sex or race (Fig. S1). White Appalachian males with stage IV OC/P were selected for further study 
due to their significantly different survival. 
The Survival Disparity in White Appalachian Male Stage IV OC/P is Specific to Appalachian Counties 
within Select Appalachian States 
To elucidate whether the observed stage IV white Appalachian male OC/P survival disparity is specific to 
Appalachian counties within Appalachian states, patients were stratified by Appalachian or non-Appalachian 
county and state residency. Appalachian states-Appalachian counties (n=5,014/42,857; CRS=44.9%) displayed 
a significantly lower CRS compared to Appalachian states-non-Appalachian counties (n=9,700/42,857; 
CRS=47.9%), P=0.00017 and non-Appalachian states (n=28,143/42,857; CRS=49.6%), P=0.00032 (Fig. 2a and 
b). This indicates that the survival disparity is specifically due to cancer survival within Appalachia, not to 
contributions from adjacent non-Appalachian counties within Appalachian state borders. There was no significant 
difference in CRS between non-Appalachian states and Appalachian states-non-Appalachian counties (Fig. 2a).  
To determine if the stage IV white Appalachian male OC/P survival disparity could be identified at the state level, 
patients within Appalachian counties were stratified by state residency. Significantly lower CRS was observed 
for Appalachian counties in Alabama (n=626/31,423; CRS=39.7%), P=0.0006, Kentucky (n=372/31,423; 
CRS=39.6%), P=0.0101, Pennsylvania (n=1,695/31,423; CRS=45.3%), P=0.0047, and West Virginia 
(n=587/31,423; CRS=35.3%), P=0.007 compared to non-Appalachian states (n=28,143/31,423; CRS=49.6%) 
(Fig. 2c and d). All other analyzed Appalachian states did not have a significantly different CRS (Supplementary 
Figure S2). 
The White Appalachian Male Stage IV OC/P Survival Disparity is Primarily Found in HPV-Associated 
Oropharyngeal Subsites 
To determine if the stage IV white Appalachian male OC/P disparity is predominantly present within a specific 
OC/P subregion, cases were initially divided into non-HPV-associated or HPV-associated cancer subtypes for 
survival analysis. HPV-associated cancers frequently contain oral mucosa with HPV DNA, and are defined as 
HPV-associated oropharynx by the CDC[33]. Remaining subsites are not associated with HPV infection and 
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represent non-HPV-associated cancer (Fig. 3a). First, we evaluated the CDC definitions as predictors of HPV 
infection in HNSCC by using patients in the TCGA cohort, where all patients have known HPV status. Importantly, 
patients were evaluated for overall survival, since HPV is not a variable collected by NAACCR and thus could 
not be assessed in the Appalachian cohort. TCGA patients were additionally stratified as HPV-associated and 
non-HPV-associated using subsite information, then compared to outcomes based on confirmed HPV status. 
HPV-positive white male stage IV TCGA patients have an undefined median survival with five-year overall 
survival of 71%, whereas HPV-negative patients have median survival of 47.0 months and five-year overall 
survival of 38% (Fig. 3b). Similarly, HPV-associated cancer patients from the same cohort have median survival 
of 68.4 months and five-year overall survival of 61%, while non-HPV-associated patients have lower median 
survival of 30.1 months and five-year overall survival of 37%. While the survival trends regarding HPV status are 
in general agreement between the NAACCR and TCGA cohorts, the difference in five-year overall survival is 
greater when comparing HPV-positive (71%) and HPV-associated (61%) patients than between HPV-negative 
(38%) and non-HPV-associated (37%) patients. This suggests that the CDC non-HPV-associated subsite 
designation is a better predictor for HPV negativity than the HPV-associated subsite designation is for HPV 
positivity.  
To elucidate the discordance between HPV-positive and HPV-associated patients in explaining the observed 
Appalachian survival differences, TCGA patients were separated into non-HPV-associated cancers and into the 
specific HPV-associated oropharynx subsites, with the HPV status determined for each grouping. Using this 
breakdown, non-HPV-associated cancers are mostly HPV-negative, whilst HPV-associated cancers contain a 
mixture of HPV-positive and HPV-negative cases (Fig. 3c). These findings potentially explain the discrepancy 
between HPV-positive and HPV-associated outcomes, and also point to confounding factors such as 
tobacco/alcohol use or socioeconomic status (SES) that may exist in patient cohorts stratified solely on the basis 
of HPV-association. 
White male stage IV cancer cases in the NAACCR cohort were next stratified by HPV-association and 
Appalachian residency. Appalachian patients with HPV-associated cancers (n=3,449/33,281; CRS=53.1%) 
displayed a significantly lower CRS compared to HPV-associated patients in non-Appalachian states 
(n=20,399/33,281; CRS=57.7%), P=0.0118 (Fig. 3d). No significant difference was found in CRS between non-
HPV-associated patients in Appalachian counties (n=1,577/33,281; CRS=29.5%) compared to non-HPV-
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associated patients in non-Appalachian states (n=7,856/33,281; CRS=30.9%). These results suggest that the 
stage IV white Appalachian male OC/P survival disparity is driven by lower survival of HPV-associated 
oropharyngeal patients. Appalachian states with the overall stage IV white Appalachian male OC/P survival 
disparity identified in Figure 2c were evaluated separately and trended in a similar manner (Supplementary 
Figure 3).  
White male stage IV patients in the NAACCR cohort were subsequently stratified by each HPV-associated 
oropharyngeal region to delineate the contributions of each subsite on Appalachian survival. A significant 
difference in survival was observed between patients with primary oropharynx tumors in Appalachia 
(n=325/2,807; CRS=24.4%) and non-Appalachian counties (n=649/2,807; CRS=36.9%), p=0.0399 as well as 
non-Appalachian states (n=1,833/2,807; CRS=37.5%), P=0.0394 (Fig. 3e). No significant differences were 
observed between patients with primary tonsil tumors in Appalachia (n=1,603/14,110; CRS=55.8%) and non-
Appalachia states (n=9,240/14,110; CRS=63.3%) or counties (n=3,267/14,110; CRS=59.6%). Similarly, no 
significant differences were observed between patients with primary tongue tumors in Appalachia 
(n=1,579/14,345; CRS=54.8%) and non-Appalachian states (n=9,625/14,345; CRS=55.9%) or counties 
(n=3,141/14,345; CRS=55.1%) (Fig. 3f, 3g). Other oropharyngeal subsites lacked sufficient numbers for 
individual analysis but were combined with tonsil and (base of) tongue to generate an “other HPV-Associated” 
subset (Fig. 3a). 
Regarding survival driven by oropharyngeal tumors, “other HPV-associated” and non-HPV-associated 
stratification reveals three distinct outcomes in non-Appalachia (Fig. 3h): “Other HPV-associated” 
(n=18,627/33,347; CRS=59.7%) has the best outcome, followed by oropharynx (n=1,833/33,347; CRS=37.5%), 
then non-HPV-associated (n=7,856/33,347; CRS=30.9%). However, in Appalachia, only two distinct outcomes 
are revealed: “Other HPV-associated” (n=3,129/33,347; CRS=56.7%) has the best outcome, whereas 
oropharynx (n=325/33,347; CRS=24.4%), has a statistically similar outcome to non-HPV-associated 
(n=1,577/33,347; CRS=29.5%) (Fig. 3h). These results suggest that the observed Appalachian survival disparity 
is largely driven by lower survival in the oropharynx subregion of HPV-associated stage IV male oropharyngeal 
patients.   
High Appalachian Tobacco Use Correlates with Stage IV White Appalachian Male OC/P outcomes 
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The lower survival of stage IV white Appalachian male HPV-associated cancer compared to confirmed HPV-
positive national cases implies that risk factors other than HPV are driving poorer survival in the Appalachian 
cohort (Fig. 3b). Since smoking and smokeless tobacco use are highest in Appalachia[19], and current smoker 
prevalence rates have remained higher in West Virginia (a state with all counties within Appalachia) than the 
nation for several decades[36] (Fig. 4a), we evaluated tobacco use prevalence rates in Appalachian states from 
state BRFSS registries stratified by Appalachian residency and sex using data from 2016 as a representative 
year. 
In males, smoking prevalence rates were significantly higher in Appalachian counties compared to non-
Appalachian counties, P=4.441e-16 and non-Appalachian states, P<2.2e-16. Specifically, male smoking 
prevalence rates were significantly higher in Appalachian counties compared to non-Appalachian counties in 
Kentucky (P=2.80e-04), New York (P=2.55e-04), Ohio (P=0.02965), and Virginia (P=0.008904) (Fig. 4b, top). 
Male smokeless tobacco prevalence rates were significantly higher in Appalachian counties compared to non-
Appalachian counties, P<2.2e-16 and non-Appalachian states, P<2.2e-16. Specifically, male smokeless tobacco 
prevalence rates were significantly higher in Appalachian counties compared to non-Appalachian counties in 
Kentucky (P<2.2e-16), New York (P=9.03e-7), North Carolina (P=5.44e-6), Ohio (P=1.87e-12), South Carolina 
(P=0.00419), and Virginia (P=6.63e-9). Significant differences were also observed in Maryland and 
Pennsylvania, but these regions had fewer than 50 respondents. 
West Virginia contains no non-Appalachian counties for comparison, but the smoking tobacco rate of 
25.8% and the smokeless tobacco rate of 15.9% are similar to that of other states with significant 
differences in the region (Fig. 4b, top). Interestingly, except for Alabama, states with significantly higher 
male smokeless tobacco use include every state with a significant difference in CRS for stage IV white 
Appalachian male OC/P and HPV-associated cancers (Fig. 4d).  
In females, average smoking prevalence rates were higher in Appalachian counties compared to non-
Appalachian counties, P<2.2e-16, and non-Appalachian states, P<2.2e-16 (Fig. 4b, bottom) and were 
statistically different than that of Appalachian males (20.7% males vs. 19.2% females) (Fig. 4c). Smoking 
prevalence rates were significantly higher in Appalachian counties compared to non-Appalachian counties in 
Alabama (P=1.5e-4), Kentucky (P=1.33e-9), Maryland (P=0.02284), New York (P=3.4e-9), Ohio (P=9.38e-5), 
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Pennsylvania (P=1.44e-4), and Virginia (P=0.0362). Female smokeless tobacco prevalence rates were 
significantly higher in Appalachian counties compared to non-Appalachian counties, P=8.76e-4 and non-
Appalachian states, P=2.912e-05, and were significantly different than that of Appalachian males (10.9% males 
vs. 1.2% females), P<2.2e-16 (Fig. 4c). Significant differences were observed in Kentucky and Maryland, 
although these regions had fewer than 50 respondents. These data indicate that significantly higher smoking 
and smokeless tobacco rates within Appalachia correlate with disparate survival of stage IV white Appalachian 




With a majority of population and geographical coverage, our direct, non-exploratory analysis of HNSCC survival 
from available states representing all ARC-defined Appalachian subregions[16] identifies stage IV white 
Appalachian males with OC/P cancer as having lower cancer-related survival compared to non-Appalachian 
males. Based on available data, this stage- and sex-specific disparity is manifest within the Appalachian areas 
of four states. The disparity is restricted to the ICD-O-3 defined oropharynx (C10.0-10.9) within the CDC-defined 
HPV-associated oropharyngeal region. This disparity predominantly occurs in states with significantly higher 
male smoking and smokeless tobacco use, consistent with high risk-factor exposure in Appalachia known to 
contribute to increased HNSCC incidence[22,24,25]. 
Previous work evaluating Appalachian oral cancer survival using 2004 SEER data identified higher combined 
male and female survival in 10 states without consideration of stage or race[25]. When stratified by stage, race 
and sex, our multivariate analysis indicates that the only significant difference in CRS occurs in white 
Appalachian stage IV male OC/P patients diagnosed under AJCC-6[37]. RS values for stage IV white 
Appalachian and non-Appalachian male OC/P are higher than that of black males or black females, in agreement 
with a recognized national survival disparity for black OC/P cancers attributed to lower overall SES and cultural 
barriers[9,11]. In addition, female white stage IV OC/P patients have a lower CRS than male white stage IV OC/P 
regardless of Appalachian status, likely reflecting the lower rate of HPV-positive oropharyngeal disease in 
females[38,39]. Emerging national trends indicate that HPV-associated oropharyngeal cancers occur more 
frequently in younger, white male patients with limited tobacco use, and within rural areas[4,14,38]. These 
factors, coupled with blacks and white females having higher percentages of HPV-negative disease[12,13] are 
congruent with HPV-positive and/or HPV-associated white male oropharyngeal patients having higher survival 
at the national level.  
OC/P patient populations consist of a mixture of HPV-negative and HPV-positive disease. White Appalachian 
males have a higher incidence in HPV-positive OC/P cancers, which would be expected to result in increased 
survival. However, stage IV-matched CRS for white Appalachian males is closer to the lower survival prevalence 
rates observed for white females than for non-Appalachian white males (Fig. 1c). Furthermore, male Appalachian 
stage IV HPV-associated oropharynx patients exhibit outcomes similar to non-HPV-associated male stage IV 
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disease within and outside of Appalachia. Of the recognized cancer risk factors endemic to Appalachia, age at 
diagnosis, travel distance to critical care centers and disproportionate presentation of patients at stage IV have 
been reported to have no impact on survival in Appalachian subpopulations[40,41] (Table 1). However, increased 
smoking and smokeless tobacco use within Appalachia have been linked to low SES and increased HNSCC 
incidence[42–44], and thus are presumably factors contributing to the decreased male stage IV oropharyngeal 
cancer survival. 
Our findings also indicate that Appalachian smoking tobacco prevalence rates, represented by West Virginia, 
have been higher than national averages for several decades (Fig. 4a), and while Appalachian smoking tobacco 
use is significantly higher in males and females, smokeless tobacco use is primarily higher in males compared 
to national averages (Fig. 4b). Smokeless tobacco use has been specifically linked to increased cancer risk in 
OC/P and oropharyngeal subsites[45–48]. Elevated smoking and smokeless tobacco use in most Appalachian 
states with significantly different CRS corresponds with decreased CRS in white male stage IV OC/P cancers. 
This has the potential to result in the male patient population garnering a higher percentage of tobacco-induced 
HPV-negative disease at all oral subsites, including the oropharynx. While the lack of diagnostic HPV detection 
by p16 staining as a variable in the NAACCR cohort precludes direct analysis of viral status, segregation of white 
male stage IV OC/P patients by non-HPV-associated OC/P and HPV-associated oropharynx indicates that HPV-
associated oropharyngeal cancer is responsible for the Appalachian male stage IV disparity within ICD-O-3 
oropharynx codes. The predominant subsites under this delineation are C10.0 (vallecula), C10.1 (anterior 
surface of epiglottis), C10.2 (lateral wall of oropharynx), C10.3 (posterior wall of pharynx) and C10.4 (branchial 
cleft). These oropharyngeal regions exclude palatine and lingual tonsils, as well as most other HPV-associated 
oropharyngeal sites containing the reticular epithelium lining the tonsillar crypts that constitute the primary sites 
of oropharyngeal HPV infection and neoplasia[49–51]. Higher aggregate tobacco use by Appalachian males 
may therefore result in more frequent carcinogen-induced malignancy at oropharynx subsites, resulting in a 
greater percentage of HPV-negative disease in the oropharynx and corresponding worse CRS, similar to that 
observed in other tobacco-heavy oropharyngeal cohorts[3,52,53].  
The Appalachian-specific OC/P and oropharynx-specific disparities found in this study were diagnosed under 
the AJCC-6 timeframe, having clinical and pathological staging guidelines independent of HPV status. Restaging 
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of HPV-positive oropharynx in 2018 under AJCC-8 due to the favorable prognosis of HPV-positive oropharyngeal 
cancers would shift most HPV-positive oropharynx in AJCC-6 to lower clinical stages. Such restaging would 
have the effect of potentially eliminating or downstaging the Appalachian male disparity described in this report. 
However, an additional ramification from this work is that male Appalachian or other populations with multi-
factorial oropharyngeal tobacco exposure may actually be under-staged using current AJCC-8 guidelines. This 
is an important consideration, since National Comprehensive Cancer Network (NCCN) guidelines recommend 
staging and treatment dependent on p16 status[52,54], where treatment de-escalation of HPV-associated 
oropharyngeal cancers continues to be evaluated[55–57]. Future efforts towards definitively determining the 
extent of HPV involvement in Appalachian OC/P and oropharynx through comprehensive p16 staining and 
PCR[58] will be required to better clarify the predominant factors underlying oropharynx-driven, stage-based 
disparities in past and future Appalachian cohorts. 
Limitations and Implications 
While the current study covers the majority of the Appalachian population and is the most comprehensive study 
of HNSCC survival of the region to date, lack of available qualified survival data from five Appalachian states 
prevented complete assessment of survival in the region. The association between heavy aggregate tobacco 
use and poor male stage IV oropharyngeal survival in states with significantly different CRS suggests that stage 
IV oropharyngeal patients from states with Appalachian regions containing similar tobacco use patterns may 
also harbor disparate outcomes. Our findings, in conjunction with the poor survival of HPV-positive oropharynx 
patients with high smoking histories[59,60], underscore the need for the comprehensive tobacco history of any 
HPV-positive oropharynx patient to be considered prior to treatment. In addition to smoking, the significantly 
higher smokeless tobacco use by the male Appalachian population further increases the risk of tobacco-induced 
cancer at HPV-associated oropharyngeal sites, leading to oropharynx tumors that are either HPV-negative, or 
are HPV-positive but exhibit aggressive HPV-negative tumor behavior.  
Conclusions 
These findings provide novel and in-depth insight into a specific demographic within a chronically underserved, 
rural population that is at higher clinical risk for poor OC/P outcome. Persistent high tobacco usage in Appalachia, 
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in spite of increased tobacco cessation efforts, reinforces the need for continued targeted risk awareness. This 
includes emerging forms of supposed safer nitrosamine-containing products, such as e-cigarettes, that 
contribute to the cumulative patient tobacco load[61]. Inclusion of patient use of these products as standard 
registry variables should be considered for improved monitoring of tobacco-related disparities in future 
populations. The described male oropharynx disparity may also be present in male patients from other regions 
with heavy smoking, smokeless tobacco[62] or betel-quid[63] use, and should be monitored accordingly for 
similar poor survival and continued cessation intervention policies. 
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Figures and Tables 
 
Figure 1. Identification of a Survival Disparity in White Appalachian Male Stage IV OC/P cancer. A. Flow 
diagram of procedures used to evaluate Appalachian-specific survival data. Boxes contain rationale and steps 
involved in the sequential stratification and cohort analysis for OC/P cancer. B. Survival analysis of Appalachian 
OC/P cancer stratified by clinical stage. CRS values are plotted for each year after diagnosis, with five-year (60 
month) ratios evaluated across all AJCC-6 stages. C and D. Survival analysis of white (C) and black (D) stage 
IV OC/P cancer stratified by Appalachian residency and sex. CRS values are plotted as in (B). Patient N, five-
year CRS with 95% CI and P-values between significant groups are shown at the top of each graph; n.s., not 
significant. Black patients were evaluated for significance at 36 months due to lack of complete female survival 




Figure 2. State-level analysis of Appalachian OC/P survival. A. Disparate stage IV white Appalachian male 
OC/P survival is restricted to Appalachian counties. Plotted CRS values over time are shown for non-
Appalachian states (black), non-Appalachian counties within Appalachian states (green) and Appalachian 
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counties within Appalachian states (red). Patient N, five-year CRS with 95% CI and P-values at 60 months are 
shown at the top of the graph; n.s., not significant. B. Mapping of the denoted geographic regions evaluated in 
(A). C. Select Appalachian states with significantly different CRS values contain a survival disparity in OC/P 
cancer. Appalachian states with significant CRS values are shown plotted over time. Patient N, five-year CRS 
with 95% CI and P-values at 60 months for states with significant survival differences between Appalachian and 
non-Appalachian counties are shown at the top of the graph. D. Map of Appalachian region displaying states 
with significantly different stage IV white Appalachian male OC/P CRS. States with significant survival differences 
between Appalachian and non-Appalachian counties are in black, states with no available data are marked with 




Figure 3. The Stage IV White Appalachian Male OC/P survival disparity is predominant in HPV-associated 
oropharyngeal cancers. A. Schematic of the head and neck showing location of non-HPV-associated pharynx 
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and oral cavity (blue), and CDC-defined HPV-associated oropharynx (green) cancers. A subset of the CDC-
defined HPV-associated oropharynx is denoted in orange. ICD-O-3 site groups and corresponding site codes for 
each cancer type are indicated (see Materials & Methods for detailed description of each site group). B. Overall 
survival between confirmed and HPV-associated OC/P subtypes. Kaplan-Meier analysis of overall survival of 
stage IV white males from the TCGA HNSC cohort stratified by HPV status (HPV-positive or HPV-negative) or 
by ICD-O-3-coded HPV association (HPV-associated and non-HPV-associated). P-values calculated using 
Mantel-Cox log-rank test, patient N, median and five-year overall survival for each group are noted. C. HPV 
status of OC/P subsites in stage IV white male TCGA patients. Percent of patients with confirmed HPV-negative 
(red) or HPV-positive (black) disease for each indicated subsite is shown. Denoted subsite groupings are 
indicated at the bottom as non-HPV-associated (blue), oropharynx (green), or other HPV-associated (orange). 
D. The stage IV white Appalachian male OC/P survival disparity is present in HPV-associated oropharyngeal 
cancer. CRS values are plotted over time for stage IV white Appalachian male OC/P patients stratified by 
Appalachian and non-Appalachian counties and HPV- or non-HPV-associated status. E-G. Stage IV white males 
stratified by HPV-associated oropharynx subsites. Oropharynx (E), tonsil (F), and tongue (G). CRS values are 
plotted over time with patients stratified by Appalachian counties (red), non-Appalachian counties (green) and 
non-Appalachian states (black). H. Stage IV white males stratified by non-HPV-associated, oropharynx, other 
HPV-associated subsites and Appalachian residency. For D-H, RS values are plotted over time with patients 
stratified by Patient N, five-year CRS with 95% CI and P-values at 60 months for each group are shown at the 






Figure 4. High combined tobacco use in Stage IV white Appalachian male OC/P disparity states. A. Overall 
smoking prevalence rates in West Virginia (as a representation of Appalachia, gold) compared to the United 
States (grey). Years 2011-2018 cannot be directly compared to earlier years due to differences in weighting 
methodology across time. B. Elevated tobacco use by Appalachian males (top) and females (bottom). Data for 
2016 smoking weighted prevalence estimates for males in Appalachian states stratified by county status (blue, 
Appalachian counties; gold, non-Appalachian counties; grey, non-Appalachian states), smoking (solid) or 
smokeless (cross-hatched) tobacco use with P-values calculated using G-test for independence without Yates’ 
correction are shown at top. Error bars represent 95% CI. C. Combined Appalachia county smoking (solid) and 
smokeless (cross-hatched) weighted prevalence estimates with P-value calculated using G-test for 
independence without Yates’ correction are shown above significant results. D. Mapping of Appalachian counties 
smokeless tobacco use. Appalachian counties with significantly higher (red) and non-significantly different 
(black) smokeless tobacco use are shown compared to non-Appalachian counties within each respective 
Appalachian state. West Virginia (hatched; non-applicable) lacks non-Appalachian counties for comparison. 
83 
 
2007 - 2013 NAACCR 
Cohort Characteristics† 
Total OC/P and 
Laryngeal 
n = 214821 (100%) 
Total OC/P 
n = 154525 (100%) 
Appalachian OC/P 
n = 16366 (10.59%) 
Non-Appalachian OC/P 
n = 138159 (89.41%) 
Total Laryngeal 
n = 60296 (100%) 
Appalachian 
Laryngeal 
n = 7614 (12.63%) 
Non-Appalachian 
Laryngeal 
n = 52682 (87.37%) 
  Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD 
Age (years) 63.05 ± 12.01 62.35 ± 12.22 61.99 ± 12.05 62.39 ± 12.24 64.83 ± 11.26 63.73 ± 11.10 64.99 ± 11.28 
  CRS ± SEM CRS ± SEM CRS ± SEM CRS ± SEM CRS ± SEM CRS ± SEM CRS ± SEM 
Relative Survival (%) 56.9 ± 0.2 55.0 ± 0.2 52.7 ± 0.7 55.3 ± 0.2 60.1 ± 0.4 58.1 ± 1.1 60.4 ± 0.4 
  n (%) n (%) n (%) n (%) n (%) n (%) n (%) 
Sex        
     Male 160,108 (74.5) 111,900 (72.4) 11,779 (72) 100,121 (72.5) 48,208 (80) 6,021 (79.1) 42,187 (80.1) 
     Female 54,713 (25.5) 42,625 (27.6) 4,587 (28) 38,038 (27.5) 12,088 (20) 1,593 (20.9) 10,495 (19.9) 
Race        
     White 183,029 (85.2) 132,955 (86) 15,049 (92) 117,906 (85.3) 50,074 (83) 6,892 (90.5) 43,182 (82) 
     Black 23,385 (10.9) 14,769 (9.6) 1,123 (6.9) 13,646 (9.9) 8,616 (14.3) 661 (8.7) 7,955 (15.1) 
     Other 8,407 (3.9) 6,801 (4.4) 194 (1.2) 6,607 (4.8) 1,606 (2.7) 61 (0.8) 1,545 (2.9) 
AJCC-6 Stage        
     I 40,356 (18.8) 21,555 (13.9) 2,431 (14.9) 19,124 (13.8) 18,801 (31.2) 2,271 (29.8) 16,530 (31.4) 
     II 23,202 (10.8) 14,622 (9.5) 1,666 (10.2) 12,956 (9.4) 8,580 (14.2) 1,136 (14.9) 7,444 (14.1) 
     III 28,895 (13.5) 19,498 (12.6) 2,208 (13.5) 17,290 (12.5) 9,397 (15.6) 1,332 (17.5) 8,065 (15.3) 
     IV 79,924 (37.2) 64,794 (41.9) 7,105 (43.4) 57,689 (41.8) 15,130 (25.1) 1,968 (25.8) 13,162 (25) 
     Missing 40,938 (19.1) 33,023 (21.4) 2,868 (17.5) 30,155 (21.8) 7,915 (13.1) 850 (11.2) 7,065 (13.4) 
Primary Site        
    Oral Cavity 55,620 (25.9) 55,620 (36) 6,028 (36.8) 49,592 (35.9) - - - 
    Oropharynx 81,174 (37.8) 81,174 (52.5) 8,551 (52.2) 72,623 (52.6) - - - 
    Other Pharynx 17,731 (8.3) 17,731 (11.5) 1,787 (10.9) 15,944 (11.5) - - - 
    Larynx 60,296 (28.1) - - - 60,296 (100) 7,614 (100) 52,682 (100) 
ARC Economy FY2017‡        
     Distressed 1,842 (0.9) 1,112 (0.7) 1,112 (6.8) - 730 (1.2) 730 (9.6) - 
     At-Risk 3,491 (1.6) 2,303 (1.5) 2,303 (14.1) - 1,188 (2) 1,188 (15.6) - 
     Transitional 15,935 (7.4) 11,022 (7.1) 11,022 (67.3) - 4,913 (8.1) 4,913 (64.5) - 
     Competitive 2,402 (1.1) 1,701 (1.1) 1,701 (10.4) - 701 (1.2) 701 (9.2) - 
     Attainment 310 (0.1) 228 (0.1) 228 (1.4) - 82 (0.1) 82 (1.1) - 
     Not Applicable 190,841 (88.8) 138,159 (89.4) - 138,159 (100) 52,682 (87.4) - 52,682 (100) 
† Includes data from Alabama, Alaska, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, 
Michigan, Mississippi, Montana, Nebraska, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Pennsylvania, Rhode Island, Seattle, South Carolina, Utah, West 
Virginia, Wisconsin, and Wyoming. 
‡ ARC County Economic Status designation for Appalachian counties[26] is categorized by Distressed (Worst 10% of U.S. Counties), At-Risk (Worst 10+ to 25% of U.S. Counties), 
Transitional (Worst 25% to Best 25% of U.S. Counties), Competitive (Best 10+ to 25% of U.S. Counties), and Attainment (Best 10% of U.S. Counties) based on National Index Value 
Rank which is indicated by Three-Year Average Unemployment Rate, Per Capita Market Income, and Poverty Rate. 
SD: standard deviation; SEM: standard error of the mean 
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Supplementary Figure S1. Survival analysis of Appalachian Stage IV laryngeal cancer. A. Flow diagram 
of procedures used to evaluate Appalachian-specific laryngeal cancer survival data. Boxes contain sequential 
operational steps utilized in the stratification and cohort analysis, noting no difference in survival within the cohort. 
B. Survival analysis of Appalachian laryngeal cancer stratified by clinical stage. RS values are plotted for each 
year after diagnosis, with five-year (60 month) ratios evaluated across all AJCC-6 stages. C and D. Survival 
analysis of white (C) and black (D) stage IV laryngeal cancer stratified by Appalachian residency and sex. RS 
values are plotted as in (B). P-values between significant groups are shown at the top of each graph; n.s., not 
significant; NA, not available. Black patients were evaluated for significance at 48 months due to incomplete 





Supplementary Figure S2. Survival analysis of Appalachian states with non-significant OC/P survival. A. 
States lacking disparate RS of stage IV white Appalachian male OC/P. Plotted RS values over time are shown 
for non-Appalachian states (black), and Appalachian states with non-significant (n.s.) survival. Patient N, five-
year CRS with 95% CI and P-values at 60 months for each significant Appalachian state are shown at the top of 
the graph. B. Map of Appalachian region displaying states with non-significant stage IV white Appalachian male 
OC/P survival. Colored states are non-significant, and significant states are in black; states with no available 







Supplementary Figure S3. Survival analysis of Appalachian states with non-significant OC/P survival. A-
D. Identification of states with disparate stage IV white Appalachian male HPV-associated oropharyngeal cancer 
survival. RS values were plotted for patients stratified as in Figure 3D for each OC/P disparity state. A, Alabama; 
B, Kentucky; C, Pennsylvania; D, West Virginia. Patient N, five-year CRS with 95% CI and P-values at 60 months 
for each Appalachian state are shown at the top of the graph; n.s., not significant. 
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Cigarette smoking is a risk factor for the development of head and neck squamous cell carcinoma (HNSCC), 
partially due to tobacco-induced large-scale chromosomal copy-number alterations (CNAs). Identifying CNAs 
caused by smoking is essential in determining how gene expression from such regions impact tumor progression 
and patient outcome. We utilized The Cancer Genome Atlas (TCGA) whole genome sequencing data for HNSCC 
to directly identify amplified or deleted genes correlating with smoking pack-year based on linear modeling. 
Internal cross-validation identified 35 CNAs that significantly correlated with patient smoking, independent of 
human papillomavirus (HPV) status. The most abundant CNAs were chromosome 11q13.3-q14.4 amplification 
and 9p23.1/9p24.1 deletion. Evaluation of patient amplicons reveals four different patterns of 11q13 gene 
amplification in HNSCC resulting from breakage-fusion-bridge (BFB) events responsible for SAES amplification. 
Predictive modeling identified 16 genes from these regions that denote poorer overall and disease-free survival 
with increased pack-year use, constituting a smoking-associated expression signature (SAES). Patients with 
altered expression of signature genes have increased risk of death and enhanced cervical lymph node 
involvement. The identified SAES can be utilized as a novel predictor of increased disease aggressiveness and 





HNSCC is an aggressive neoplasm of the upper aerodigestive tract caused by exposure to tobacco, alcohol, 
and high-risk HPV infection(1). Over 53 000 new cases and 11 000 deaths are predicted to occur in the U.S. due 
to HNSCC in 2020(2) with five-year post-treatment survival near 50%(3). Cervical nodal metastasis is frequently 
found in HNSCC, and is an important prognostic indicator associated with late stage (American Joint Committee 
on Cancer (AJCC) stage III/IV) disease in aggressive smoking-associated HPV-negative cancers(4,5).  
Widespread next-generation sequencing of HNSCC cohorts has identified driver mutations, common tumor 
suppressor/oncogenes, and molecular subtypes(6–9). Conclusions from this work indicate that HPV-positive 
tumors harbor fewer mutations and CNAs than HPV-negative cancer. This is congruent with HPV-positive 
patients exhibiting better overall survival, stratifying the disease into distinct prognostic subtypes(3,10). Over 
50% of HPV-negative patients present with stage IV disease, where tobacco-generated tumors contain high 
genomic instability, increased lymphovascular invasion, enhanced therapeutic resistance, poor prognosis and 
decreased time of survival(6,7,11–13). 
CNAs involved in HPV-negative HNSCC progression include gene gains (two extra copies), amplifications (more 
than two extra copies), loss of heterozygosity, and homozygous deletion of chromosomal segments(6,9,10,14). 
Widespread loss of chromosomal segments, along with concurrent frequency of mutations in tumor suppressor 
genes, supports the generalized concept that HNSCC is largely driven by genomic relief of tumor 
suppression(15). In addition, HPV-negative HNSCC is driven by overexpression of oncogenes in genomically 
amplified regions(16,17). Large-scale CNAs primarily arise through double-strand DNA breakage at fragile sites 
and subsequent telomeric loss(18). This initiates a BFB cycle through chromatid annealing, leading to uneven 
separation during mitosis and increased chromosome segment copy numbers(19). 
While smoking-driven genomic damage is well known in HNSCC(10,20), the precise CNAs correlated with 
smoking have not been previously defined. Here, we utilized an unbiased, internally-validated statistical 
approach with the TCGA-HNSC cohort to identify chromosomal homozygous deletions and amplifications in 
HNSCC that correlated with patient smoking. Currently, this is the only publicly available HNSCC cohort that 
contains necessary molecular and clinical parameters for patients suitable for such evaluation. Within this cohort, 
amplification of genes within chromosome 11q13.3-q13.4 and homozygous deletions of genes within 
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chromosome 9p21.3/9p24.1 were the only CNAs that correlated significantly with cigarette pack-year usage in 
an appreciable percentage of patients. A gene subset with altered transcript expression from these regions 
constitute a smoking-associated expression signature (SAES) predictive of patient pack-year use, corresponding 
with elevated risk of death and enhanced regional lymph node metastasis. Alignment-based mapping of patient 
11q13.3-q13.4 amplicons identifies underlying BFB scenarios responsible for amplified SAES genes. Collectively 
these results identify CNAs and corresponding genes in HNSCC that correlate positively with cigarette use, 
confirming known and identifying new oncogenic drivers that may serve as novel biomarkers and targets for 




Materials and Methods 
Samples and Clinical Data 
Data were obtained from the 2016_01_28 TCGA-HNSC cohort, downloaded from Broad Genomic Data Analysis 
Center (GDAC) Firehose(21), consisting of 529 patients with tumors of the oral cavity (n=320/529, 60.5%), 
pharynx (n=92/529, 17.4%), and larynx (n=117/529, 22.1%). The majority of patients were male (n=386/529, 
73%) and smoked (n=299/529, 56.5%), with mean 32.4 pack-years exposure. Patients were diagnosed from 
1992-2013 with a mean age of 60.7 years. 20 patients were excluded that lacked copy-number or smoking 
history. Clinical data were retrieved from the level 4 TCGA data file All_CDEs.txt and cBioPortal(22). Alcohol use 
was calculated by multiplying Alcohol Frequency and Daily Drinks. Patients with no pack-year data were 
excluded from pack-year correlations. Statistical significance was determined using chi-square test and 
Bonferroni correction or one-way ANOVA and Tukey’s post-hoc with an alpha of 0.05. 
Determination of Smoking-Associated CNAs 
Smoking-associated CNAs were determined by Genomic Identification of Significant Targets in Cancer 
(GISTIC)2(23) analysis of TCGA 2016_01_28 level 4 data for 24,776 genes(21). Briefly, raw GISTIC2 values 
within all_data_by_genex.txt were used for analysis. A linear regression model was used to assess the 
association between gene GISTIC2 value as a dependent variable and smoking in pack-years as an independent 
variable, adjusting for age, sex, and disease stage. For multiple testing, p-value sets were modeled using a beta-
uniform mixture model(24), permitting selection of p-value cutoffs bracketing the false discovery rate (FDR). 
Genes that reached statistical significance (100 maximum) in each analysis, or the top 100 genes if significance 
was not reached, were analyzed further. Prediction modeling was validated using multiple methods. First, the 
dataset was randomly separated into training and validation sets, each containing 50% of patients. Second, the 
Leave-One-Out cross validation (LOOCV) method was used(25). For each gene in each method, a linear 
regression model was fit using pack-year value as the explanatory variable, and gene GISTIC2 value as the 
response using half of all samples (50%), or all but one sample (LOOCV). The fitted models were used to 
examine the accuracy of the remaining samples. Predictive capabilities were evaluated through concordance, 
sensitivity, and specificity after performed for each gene. Third, the “stability selection” method was used to 
assess the prediction for each gene, which combines the techniques of sub-sampling and randomized Lasso 
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algorithms(26). Validated genes were combined by cytogenetic sub-sub band (cytoband). Cytobands altered in 
fewer than 10% of patients and those dependent on HPV-status were excluded. Predicted CNA probabilities 
were graphed based on the fitted model, with data sorted by ascending pack-year. In the time-to-event analysis, 
survival functions by amplified genes (yes/no) were assessed by Kaplan-Meier and log-rank testing for overall 
and progression-free survival.  
Evaluation of Common Mutations 
Patient individual gene mutations and Total Mutations were obtained from TCGA-HNSC 2016_01_28 level 3 
Mutation Packager Raw Calls and the cBioPortal “Mutated Genes” analysis(21,22). Data were stratified by 
smoking and CNA status. Smoking status was divided into “Never Smoker” (pack-year=0), “Ever Smoker” (pack-
year>0), “Heavy Smoker” (pack-year>10), “Light Smoker” (0<pack-year≤10) and “Low Risk” (pack-year≤10), 
similar to other reports(27). 
Determination of the Smoking-associated Expression Signature 
Expression levels of genes identified from the CNA analysis were determined using the TCGA-HNSC 
2016_01_28 level 3 RNAseq gene expression dataset(21). Analysis was conducted using z-scores calculated 
from reads per kilobase of transcript, per million reads (RPKM) in normal adjacent tissues as baseline. Gene 
expression for overall survival was assessed by comparing the first quartile (lowest 25%) of expression to the 
fourth quartile (highest 25%) of expression levels. Genes where differential expression significantly affected 
overall survival were combined to create the SAES. A linear regression model was used to assess the 
association between the z-score as a dependent variable and smoking pack-year as an independent variable. 
LOOCV validation was performed as described. The predicted SAES gene expression probability is based on 
the fitted model, with patients sorted by ascending pack-year. For correlative analysis between lymph node 
(yes/no) and gene overexpression (z-score>2) or underexpression (z-score<-2), odds ratios and the 95% 
confidence intervals (CI) for each gene was estimated from a fitted logistic model. Time-to-event survival 
functions were assessed using the Kaplan-Meier and log-rank testing for overall and progression-free survival 
(yes/no for overexpression). Cox models were used to assess the association between SAES genes and 
survival. Estimated relative risk of death was presented graphically based on the fitted model where the data 
were sorted by standardized SAES expression. 
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Amplicon Alignment and Segment Determination 
Thresholded GISTIC2.0 CNA values were downloaded from the GDAC Firehose(21). Values were sorted and 
aligned in relation to the total length of the entire 11q13 chromosomal segment and flanking regions. Amplicon 
segments were derived from previous mapping studies(28–31), aided by natural breaks in the alignment data 
across cohort patients with 11q13 amplified genes. SAES gene positions were aligned using the University of 





Cigarette Smoking Correlates with Specific Copy Number Alterations In HNSCC  
To identify smoking-associated CNAs in HNSCC, CNAs containing amplified and deleted genes were extracted 
and independently evaluated for correlation with pack-year (Fig. 1A) (Supplementary Table S2). 1 775 amplified 
genes were identified that correlated significantly, mapping to 92 cytobands (Fig. 1A). To assess HPV-status as 
a potential confounding variable, identified genes were correlated with confirmed HPV-status. None of the 92 
amplified cytobands exclusively correlated with HPV-positive tumors, whereas 17 cytobands showed selective 
correlation to HPV-negative tumors. The remaining two cytobands were amplified independent of HPV-status 
and further evaluated (Fig. 1B). As expected, smokers were more commonly HPV-negative than non-smokers 
(Supplementary Table S1). 
Of the amplified genes that correlated with pack-year, genes located on chromosome 11q13.3 (n=20) and 
11q13.4 (n=10) were from the only cytobands amplified independent of HPV status and in at least 10% of patients 
with pack-year data (Fig. 1C). This region contains the chromosomal fragile sites (CFSs) FRA11H and FRA11F 
and is flanked by two segmental duplications (SDs)(28–31,33–35). 11q13.3 amplification is significantly enriched 
in patients that smoked (85.6%) compared to non-smokers (65.1%) (Fig. 1D). Patients with any 11q13.3 gene 
amplification had a 36.3-month median overall survival and a 38.4% five-year overall survival rate, whereas non-
amplified patients had a 65.7-month median overall survival and a 51.8% five-year overall survival rate (Fig. 1E). 
Disease-free survival for 11q13.3 amplified patients trended lower but failed to reach significance (Fig. 1F). 
Similarly, 11q13.4 amplified patients were significantly enriched for smokers (87.5%) compared to non-smokers 
(66.2%) (Fig. 1G). Patients with 11q13.4 gene amplification showed lower overall and progression-free survival, 
with a 26.8-month median overall survival, and 34.0% five-year overall survival rate. Non-amplified patients had 
a 65.7-month median overall survival and 50.4% five-year overall survival rate (Fig. 1H). Five-year disease-free 
survival for 11q13.4 amplified individuals was 38.4% compared with 56.5% in non-amplified cases (Fig. 1I). The 
majority of patients with 11q13.3 gene amplification also had 11q13.4 gene amplification (73.4%), consistent 
with the cytobands being contiguous. Due to lack of suitable external validation sets, multiple internal validation 
methods were used. Separating the dataset into training and validation sets for analysis demonstrated a high 
specificity (>95%) and concordance (>73.8%). LOOCV analysis on each significant gene also demonstrated 
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high specificity (>97.4%) and concordance (>74%). This unbiased approach independently confirms that 
amplification of genes within chromosome 11q13.3-q13.4 correspond with this region being the most frequent 
CNA in HNSCC(6,16), and that 11q13.3-q13.4 gene amplification correlates with cigarette use and poor HNSCC 
outcome as suggested in previous work(6,16). 
In addition, our analysis identified five cytobands that correlated with homozygous deletion and pack-year (Fig. 
2A). After evaluating by HPV-status as in Figure 1B, five genes from these cytobands were found to be deleted 
independent of HPV (Fig. 2B). One gene mapped to cytoband 9p24.1 and four genes mapped to cytoband 
9p21.3 (Fig. 2C). This region contains an unnamed CFS (9CFS) and the CFS FRA9C, promoting chromosome 
breakage and gene deletion(36). Deletion of 9p21.3 was enriched for smokers (80.4%) compared to non-
smokers (66.2%) (Fig. 2D). Patients with any 9p21.3 gene deletion had a 35.9-month median overall survival 
and a 38.5% five-year overall survival rate, whereas non-deleted patients had a 66.7-month median overall 
survival and a 51.2% five-year overall survival rate (Fig. 2E). Disease-free survival for 9p21.3 deleted patients 
failed to reach significance (Fig. 2F). Deletion of cytoband 9p24.1 was not enriched for smokers (Fig. 2G) and 
no difference in overall (Fig. 2H) or disease-free survival (Fig. 2I) was observed. Training and validation analysis 
demonstrated high specificity (>98%) and concordance (>69.5%). 
The Majority of Smoking-associated Amplified Genes are Contained Within the Most Frequently 
Amplified 11q13 Segment in HNSCC.  
The worse outcomes and higher clinical risk parameters associated with genes in 11q13.3.-11q13.4, combined 
with the variation in amplicon lengths led us to determine the underlying 11q13 amplification mechanisms. 87% 
of 11q13 amplified patients had distal 11q loss, suggesting BFB as the predominant amplification mechanism. 
Chromosomal alignment and clustering of all 11q13.3-q13.4-amplified patients from the TCGA-HNSC cohort 
identified three distinct alignment patterns of amplified regions, grouped as segments 1, 2 and 3 (Fig. 3A). All or 
part of the segment 2 region is present in every patient with 11q13.3-q13.4 amplification. Based on segment 
distribution and the FRA11H and FRA11F, four possible BFB scenarios account for all observed 11q13 
amplification patterns in HNSCC (Fig. 3B). Scenario 1 occurs in 17% of patients, where the first break occurs at 
the telomeric end of FRA11H before Segment 3 to delete this region. This results in sister chromatid end fusion 
at segment 2. A subsequent second break at FRA11H between segment 1 and segment 2 results in inverted 
segment 1 loss, repeated through subsequent rounds of BFB to increase amplicon number (Fig. 3). Additional 
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scenarios (2-4) involving breakage at different FRA11H sites, FRA11F, or other combinations also occur at lower 
frequencies than scenario 1 (Fig. 3B). 13% of amplified patients have intact 11q telomeres, indicating that SD-
mediated amplification occurs at lower frequency. Regardless, the resulting segment 2 region in all amplification 
events contains the 11q13.4-q13.4 chromosomal region that harbors the majority of identified smoking-
associated genes (Fig. 1C). 
Smoking-associated Copy-number Alteration Corresponds with Elevated Risk Factor Exposure 
Patients with smoking-associated CNAs stratified by cytoband and smoking status were evaluated for clinical 
characteristics and additional HNSCC risk factors across the cohort (Supplementary Table S1). All patients with 
11q13.3-q13.4 amplification (Total Amplified) had significantly higher mean pack-year usage than patients 
lacking amplification (Total Non-Amplified) (46.6 vs. 27.1). The majority of 11q13.3-q13.4 Amplified Smokers 
were male with stage IV disease, had positive lymph node involvement, higher alcohol consumption, higher 
pack-year and were HPV-negative. In addition, the majority of 9p21.3/9p24.1 Deleted Smokers were male with 
stage IV disease, had positive lymph node involvement, and were HPV-negative. 
Differences in the Mutational Profile of Commonly Altered HNSCC Driver Genes in Smoking-associated 
Copy-number Altered HNSCC 
Tobacco-associated HNSCC demonstrates characteristic mutational signatures that result in oncogene 
activation or loss of tumor suppression(6,37). Since 11q13.3-q13.4 amplification and 9p21.3 deletion occurs in 
a greater percentage of cigarette-smoking patients, we examined the mutational occurrence of the most 
frequently altered HNSCC genes in patients that smoked and contained these CNAs (Table 1). The top ten most 
commonly mutated cancer-related HNSCC genes were evaluated(6). When stratified by smoking status, the 
mutation rates of LRP1B (19.6% smokers; 8.2% non-smokers), NSD1 (14.2% smokers; 4.1% non-smokers) and 
CASP8 (8.3% smokers; 16.4% non-smokers) differed significantly. Smoking was also associated with 11q13.3, 
11q13.4 and 9p21.3 gene CNA. Interestingly, the mutation rate difference of TP53, the most commonly mutated 
gene in HNSCC(6,9), did not differ significantly by smoking status (71.1% smokers; 63.9% non-smokers) when 
defining smokers as patients with an above zero pack-year or with a reported smoking history (Table 1, 
Supplementary Table S3). When patients were stratified by 11q13.3-q13.4 amplification, the mutation rates of 
CASP8 (2.2% amplified; 13.1% non-amplified), KMT2D (0.7% amplified; 15% non-amplified), NOTCH1 (16.2% 
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amplified; 17.4% non-amplified), NSD1 (6.7% amplified; 13.7% non-amplified), PCLO (19.1% amplified; 14.2% 
non-amplified), and TP53 (83.8% amplified; 64.1% non-amplified) were significantly different. 11q13.3-q13.4 
amplification was also significantly associated with 9p21.3 deletion. When patients were stratified by 
9p21.3/9p24.1 deletion, the mutation rates of NOTCH1 (23% deleted; 13.5% non-deleted) and TP53 (76.4% 
deleted; 65.1% non-deleted) were significantly different. 9p21.3/9p24.1 deletion was also significantly associated 
with 11q13.3-q13.4 amplification. CDKN2A mutation rate was also significantly different (8.9% deleted; 29.2% 
non-deleted); however, CDKN2A is located in the deleted 9p21.3 region. All other evaluated gene mutation rates 
were not significantly different across the cohort, regardless of smoking or CNA status. 
Identification of the Smoking-associated Expression Signature in HNSCC Patients with Smoking-
associated CNAs 
To determine the expression of actionable drivers in smoking-associated CNAs, mRNA expression was analyzed 
for each cross-validated gene. Inclusion criteria were restricted to patients with full mRNA sequencing data and 
RPKM values for each gene, known copy-number status and smoking history. 260 patients contained suitable 
RNAseq data for analysis (Figure 4A); nine non-protein coding genes in the 11q13.3-q13.4 region (DEFB108B, 
MIR3164, MIR548K, ENPP7P8, ZNF705E, UNC93B6, FAM86C1, MIR3664, and RNA5SP342) did not have 
reported RPKM values and could not be analyzed. The remaining genes were assessed for expression 
differences between patients with CNAs and euploid patients. Patients with CNAs had significantly higher 
percentages of overexpression or underexpression of most genes (Figure 4B). Genes from this group with 
expression differences that significantly decreased overall survival were combined to generate a HNSCC CNA-
based SAES (Fig. 4C). Ten genes did not alter overall survival based on expression and were summarily 
excluded (Supplementary Table S4, Supplementary Figure S1). Patients with overexpression or 
underexpression of one SAES gene demonstrated lower overall survival (Fig. 4D), where patients with 
overexpression or underexpression of at least three SAES genes also had significantly worse progression-free 
survival (Fig. 4E). The impact of SAES gene expression on survival was additive, with decreased survival 
observed in patients with increasing numbers of SAES genes (Fig. 4D and E, Supplementary Figure S2). 
Multivariate analysis with age, sex, AJCC stage, HPV status, extracapsular spread, perineural invasion, and 
lymphovascular invasion confirmed overexpression of ANO1, CCND1, CTTN, FADD, MRPL21, and TPCN2 as 
independent predictors of overall survival in the SAES (Supplementary Table S5). 
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Increased Cigarette Smoking Predicts Smoking-associated CNAs and the Smoking Expression 
Signature 
We evaluated patient pack-year data with smoking-associated gene CNA to determine if it could be used to 
determine CNA risk. Each gene was fit into a linear regression model, with pack-year as the explanatory variable 
and gene amplification for the response of one testing sample. This was used to determine the probability of 
CNA for each gene (Supplementary Table S6). Significant genes were combined to create average curves for 
log odds changes with smoking pack-year and the log odds of gene CNA in non-smokers across all genes, using 
parameter averages for linear regression models for each gene (Fig. 5A). A parallel analysis was utilized based 
on the gene RPKM values in the SAES with smoking pack-year to generate regression curves for overexpressed 
or underexpressed genes mapping to SAES regions (Fig. 5B). Only genes mapping to 11q13.3-q13.4 were 
significant for both analyses (Supplementary Table S7). Mean gene amplification and overexpression levels 
were predicted to increase with increasing pack-year value, correlating increased smoking levels with higher risk 
of 11q13.3-q13.4 amplification and SAES transcript overexpression in HNSCC.  
Smoking-associated Expression Signature Genes Predict Increased Risk of Death and Cervical Lymph 
Node Metastasis 
Since regional cervical lymph node metastasis in HNSCC is the primary clinical parameter for poor clinical 
outcome(38,39), we determined the relative risk of death and lymph node involvement in HNSCC patients with 
the SAES. All patients in the TCGA-HNSC cohort were evaluated regardless of smoking status to compensate 
for the presence of SAES in patients using other tobacco forms that can potentially result in tobacco-
associated CNA(40). For each SAES gene, a positive correlation was observed between risk of death and 
standardized expression (Fig. 5C, Supplementary Figure S3). Overexpression of an eight-gene SAES subset 
predicted significantly an increased odds of lymph node metastasis, (Fig. 5D), identifying specific SAES genes 





Genes mapping to the amplified 11q13.3-q13.4 cytobands and the deleted 9p21.3 and 9p24.1 cytobands were 
the only CNAs that correlated with pack-year in a significant number of HNSCC patients in this cohort. Patients 
with smoking-associated CNAs have worse overall survival, smoked more, were predominantly male, and HPV-
negative. Correlation analysis of transcript expression of smoking-associated CNA genes identified an 
expression subset associated with poor outcome and nodal involvement. Increased CNA risk and transcript over- 
or underexpression are associated with elevated patient smoking levels, identifying a novel gene group that can 
be used for improved screening and target investigation for treatment of late stage HNSCC patients with smoking 
histories. 
Correlation of clinical parameters with molecular markers from comprehensive genomic analyses has emerged 
as a powerful tool for prognostic analysis in cancer medicine(41,42). Integrated analysis of TCGA and other non-
public HNSCC molecular cohorts have identified genomic and mutational patterns that have been instrumental 
in determining prognostic aspects of HPV involvement, molecular subtyping and mutational status associated 
with different HNSCC medical aspects(6,7,43–45). Many CNAs identified in these studies have been previously 
noted in HNSCC and proposedly due to tobacco-induced genomic instability(6,16,37). In addition, our analysis 
identified other smoking-associated CNAs that reached significance in an HPV-dependent manner (Figures 1B 
and 2B). Of these, genes mapping to amplified 3q23-q29 (SOX2/TP63/PIK3CA), deleted 2q22.1 (LRP1B) and 
8p23.2 (CSMD1) have been previously noted to be amplified or deleted in HNSCC(46–48), supporting the 
utilized correlation methodology. 
Although recent sequencing work supports near-mutual exclusion between tobacco-induced, HPV-negative 
tumors with tobacco-associated CNAs and HPV-positive tumors lacking tobacco-associated CNAs(6,37,49–51), 
other studies report smoking-associated CNAs present in HPV-positive patients, although at lower levels than 
HPV-negative cancers(52). HPV-positive patients with smoking histories have progressively worse outcomes 
corresponding with elevated pack year(53). Such patients would have an increased likelihood of smoking-
associated CNAs and thus manifestation of the SAES in HPV-positive tumors, supporting the observed lack of 
HPV-positivity with smoking and smoking-associated CNAs revealed in this study. 
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The tobacco-associated CNAs have been well documented to negatively impact patient prognosis and have 
been an area of intense study for several decades(54–60). Tobacco-associated CNAs can occur early in 
malignant development and throughout dysplastic progression to invasive carcinoma(54). Initial TCGA analysis 
indicated that smoking-associated CNAs corresponded with TP53 mutation and worse outcome in HPV-negative 
patients(6). Consistent with this, we found higher TP53 mutation and smoking-associated CNA frequency, but 
note that TP53 mutational status is independent of patient smoking history using a univariate approach 
(Supplementary Table S1). While this contrasts with previous work linking TP53 mutation with cigarette smoking 
in HNSCC(61), it is consistent with the TCGA-HNSC Clinical vs. Mutation Level 4 D1V10 analysis, showing no 
relationship between TP53 status and pack-year(6,21). This may be due to varying cutoffs of pack-year usage 
(Supplementary Table S3). Regardless, there is clear evidence that smoking leads to TP53 mutation and 
increases DNA damage through continued cigarette use(62,63). Mutated TP53 unable to properly surveil and/or 
repair double-strand DNA breaks will lead to increased instability during replicative stress(28,64). Distal 11q loss 
and deletion of the ATM DNA damage repair gene is frequent in 11q13 amplified HNSCC(16,18,65). Telomeric 
11q loss is also associated with 11q22 co-amplification in 11q13-amplified HNSCC, with cooperativity between 
genes proposed as a selective pressure for co-amplification(6). We note that co-amplification of these regions 
in the TCGA cohort occurs at low frequency (3.6%) and that 11q22 gene amplification does not correlate with 
smoking. 11q13/11q22 co-amplification may therefore be driven by other factors that promote DNA breakage 
near the chromosome 11q telomere.  
11q13 amplicon sizes vary from 0.65Mb to over 5Mb(34). Amplicon alignment allows for identification of 
conserved amplification patterns, providing insight into smoking-induced genomic damage. Segment alignment 
with FRA11H and FRA11F indicate that 11q13.3-q13.4 SAES genes cluster within segment 2. This is similar to 
previous 11q13 amplicon gene alignments in HNSCC, breast and other cancers(16,66,67). Harmonizing with 
these designations, the previously established core 1 alignment corresponds with segment 1, core 2 with 
segment 2, and cores 3 and 4 with segment 3(67). Over half of 11q13-amplified HNSCC patients exhibit the 
scenario 1 event involving successive breakage at FRA11F and FRA11H (Fig. 4B). Increased fragile site 
breakage involving FRA11F and FRA11H in BFB formation has been previously proposed as a tobacco-
mediated mechanism utilized in 11q13 amplification(19,31,68), collectively suggesting that progressive breakage 
at these sites is preferentially favored during the scenario 1 BFB cycle. Irrespective of the amplification scenario, 
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segment 2 amplification levels and subsequent SAES gene expression is predicted to increase with elevated 
smoking rates, consistent with tobacco-induced fragile site involvement in generating SAES gene amplification. 
Simultaneous 11q13 amplicon gene overexpression implies cooperativity between gene products impacting 
multiple cancer hallmarks to maintain and enhance the neoplastic phenotype. Previous work on 11q13 amplicon 
genes has proposed that the cell cycle regulator CCND1, actin cytoskeletal protein CTTN and apoptosis scaffold 
FADD function as the primary 11q13 amplicon drivers in HNSCC, since amplification and overexpression of each 
of these genes accelerates patient mortality(54,56). These genes are included in the SAES and were validated 
as independent predictors of overall survival, underscoring their importance in promoting the poor outcomes 
observed in 11q13-amplified HNSCC cohorts(50,69). Additional amplified SAES genes with known roles in 
HNSCC include the ORAOV1/LTO1(70), PPFIA1(71), ANO1(72) and FGF19(73). Functions of the remaining 
SAES genes in HNSCC are largely unknown, warranting future investigation to determine their respective 
contributions in 11q13-amplified HNSCC. 
CCND1 and CTTN amplification and overexpression corresponds with increased lymph node involvement in 
numerous cohorts, suggesting their use as biomarkers of aggressive disease(74,75). These genes predict 
increased metastatic lymph node risk (Fig 5D). Importantly, CCND1 had the highest lymph node metastatic odds 
ratio in our study, congruent with overexpression utilized as a biomarker for increased metastatic risk(76). Apart 
from CTTN, the remaining SAES with significantly higher lymph node risk remain to be evaluated as independent 
markers of lymph node involvement and/or investigated as novel targets in aggressive disease. The importance 
of understanding how 11q13 amplification and resultant gene overexpression contributes to poor outcome in 
smoking-induced HNSCC is further underscored by increased resistance to chemotherapy and epidermal growth 
factor receptor targeting in 11q13-amplified HNSCC(77–79). This highlights a persistent need for earlier and 
precise diagnosis for patients with SAES CNA and expression status to provide improved clinical management 
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Figure 1. 11q13.3 and 11q13.4 amplification in HNSCC is correlated with genomic instability resultant 
from smoking. A. Schematic depicting experimental determination of smoking correlated CNAs from the TCGA-
HNSC dataset containing 509 patients with CNA and pack-year data. B. Segregation of smoking correlated 
CNAs based on HPV-status. CNAs independent of HPV are denoted in the center of the diagram. C. 
Diagrammatic representation of chromosome 11 with location of significantly smoking-associated amplified 
11q13.3-q13.4 genes. Fragile sites FRA(11H), FRA(11F), and SDs are shown at their respective locations. Loci 
position and size are drawn to scale based on coordinates from the UCSC Genome Browser. D. Waterfall plot 
showing patient pack-year distribution stratified by 11q13.3 cytoband amplification status. E-F. Overall (E) and 
disease-free (F) survival analysis of patients with 11q13.3 amplification. G. Waterfall plot showing patient pack-
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year distribution stratified by 11q13.4 amplification status. H-I. Overall (H) and disease-free (I) survival analysis 
of patients with amplification of 11q13.4. 
 
Figure 2. 9p21.3 and 9p24.1 deletion in HNSCC is correlated with patient smoking status. A. Schematic 
depicting experimental determination of smoking correlated deletions from the TCGA-HNSC dataset. B. Smoking 
correlated homozygous deletions grouped by HPV-status. CNAs independent of HPV are in the center of the 
diagram. C. Diagrammatic representation of chromosome 9 with location of significantly smoking-associated 
deleted 9p21.3 and 9p24.1 genes. Fragile site FRA(9C) and the unnamed CRS (9CRS) are shown. Loci position 
and size are drawn to scale based on coordinates from UCSC Genome Browser. D. Waterfall plot showing 
patient pack-year distribution stratified by 9p21.3 cytoband deletion status. E-F. Overall (E) and disease-free (F) 
survival analysis of patients with 9p21.3 amplification. G. Waterfall plot showing patient pack-year distribution 
115 
 
stratified by 9p24.1 deletion status. H-I. Overall (H) and disease-free (I) Kaplan-Meier survival analysis of patients 
with amplification of 9p24.1. 
 
Figure 3. 11q13 Amplification Patterns Identify a Distinct Chromosomal Segment Containing Smoking 
Overexpression Signature Genes in HNSCC. A. Heat map displaying all 11q13 amplified HNSCC patients 
aligned by amplicon frequency and size. Patient genomic status was categorized by amplification (>2 extra 
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copies; dark red), gene gain (2 extra copies; light red), heterozygous deletion (light blue), and homozygous 
deletion (dark blue). Fragile sites 11H (FRA11H; orange) and 11F (FRA11F; purple) and segmental duplications 
(SD; magenta) with respective genomic location and approximate coordinates are displayed at the top and on 
the left. Corresponding chromosome 11q cytoband positions are located on the right. Patients are grouped by 
decreasing amplicon length, with conserved breakage coordinates indicated by segment position. Segment 1 
(red); segment 2 (blue); segment 3 (green) are noted with their respective estimated chromosomal ranges. B. 
Frequency of 11q13 amplification scenarios in HNSCC. BFB cycles illustrate each possible amplification event 
based on chromosomal alignment and frequency of occurrence in the TCGA-HNSC cohort. Fragile site, SD, and 
amplicon segment locations are color-coded as in (A). 
 
Figure 4. Smoking-associated gene expression identifies a transcriptional signature that negatively 
impacts HNSCC outcome. A. Schematic diagram showing experimental determination of the SAES from the 
TCGA-HNSC dataset. 260 patients with full mRNA sequencing and pack-year data were evaluated as indicated. 
B. Percentage of patients overexpressed and amplified (red), underexpressed and deleted (blue) compared to 
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patients that are over- or underexpressed that lack a CNA (black) for each SAES gene. C. Genes with overall 
survival differences between the first and fourth quartile of transcript expression. The list constitutes the SAES 
in HNSCC. D-E. Overall (D) and disease-free (E) survival analysis of all patients harboring genes from the SAES. 
Black lines in each graph represent patients with no positive SAES genes, red line represents patients with one 
positive SAES gene. Light gray lines represent the additive range of patients with multiple positive SAES genes.  
 
Figure 5. Predictive modeling and odds analysis of smoking-associated 11q13 genes in HNSCC survival 
and lymph node metastasis. A-B. Probability analysis of 11q13.3-q13.4 gene (MTL5, MRPL21, TPCN2, 
CCND1, ORAOV1, FGF19, ANO1, FADD, PPFIA1, CTTN, SHANK2, DHCR7, and RNF121) amplification (A) 
and 11q13.3-q13.4 SAES gene (CCND1, CTTN, FADD, FGF19, MRPL21, MTL5, ORAOV1, PPFIA1, SHANK2, 
and DHCR7) overexpression (B) in patients with increasing pack-year use. 95% confidence interval (95% CI) 
shown in shaded regions. C. Relative risk of death for overexpressed 11q13.3-q13.4 SAES genes (positive 
slope) and underexpression of 9p21.3 and 9p24.1 SAES genes (negative slope). Left vertical dashed line 
represents a z-score of -2 (underexpressed). Right vertical dashed line represents a z-score of 2 
(overexpressed). Horizontal dashed line represents a relative risk of 1. D. Odds ratio analysis of SAES genes 
significant for lymph node metastasis due to 11q13.3-q13.4 overexpression. Total patients with lymph node 
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metastasis (LN) and total patients with overexpression (OX) are shown for each gene with the corresponding 
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Total CNA (Amp.) 333.8 ± 436.6 359.7 ± 459.3 251.5 ± 344.4 528.7 ± 475.3 * 541.3 ± 495.5 ‡ 434.1 ± 272.1 262.7 ± 399.3 * 278.1 ± 417.9 ‡ 224 ± 346.8
Total CNA (Del.) 97.27 ± 242 89.74 ± 202.6 121.1 ± 338 104.3 ± 218.2 97.22 ± 199.4 157 ± 331.1 94.72 ± 250.4 86.39 ± 204.3 115.7 ± 340.3
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  CDKN2A 110 (21.6) 78 (20.2) 32 (26.2) 29 (21.3) 23 (19.2) 6 (37.5) 81 (21.7) 55 (20.6) 26 (24.5)
  FAT1 112 (22) 89 (23) 23 (18.9) 22 (16.2) 21 (17.5) 1 (6.3) 90 (24.1) 68 (25.5) 22 (20.8)
  KMT2D 57 (11.2) 41 (10.6) 16 (13.1) 1 (0.7) * 0 (0) †‡ 1 (6.3) † 56 (15) * 41 (15.4) ‡ 15 (14.2)
  LRP1B 86 (16.9) 76 (19.6) * 10 (8.2) * 25 (18.4) 25 (20.8) † 0 (0) † 61 (16.4) 51 (19.1) † 10 (9.4) †
  NOTCH1 87 (17.1) 70 (18.1) 17 (13.9) 22 (16.2) * 19 (15.8) 3 (18.8) 65 (17.4) * 51 (19.1) 14 (13.2)
  NSD1 60 (11.8) 55 (14.2) * 5 (4.1) * 9 (6.6) * 9 (7.5) ‡ 0 (0) 51 (13.7) * 46 (17.2) †‡ 5 (4.7) †
  PCLO 79 (15.5) 66 (17.1) 13 (10.7) 26 (19.1) * 23 (19.2) 3 (18.8) 53 (14.2) * 43 (16.1) 10 (9.4)
  PIK3CA 88 (17.3) 71 (18.3) 17 (13.9) 20 (14.7) 17 (14.2) 3 (18.8) 68 (18.2) 54 (20.2) 14 (13.2)
  TP53 353 (69.4) 275 (71.1) 78 (63.9) 114 (83.8) * 102 (85) ‡ 12 (75) 239 (64.1) * 173 (64.8) ‡ 66 (62.3)
CNA  n (%)  n (%)  n (%)  n (%)  n (%)  n (%)  n (%)  n (%)  n (%)
  11q13.3 (Amp.) 135 (26.5) 119 (30.7) * 16 (13.1) * 135 (99.3) * 119 (99.2) ‡ 16 (100) ‡ 0 (0) * 0 (0) ‡ 0 (0) ‡
  11q13.4 (Amp.) 103 (20.2) 93 (24) * 10 (8.2) * 103 (75.7) * 93 (77.5) ‡ 10 (62.5) ‡ 0 (0) * 0 (0) ‡ 0 (0) ‡
  11q13.3 and 11q13.4 (Amp.)102 (20) 92 (23.8) * 10 (8.2) * 102 (75) * 92 (76.7) ‡ 10 (62.5) ‡ 0 (0) * 0 (0) ‡ 0 (0)
  9q21.3 (Del.) 164 (32.2) 139 (35.9) * 25 (20.5) * 65 (47.8) * 60 (50) ‡ 5 (31.3) 99 (26.5) * 79 (29.6) †‡ 20 (18.9) †‡
  9p24.1 (Del.) 55 (10.8) 40 (10.3) 15 (12.3) 16 (11.8) 15 (12.5) 1 (6.3) 39 (10.5) 25 (9.4) 14 (13.2)
  9q21.3 and 9q24.1 (Del.) 28 (5.5) 22 (5.7) 6 (4.9) 10 (7.4) 10 (8.3) 0 (0) 18 (4.8) 12 (4.5) 6 (5.7)
Chr9 Deletion Genomic 
Alterations
Total
n = 509 (100%)
Smokers
n = 387 (100%)
Non-Smokers
n = 122 (100%)
Total Deleted
n = 191 (100%)
Deleted Smokers
n = 157 (100%)
Deleted Non-
Smokers
n = 34 (100%)
Total Non-
Deleted
n = 318 (100%)
Non-Deleted 
Smokers
n = 230 (100%)
Non-Deleted 
Non-Smokers
n = 88 (100%)
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Total SNA 149.9 ± 190.2 154.9 ± 141.8 134.4 ± 294.8 149.8 ± 137.4 155 ± 146.3 125.3 ± 81.85 150 ± 216.2 154.7 ± 138.9 137.9 ± 343.6
Total CNA (Amp.) 333.8 ± 436.6 359.7 ± 459.3 251.5 ± 344.4 388.4 ± 508.3 406.7 ± 519.4 304.2 ± 451 300.9 ± 384.4 327.6 ± 411.3 231.2 ± 293.9
Total CNA (Del.) 97.27 ± 242 89.74 ± 202.6 121.1 ± 338 120.8 ± 202.9 110.5 ± 193.3 168.7 ± 240 83.1 ± 262 75.6 ± 207.9 102.7 ± 368.6
SNA  n (%)  n (%)  n (%)  n (%)  n (%)  n (%)  n (%)  n (%)  n (%)
  CASP8 52 (10.2) 32 (8.3) * 20 (16.4) * 22 (11.5) 12 (7.6) † 10 (29.4) †‡ 30 (9.4) 20 (8.7) 10 (11.4) ‡
  CDKN2A 110 (21.6) 78 (20.2) 32 (26.2) 17 (8.9) * 12 (7.6) ‡ 5 (14.7) 93 (29.2) * 66 (28.7) ‡ 27 (30.7)
  FAT1 112 (22) 89 (23) 23 (18.9) 46 (24.1) 32 (20.4) † 14 (41.2) †‡ 66 (20.8) 57 (24.8) † 9 (10.2) †‡
  KMT2D 81 (15.9) 65 (16.8) 16 (13.1) 33 (17.3) 29 (18.5) 4 (11.8) 48 (15.1) 36 (15.7) 12 (13.6)
  LRP1B 86 (16.9) 76 (19.6) * 10 (8.2) * 31 (16.2) 28 (17.8) 3 (8.8) 55 (17.3) 48 (20.9) † 7 (8) †
  NOTCH1 87 (17.1) 70 (18.1) 17 (13.9) 44 (23) * 37 (23.6) ‡ 7 (20.6) 43 (13.5) * 33 (14.3) ‡ 10 (11.4)
  NSD1 60 (11.8) 55 (14.2) * 5 (4.1) * 22 (11.5) 21 (13.4) 1 (2.9) 38 (11.9) 34 (14.8) † 4 (4.5) †
  PCLO 79 (15.5) 66 (17.1) 13 (10.7) 28 (14.7) 25 (15.9) 3 (8.8) 51 (16) 41 (17.8) 10 (11.4)
  PIK3CA 88 (17.3) 71 (18.3) 17 (13.9) 25 (13.1) 19 (12.1) ‡ 6 (17.6) 63 (19.8) 52 (22.6) † 11 (12.5) †
  TP53 353 (69.4) 275 (71.1) 78 (63.9) 146 (76.4) * 127 (80.9) †‡ 19 (55.9) † 207 (65.1) * 148 (64.3) ‡ 59 (67)
CNA  n (%)  n (%)  n (%)  n (%)  n (%)  n (%)  n (%)  n (%)  n (%)
  11q13.3 (Amp.) 135 (26.5) 119 (30.7) * 16 (13.1) * 70 (36.6) * 64 (40.8) †‡ 6 (17.6) † 65 (20.4) * 55 (23.9) †‡ 10 (11.4)
  11q13.4 (Amp.) 103 (20.2) 93 (24) * 10 (8.2) * 52 (27.2) * 48 (30.6) †‡ 4 (11.8) † 51 (16) * 45 (19.6) †‡ 6 (6.8)
  11q13.3 and 11q13.4 (Amp.)102 (20) 92 (23.8) * 10 (8.2) * 51 (26.7) * 47 (29.9) †‡ 4 (11.8) † 51 (16) * 45 (19.6) †‡ 6 (6.8)
  9q21.3 (Del.) 164 (32.2) 139 (35.9) * 25 (20.5) * 164 (85.9) * 139 (88.5) †‡ 25 (73.5) †‡ 0 (0) * 0 (0) ‡ 0 (0) ‡
  9p24.1 (Del.) 55 (10.8) 40 (10.3) 15 (12.3) 55 (28.8) * 40 (25.5) ‡ 15 (44.1) †‡ 0 (0) * 0 (0) ‡ 0 (0) ‡
  9q21.3 and 9q24.1 (Del.) 28 (5.5) 22 (5.7) 6 (4.9) 28 (14.7) * 22 (14) ‡ 6 (17.6) ‡ 0 (0) * 0 (0) ‡ 0 (0) ‡
* p<0.05 Total Amplified/Deleted vs Total Non-Amplified/Deleted or Total Smoker vs Total Non-Smoker by Pearson chi-squared test (bottom)
† p<0.05 Amplified/Deleted Smoker vs Amplified/Deleted Non-Smoker or Non-Amplified/Deleted Smoker vs Non-Amplified/Deleted Non-Smoker by one-way ANOVA (top) or Pearson chi-squared test (bottom)
‡ p<0.05 Amplified/Deleted Smoker vs Non-Amplified/Deleted Smoker or Amplified/Deleted Non-Smoker vs Non-Amplified/Deleted Non-Smoker by one-way ANOVA (top) or Pearson chi-squared test (bottom)
SD: Standard Deviation
Smokers: Pack-year > 0 or Patient Smoking History; Non-Smokers: Pack-year = 0 or no reported Patient Smoking History
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Table 1. Mutational Frequency of Common HNSCC-associated Genes in Smoking and non-Smoking 
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Supplementary Table S1. Clinical Characteristics of HNSCC Patients by Smoking, 11q13.3 and 




n = 509 (100%)
Total Smokers
n = 364 (100%)
Total Non-Smokers
n = 145 (100%)
Total Amplified
n = 136 (100%)
Amplified Smokers
n = 120 (100%)
Amplified Non-
Smokers
n = 16 (100%)
Total Non-
Amplified
n = 373 (100%)
Non-Amplified 
Smokers
n = 244 (100%)
Non-Amplified 
Non-Smokers
n = 129 (100%)
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Age (years) 60.7 ± 12.2 61.2 ± 11.0 59.1 ± 15.1 59.8 ± 12.4 60.1 ± 12.3 57.9 ± 13.4 61 ± 12.2 61.7 ± 10.4 59.3 ± 15.4
Smoking Usage
     Pack-years 32.4 ± 36.3 45.9 ± 35.3 * 0 ± 0 * 46.6 ± 41.7 * 54.4 ± 40.1 † 0 ± 0 † 27.1 ± 32.6 * 41.7 ± 32.2 † 0 ± 0 †
Alcohol Usage
     Weekly Drinks 20.3 ± 29.9 24.4 ± 31.7 * 5.0 ± 13.8 * 26.6 ± 30.8 28.5 ± 31.0 † 0 ± 0 † 17.7 ± 29.2 22.3 ± 31.9 † 5.5 ± 14.4 †
Survival (months) 30.3 ± 28.5 30.6 ± 29.8 29.1 ± 23.9 29.3 ± 27.3 29.7 ± 28.1 26.5 ± 20.5 30.6 ± 28.9 31.1 ± 30.5 29.5 ± 24.5
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Sex
     Male 375 (73.7) 290 (79.7) * 85 (58.6) * 106 (77.9) 97 (80.8) † 9 (56.3) † 269 (72.1) 193 (79.1) † 76 (58.9) †
     Female 134 (26.3) 74 (20.3) * 60 (41.4) * 30 (22.1) 23 (19.2) † 7 (43.8) † 104 (27.9) 51 (20.9) † 53 (41.1) †
AJCC Stage
     I 26 (5.1) 16 (4.4) 10 (6.9) 6 (4.4) 6 (5) 0 (0) 20 (5.4) 10 (4.1) 10 (7.8)
     II 83 (16.3) 57 (15.7) 26 (17.9) 17 (12.5) 15 (12.5) 2 (12.5) 66 (17.7) 42 (17.2) 24 (18.6)
     III 95 (18.7) 67 (18.4) 28 (19.3) 16 (11.8) 15 (12.5) 1 (6.3) 79 (21.2) 52 (21.3) 27 (20.9)
     IV 305 (59.9) 224 (61.5) 81 (55.9) 97 (71.3) * 84 (70) 13 (81.3) 208 (55.8) * 140 (57.4) 68 (52.7)
N Status
     N Positive 255 (50.1) 189 (51.9) 66 (45.5) 82 (60.3) * 73 (60.8) ‡ 9 (56.3) 173 (46.4) * 116 (47.5) ‡ 57 (44.2)
     N Negative 182 (35.8) 127 (34.9) 55 (37.9) 37 (27.2) 30 (25) 7 (43.8) 145 (38.9) 97 (39.8) 48 (37.2)
     Missing 72 (14.1) 48 (13.2) 24 (16.6) 17 (12.5) 17 (14.2) 0 (0) 55 (14.7) 31 (12.7) 24 (18.6)
HPV Status
     Positive 98 (19.3) 59 (16.2) * 39 (26.9) * 17 (12.5) * 15 (12.5) 2 (12.5) 81 (21.7) * 44 (18) † 37 (28.7) †
     Negative 409 (80.4) 304 (83.5) * 105 (72.4) * 119 (87.5) * 105 (87.5) 14 (87.5) 290 (77.7) * 199 (81.6) † 91 (70.5) †
     Missing 2 (0.4) 1 (0.3) 1 (0.7) 0 (0) 0 (0) 0 (0) 2 (0.5) 1 (0.4) 1 (0.8)
Chr9 Deletion Patient 
Characteristics
Total
n = 509 (100%)
Total Smokers
n = 360 (100%)
Total Non-Smokers
n = 149 (100%)
Total Deleted
n = 191 (100%)
Deleted Smokers
n = 149 (100%)
Deleted Non-
Smokers
n = 42 (100%)
Total Deleted
n = 318 (100%)
Non-Deleted 
Smokers
n = 211 (100%)
Non-Deleted Non-
Smokers
n = 107 (100%)
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Age (years) 60.7 ± 12.2 61.2 ± 11.0 59.1 ± 15.1 61.5 ± 11.8 60.7 ± 11.3 65.5 ± 13.6 ‡ 60.2 ± 12.3 61.5 ± 10.9 † 56.6 ± 15.0 †‡
Smoking Usage
     Pack-years 32.4 ± 36.3 45.9 ± 35.3 * 0 ± 0 * 34.5 ± 31.4 44.3 ± 28.8 † 0 ± 0 † 31.2 ± 38.9 47.0 ± 39.2 † 0 ± 0 †
Alcohol Usage
     Weekly Drinks 20.3 ± 29.9 24.4 ± 31.7 * 5.0 ± 13.8 * 21.2 ± 24.0 23.6 ± 24.3 1.1 ± 2.45 19.8 ± 32.7 24.9 ± 35.9 † 5.8 ± 15.1 †
Survival (months) 30.3 ± 28.5 30.6 ± 29.8 29.2 ± 23.9 29.4 ± 29.3 29.5 ± 29.5 28.9 ± 28.9 30.8 ± 28.0 31.4 ± 30.0 29.1 ± 21.9
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Sex
     Male 375 (73.7) 288 (80) * 87 (58.4) * 131 (68.6) 114 (76.5) † 17 (40.5) †‡ 244 (76.7) 174 (82.5) † 70 (65.4) †‡
     Female 134 (26.3) 72 (20) * 62 (41.6) * 60 (31.4) 35 (23.5) † 25 (59.5) †‡ 74 (23.3) 37 (17.5) † 37 (34.6) †‡
AJCC Stage
     I 26 (5.1) 15 (4.2) 11 (7.4) 9 (4.7) 6 (4) 3 (7.1) 17 (5.3) 9 (4.3) 8 (7.5)
     II 83 (16.3) 56 (15.6) 27 (18.1) 30 (15.7) 23 (15.4) 7 (16.7) 53 (16.7) 33 (15.6) 20 (18.7)
     III 95 (18.7) 67 (18.6) 28 (18.8) 31 (16.2) 22 (14.8) 9 (21.4) 64 (20.1) 45 (21.3) 19 (17.8)
     IV 305 (59.9) 222 (61.7) 83 (55.7) 121 (63.4) 98 (65.8) 23 (54.8) 184 (57.9) 124 (58.8) 60 (56.1)
N Status
     N Positive 255 (50.1) 188 (52.2) 67 (45) 97 (50.8) 79 (53) 18 (42.9) 158 (49.7) 109 (51.7) 49 (45.8)
     N Negative 182 (35.8) 124 (34.4) 58 (38.9) 69 (36.1) 54 (36.2) 15 (35.7) 113 (35.5) 70 (33.2) 43 (40.2)
     Missing 72 (14.1) 48 (13.3) 24 (16.1) 25 (13.1) 16 (10.7) 9 (21.4) 47 (14.8) 32 (15.2) 15 (14)
HPV Status
     Positive 98 (19.3) 59 (16.4) * 39 (26.2) * 12 (6.3) * 11 (7.4) ‡ 1 (2.4) †‡ 86 (27) 48 (22.7) †‡ 38 (35.5) †‡
     Negative 409 (80.4) 300 (83.3) * 109 (73.2) * 179 (93.7) * 138 (92.6) ‡ 41 (97.6) †‡ 230 (72.3) 162 (76.8) †‡ 68 (63.6) †‡
     Missing 2 (0.4) 1 (0.3) 1 (0.7) 0 (0) 0 (0) 0 (0) 2 (0.6) 1 (0.5) 1 (0.9)
* p<0.05 Total Amplified/Deleted vs. Total Non-Amplified/Deleted or Total Smoker vs Total Non-Smoker by Pearson chi-squared test (bottom)
† p<0.05 Amplified/Deleted Smoker vs Amplified/Deleted Non-Smoker or Non-Amplified/Deleted Smoker vs Non-Amplified/Deleted Non-Smoker by one-way ANOVA (top) or Pearson chi-squared test (bottom)
‡ p<0.05 Amplified/Deleted Smoker vs Non-Amplified/Deleted Smoker or Amplified/Deleted Non-Smoker vs Non-Amplified/Deleted Non-Smoker by one-way ANOVA (top) or Pearson chi-squared test (bottom)
SD: Standard Deviation
Smokers: Pack-year > 0 or Patient Smoking History; Non-Smokers: Pack-year = 0 or no reported Patient Smoking History
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Supplementary Table S2. Gene GISTIC2 Value and Pack-Year Linear Regression Analysis. Related 
to Figures 1 and 2. Available on WVU Library EDT Website. 
 
Supplementary Table S3. Mutational Frequency of common HNSCC-associated Genes by 
Smoking Exposure. Related to Table 1. 
Mutations by Smoking Status
Total
n = 420 (100%)
Never Smoker
n = 122 (100%)
Ever Smoker
n = 298 (100%)
Heavy Smoker 
n = 270 (100%)
Low-Risk
n = 150 (100%)
Light Smoker
n = 28 (100%)
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Total SNA 130.2 ± 271.9 134.4 ± 294.8 153.6 ± 146 157.7 ± 148.9 130.2 ± 271.9 109.1 ± 101.2
Total CNA (Amp.) 381.6 ± 486.4 251.5 ± 344.4 † 381.6 ± 486.4 397.8 ± 496.9 †‡ 239.8 ± 331.9 ‡ 171.9 ± 242.5
Total CNA (Del.) 96.1 ± 251.9 121.1 ± 338 85.68 ± 205.6 89.44 ± 213.3 108 ± 309.6 48.7 ± 96.21
SNA  n (%)  n (%)  n (%)  n (%)  n (%)  n (%)
  CASP8 42 (10) 20 (16.4) * 22 (7.4) * 16 (5.9) ‡ 26 (17.3) ‡ 6 (21.4)
  CDKN2A 89 (21.2) 32 (26.2) † 57 (19.1) 49 (18.1) †‡ 40 (26.7) ‡ 8 (28.6)
  FAT1 85 (20.2) 23 (18.9) † 62 (20.8) 57 (21.1) † 28 (18.7) 5 (17.9)
  KMT2D 65 (15.5) 16 (13.1) † 49 (16.4) 46 (17) † 19 (12.7) 3 (10.7)
  LRP1B 70 (16.7) 10 (8.2) *† 60 (20.1) * 54 (20) †‡ 16 (10.7) ‡ 6 (21.4)
  NOTCH1 70 (16.7) 17 (13.9) † 53 (17.8) 44 (16.3) † 26 (17.3) 9 (32.1)
  NSD1 49 (11.7) 5 (4.1) *† 44 (14.8) * 42 (15.6) †‡ 7 (4.7) ‡ 2 (7.1)
  PCLO 61 (14.5) 13 (10.7) † 48 (16.1) 45 (16.7) † 16 (10.7) 3 (10.7)
  PIK3CA 80 (19) 17 (13.9) † 63 (21.1) 56 (20.7) † 24 (16) 7 (25)
  TP53 286 (68.1) 78 (63.9) † 208 (69.8) 193 (71.5) †‡ 93 (62) ‡ 15 (53.6)
* p<0.05 Never Smoker vs Ever Smoker
† p<0.05 Heavy Smoker vs Never Smoker
‡ p<0.05 Low Risk vs Heavy Smoker
SD: Standard Deviation
Never Smoker: Pack-year = 0; Ever Smoker: Pack-year > 0; Heavy Smoker: Pack-year > 10; Low-Risk: Pack-year <= 10; Light Smoker: Pack-year <= 10 and > 0




Supplementary Table S4. Smoking-associated Gene Overexpression of HNSCC Patients by 
Smoking, 11q13.3 and 11q13.4 Cytoband Amplification Status. Related to Figure 4. 





 OX / Amp (%)  OX / Amp (%)  OX / Amp (%)  OX / Amp (%)  OX / Amp (%)  OX / Amp (%)  OX / Amp (%)  OX / Amp (%)  OX / Amp (%)
Overexpressed
     ANO1 74 / 196 (37.8) 57 / 148 (38.5) 17 / 48 (35.4) 41 / 53 (77.4) * 37 / 48 (77.1) ‡ 4 / 5 (80) ‡ 33 / 143 (23.1) * 20 / 100 (20) 13 / 43 (30.2) ‡
     CCND1 28 / 196 (14.3) 25 / 148 (16.9) 3 / 48 (6.3) 24 / 51 (47.1) * 22 / 46 (47.8) ‡ 2 / 5 (40) ‡ 4 / 145 (2.8) * 3 / 102 (2.9) 1 / 43 (2.3) ‡
     CPT1A 21 / 196 (10.7) 19 / 148 (12.8) 2 / 48 (4.2) 11 / 24 (45.8) * 11 / 22 (50) ‡ 0 / 2 (0) 10 / 172 (5.8) * 8 / 126 (6.3) 2 / 46 (4.3)
     CTTN 57 / 196 (29.1) 48 / 148 (32.4) 9 / 48 (18.8) 50 / 53 (94.3) * 45 / 48 (93.8) ‡ 5 / 5 (100) ‡ 7 / 143 (4.9) * 3 / 100 (3) 4 / 43 (9.3) ‡
     FADD 152 / 196 (77.6) 117 / 148 (79.1) 35 / 48 (72.9) 53 / 53 (100) * 48 / 48 (100) ‡ 5 / 5 (100) 99 / 143 (69.2) * 69 / 100 (69) 30 / 43 (69.8)
     FGF19 95 / 196 (48.5) 78 / 148 (52.7) * 17 / 48 (35.4) * 37 / 51 (72.5) * 37 / 46 (80.4) †‡ 0 / 5 (0) 58 / 145 (40) * 41 / 102 (40.2) 17 / 43 (39.5)
     FGF3 13 / 196 (6.6) 13 / 148 (8.8) * 0 / 48 (0) * 9 / 51 (17.6) * 9 / 46 (19.6) ‡ 0 / 5 (0) 4 / 145 (2.8) * 4 / 102 (3.9) 0 / 43 (0)
     FGF4 16 / 196 (8.2) 11 / 148 (7.4) 5 / 48 (10.4) 7 / 51 (13.7) 7 / 46 (15.2) ‡ 0 / 5 (0) 9 / 145 (6.2) 4 / 102 (3.9) 5 / 43 (11.6)
     IGHMBP2 62 / 196 (31.6) 49 / 148 (33.1) 13 / 48 (27.1) 26 / 30 (86.7) * 24 / 28 (85.7) ‡ 2 / 2 (100) ‡ 36 / 166 (21.7) * 25 / 120 (20.8) 11 / 46 (23.9) ‡
     MRGPRD 38 / 196 (19.4) 30 / 148 (20.3) 8 / 48 (16.7) 16 / 34 (47.1) * 15 / 32 (46.9) ‡ 1 / 2 (50) 22 / 162 (13.6) * 15 / 116 (12.9) 7 / 46 (15.2)
     MRGPRF 9 / 196 (4.6) 7 / 148 (4.7) 2 / 48 (4.2) 2 / 34 (5.9) 2 / 32 (6.3) 0 / 2 (0) 7 / 162 (4.3) 5 / 116 (4.3) 2 / 46 (4.3)
     MRPL21 47 / 196 (24) 40 / 148 (27) 7 / 48 (14.6) 24 / 28 (85.7) * 23 / 26 (88.5) ‡ 1 / 2 (50) 23 / 168 (13.7) * 17 / 122 (13.9) 6 / 46 (13)
     MTL5 60 / 196 (30.6) 52 / 148 (35.1) * 8 / 48 (16.7) * 15 / 20 (75) * 14 / 18 (77.8) ‡ 1 / 2 (50) 45 / 176 (25.6) * 38 / 130 (29.2) 7 / 46 (15.2)
     MYEOV 5 / 196 (2.6) 5 / 148 (3.4) 0 / 48 (0) 4 / 46 (8.7) * 4 / 43 (9.3) ‡ 0 / 3 (0) 1 / 150 (0.7) * 1 / 105 (1) 0 / 45 (0)
     ORAOV1 106 / 196 (54.1) 84 / 148 (56.8) 22 / 48 (45.8) 51 / 51 (100) * 46 / 46 (100) ‡ 5 / 5 (100) ‡ 55 / 145 (37.9) * 38 / 102 (37.3) 17 / 43 (39.5) ‡
     PPFIA1 106 / 196 (54.1) 85 / 148 (57.4) 21 / 48 (43.8) 54 / 54 (100) * 49 / 49 (100) ‡ 5 / 5 (100) ‡ 52 / 142 (36.6) * 36 / 99 (36.4) 16 / 43 (37.2) ‡
     SHANK2 16 / 196 (8.2) 15 / 148 (10.1) 1 / 48 (2.1) 13 / 52 (25) * 13 / 47 (27.7) ‡ 0 / 5 (0) 3 / 144 (2.1) * 2 / 101 (2) 1 / 43 (2.3)
     TPCN2 103 / 196 (52.6) 79 / 148 (53.4) 24 / 48 (50) 33 / 35 (94.3) * 31 / 33 (93.9) ‡ 2 / 2 (100) 70 / 161 (43.5) * 48 / 115 (41.7) 22 / 46 (47.8)





 OX / Amp (%)  OX / Amp (%)  OX / Amp (%)  OX / Amp (%)  OX / Amp (%)  OX / Amp (%)  OX / Amp (%)  OX / Amp (%)  OX / Amp (%)
Overexpressed
     DHCR7 60 / 196 (30.6) 52 / 148 (35.1) * 8 / 48 (16.7) * 33 / 35 (94.3) * 31 (100) †‡ 2 (50) 27 / 161 (16.8) * 21 (17.95) 6 (13.64)
     NADSYN1 29 / 196 (14.8) 25 / 148 (16.9) 4 / 48 (8.3) 26 / 35 (74.3) * 23 (74.19) 3 (75) ‡ 3 / 161 (1.9) * 2 (1.71) 1 (2.27) ‡
     RNF121 60 / 196 (30.6) 39 / 148 (26.4) * 21 / 48 (43.8) * 23 / 27 (85.2) * 21 (87.5) ‡ 2 (66.67) 37 / 169 (21.9) * 18 (14.52) † 19 (42.22) †





 UX / Del (%)  UX / Del (%)  UX / Del (%)  UX / Del (%)  UX / Del (%)  UX / Del (%)  UX / Del (%)  OX / Amp (%)  OX / Amp (%)
Underexpressed
     C9ORF53 0 / 196 (0) 0 / 148 (0) 0 / 48 (0) 0 / 49 (0) 0 (0) ‡ 0 (0) 0 / 147 (0) * 0 (0) 0 (0)
     CDKN2A 12 / 196 (6.1) 12 / 148 (8.1) * 0 / 48 (0) * 11 / 50 (22) * 11 (25) ‡ 0 (0) 1 / 146 (0.7) 1 (0.96) 0 (0)
     CDKN2B 41 / 196 (20.9) 35 / 148 (23.6) 6 / 48 (12.5) 35 / 45 (77.8) * 30 (76.92) ‡ 5 (83.33) ‡ 6 / 151 (4) * 5 (4.59) 1 (2.38) ‡
     MTAP 28 / 196 (14.3) 20 / 148 (13.5) 8 / 48 (16.7) 21 / 28 (75) * 16 (69.57) ‡ 5 (100) ‡ 7 / 168 (4.2) * 4 (3.2) 3 (6.98) ‡





 UX / Del (%)  UX / Del (%)  UX / Del (%)  UX / Del (%)  UX / Del (%)  UX / Del (%)  UX / Del (%)  OX / Amp (%)  OX / Amp (%)
Underexpressed
     PTPRD 0 / 196 (0) 0 / 148 (0) 0 / 48 (0) 0 / 16 (0) 0 (0) 0 (0) 0 / 180 (0) 0 (0) 0 (0)
* p<0.05 Total Amplified/Deleted vs Total Non-Amplified/Deleted or Total Smoker vs Total Non-Smoker by Pearson chi-squareed test (bottom)
† p<0.05 Amplified/Deleted Smoker vs Amplified/Deleted Non-Smoker or Non-Amplified/Deleted Smoker vs Non-Amplified/Deleted Non-Smoker by Pearson chi-squared
‡ p<0.05 Amplified/Deleted Smoker vs Non-Amplified/Deleted Smoker or Amplified/Deleted Non-Smoker vs Non-Amplified/Deleted Non-Smoker by Pearson chi-squared
OX: Overexpressed; UX: Underexpressed; Amp: Amplified; Del: Deleted
Smokers: Pack-year > 0 or Patient Smoking History; Non-Smokers: Pack-year = 0 or no reported Patient Smoking History
124 
 
Supplementary Figure S1. Determination of smoking-associated expression signature through 
effect of differential gene expression on overall survival. Overall Survival analysis of the differential 
expression levels for each identified gene comparing the first quartile (lowest 25%) to the fourth quartile 
(highest 25%). Genes with a significant effect on overall survival were combined into the smoking-




Supplementary Figure S2. Additive effect of SAES gene over- or underexpression on overall 
survival. Kaplan-Meier survival analysis comparing the effect of additional over- or underexpression of 
a SAES genes on overall (top) and disease-free (bottom) survival. Median survival and p-value for each 





Supplementary Table S5. Multivariate Analysis Predicting Overall Survival using Age, Sex, AJCC 
Stage, HPV-Status, Extracapsular Spread, Perineural Invasion, and Lymphovascular Invasion 
Cox Hazard Ratio 2.5% CI 97.5% CI P-value Cox Hazard Ratio 2.5% CI 97.5% CI P-value
ANO1 1.050 0.940 1.174 0.386 1.298 1.088 1.549 0.004
C9orf53 0.688 0.493 0.959 0.027 0.971 0.933 1.010 0.142
CCND1 1.045 0.928 1.177 0.463 1.122 1.003 1.255 0.043
CDKN2A 0.705 0.507 0.981 0.038 0.977 0.895 1.066 0.605
CDKN2B 0.836 0.601 1.162 0.286 0.917 0.797 1.054 0.222
CPT1A 0.975 0.824 1.154 0.770 1.043 0.937 1.160 0.443
CTTN 1.043 0.934 1.164 0.455 1.109 1.018 1.207 0.017
DHCR7 1.125 0.973 1.300 0.112 1.117 0.998 1.250 0.054
FADD 1.048 0.938 1.171 0.404 1.100 1.025 1.181 0.008
FGF19 1.060 0.942 1.192 0.332 1.001 0.999 1.004 0.290
FGF3 1.074 0.956 1.207 0.227 0.996 0.980 1.013 0.653
FGF4 1.071 0.952 1.204 0.254 0.996 0.980 1.014 0.679
IGHMBP2 1.019 0.871 1.191 0.818 1.040 0.982 1.102 0.178
MRGPRD 1.058 0.912 1.227 0.459 0.994 0.940 1.051 0.823
MRGPRF 1.040 0.897 1.205 0.604 0.848 0.657 1.093 0.203
MRPL21 1.004 0.856 1.177 0.963 1.063 1.016 1.112 0.009
MTAP 0.978 0.719 1.329 0.885 0.936 0.848 1.034 0.193
MTL5 0.983 0.816 1.184 0.855 1.046 0.960 1.139 0.304
MYEOV 1.081 0.957 1.221 0.211 1.148 0.919 1.433 0.223
NADSYN1 1.125 0.973 1.300 0.112 1.037 0.881 1.220 0.664
ORAOV1 1.048 0.931 1.180 0.438 1.030 0.980 1.083 0.245
PPFIA1 1.045 0.937 1.167 0.428 1.053 0.995 1.113 0.073
PTPRD 1.121 0.921 1.364 0.254 0.964 0.890 1.044 0.364
RNF121 1.238 1.012 1.515 0.038 1.079 0.951 1.223 0.238
SHANK2 1.028 0.919 1.150 0.625 1.199 0.964 1.491 0.102
TPCN2 1.040 0.903 1.197 0.586 1.111 1.026 1.203 0.010
DEFB108B 1.129 0.928 1.373 0.224
ENPP7P8 1.090 0.910 1.306 0.350
FAM86C1 1.121 0.919 1.368 0.259
MIR3164 1.040 0.903 1.197 0.586
MIR3664 1.105 0.977 1.249 0.114
MIR548K 1.046 0.937 1.169 0.423
RNA5SP342 1.129 0.928 1.373 0.224
UNC93B6 1.177 1.008 1.374 0.039
ZNF705E 1.129 0.928 1.373 0.224
Supplementary Table S5. Multivariate Analysis Predicting Overall Survival using Age, Sex, 
AJCC Stage, HPV-Status, Extracapsular Spread, Perineural Invasion, and Lymphovascular Invasion




Supplementary Figure S3. Relative risk of death of each smoking-associated expression 
signature gene. Pearson correlations between standardized gene expression (z-score) and risk of death 




Supplementary Table S6. Predictive Probability Linear Regression of Gene CNA by GISTIC2 Value 
and Pack-Year. Related to Figure 5. 
odds ratio 2.5% CI 97.5% CI P-value
MTL5 1.013 1.005 1.020 8.05E-04
CPT1A 1.013 1.006 1.020 6.07E-04
MRPL21 1.013 1.006 1.021 2.69E-04
IGHMBP2 1.013 1.006 1.021 2.75E-04
MRGPRD 1.016 1.009 1.024 2.57E-05
MRGPRF 1.017 1.010 1.025 7.16E-06
TPCN2 1.017 1.009 1.024 1.24E-05
MIR3164 1.017 1.009 1.024 1.24E-05
MYEOV 1.017 1.010 1.024 4.16E-06
CCND1 1.016 1.010 1.024 3.92E-06
ORAOV1 1.016 1.010 1.024 3.92E-06
FGF19 1.016 1.010 1.024 3.92E-06
FGF4 1.016 1.010 1.024 3.92E-06
FGF3 1.016 1.009 1.023 6.15E-06
ANO1 1.017 1.011 1.025 1.37E-06
FADD 1.017 1.010 1.024 2.20E-06
PPFIA1 1.017 1.010 1.024 2.42E-06
MIR548K 1.017 1.010 1.024 2.42E-06
CTTN 1.016 1.010 1.024 3.36E-06
SHANK2 1.016 1.009 1.023 6.12E-06
MIR3664 1.015 1.008 1.022 3.13E-05
DHCR7 1.016 1.009 1.024 2.46E-05
NADSYN1 1.016 1.009 1.024 2.46E-05
UNC93B6 1.017 1.010 1.025 1.47E-05
ENPP7P8 1.016 1.009 1.025 4.12E-05
FAM86C1 1.016 1.009 1.025 7.30E-05
ZNF705E 1.015 1.008 1.023 1.43E-04
DEFB108B 1.015 1.008 1.024 1.25E-04
RNA5SP342 1.015 1.008 1.024 1.25E-04
RNF121 1.015 1.008 1.024 1.51E-04
MTAP 1.004 0.998 1.010 0.177
C9orf53 1.003 0.997 1.009 0.294
CDKN2A 1.003 0.997 1.008 0.362
CDKN2B 1.003 0.997 1.009 0.266




Supplementary Table S7. Predictive Probability Linear Regression of Gene Over- or 
Underexpression by Z-score and Pack-Year. Related to Figure 5. 
Estimate Standard Error z.value P.value
ANO1 0.006343591 0.004242823 1.495134 0.135
CCND1 0.012633468 0.005410455 2.33501 0.020
CPT1A 0.013633059 0.005939486 2.295327 0.022
CTTN 0.017000566 0.004766874 3.566397 0.000
DHCR7 0.021053314 0.004994869 4.214988 0.000
FADD 0.01377474 0.005896312 2.336162 0.019
FGF19 0.011723851 0.004431076 2.645825 0.008
FGF3 0.021877574 0.007099945 3.081372 0.002
FGF4 -0.000668514 0.007599246 -0.087971 0.930
IGHMBP2 0.006795303 0.004361989 1.557845 0.119
MRGPRD 0.00612869 0.004965211 1.234326 0.217
MRGPRF 0.002650902 0.009437755 0.280883 0.779
MRPL21 0.010992611 0.004682154 2.347768 0.019
MTL5 0.015144763 0.004639637 3.264213 0.001
MYEOV 0.018813873 0.010098192 1.863093 0.062
NADSYN1 0.021029108 0.005666638 3.711038 0.000
ORAOV1 0.009501594 0.004406822 2.15611 0.031
PPFIA1 0.015513346 0.004739885 3.272937 0.001
RNF121 -0.002647988 0.004567647 -0.579727 0.562
SHANK2 0.014984733 0.00651749 2.299157 0.021
TPCN2 0.006648249 0.004262356 1.559759 0.119
C9orf53
CDKN2A 1.00E-02 7.51E-03 1.33E+00 0.183
CDKN2B 5.53E-03 4.86E-03 1.14E+00 0.255
MTAPP 3.41E-03 5.66E-03 6.03E-01 0.547
PTPRD
* all values are 0 in C9orf53
* all values are 0 in PTPRD
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Background: Three prime untranslated regions (3'-UTRs) of messenger (m)RNAs can serve as competing 
endogenous (ce)RNAs through the binding and titration of regulatory micro (mi)RNAs. Inactivation of tumor-
suppressive miRNAs by UTRs with shared miRNA response elements (MREs) promotes cancer progression 
through permissive expression of miRNA-targeted oncogenic transcripts. Chromosome 11q13 amplification 
drives the progression of head and neck squamous cell carcinoma (HNSCC) and other cancer types through 
oncogenic protein overexpression. However, the collective ability of 3'-UTR regions in 11q13 overexpressed 
transcripts to function as oncogenic ceRNAs is unclear. 
Methods: We utilized TargetScan to predict MREs for the 3’-UTR of 11q13 genes and The Cancer Genome Atlas 
(TCGA) to analyze and stratify gene, exon, and protein expression values. Western blotting was used to 
determine protein expression. mRNA in-situ hybridization (mRNA-ISH) was used to quantify mRNA expression 
and localization in HNSCC cell lines. 
Results: Six transcripts from the most commonly amplified 11q13 genes in HNSCC are overexpressed and 
maintain the 3'-UTR. Of these, the CCND1 3'-UTR is predicted to bind 31 tumor suppressive miRNAs, thus has 
oncogenic ceRNA characteristics. Overexpression of the 3'-UTR encoded from CCND1 exon 5 denotes worse 
clinical outcome. HNSCC cells lines with 11q13 amplification overexpress the CCND1 3'-UTR in the cytoplasm, 
where it can function as a ceRNA. Correlation analysis of global protein expression in patients with CCND1 3'-
UTR overexpression identified significant protein overexpression from genes with 3'-UTR MREs homologous 
with CCND1. Four proteins (BID, RB1, PXN, MACC1) were positively correlated in human papillomavirus (HPV)-
positive, and eight proteins (SERPINE1, TYMS, DVL3, ITGA2, BCL2L11, CCNB1, GATA3, and E2F1) were 
positively correlated in HPV-negative HNSCC. Similar correlation analysis of four other 11q13-amplified cancer 
types identified SERPINE1, GATA3 and ITGA2 as common upregulated proteins in tumors with CCND1 3'-UTR 
overexpression, suggesting conservation of the potential CCND1 3'-UTR ceRNA mechanism. 
Conclusions: An integrated approach across multiple patient cohorts in different cancers identified several 
candidate genes potentially regulated by high CCND1 3'-UTR overexpression and ceRNA activity, which may 
be utilized for additional therapeutic strategies to improve the outcomes of patients with CCND1 amplification 




HNSCC is an aggressive neoplasm of the upper aerodigestive tract caused by tobacco, alcohol, and high-risk 
HPV infection(1–3). HPV-negative patients have a worse outcome than HPV-positive patients, stratifying the 
disease into distinct prognostic subtypes(4–6). TCGA and others have identified large-scale genomic copy 
number alterations (CNAs) in HNSCC(7,8). Of these, amplification of the 11q13 chromosome region occurs in 
25-50% of cases and is the most frequent CNA in HPV-negative HNSCC(9,10). Patients with 11q13 amplification 
have more metastatic disease, shorter time to recurrence and die sooner than HPV-negative patients lacking 
amplification(11,12). The overexpressed G1/S cell cycle promoting protein cyclin D1, encoded from the CCND1 
gene, is accepted as the main oncogenic driver in 11q13 amplified cancer through increased cyclin-dependent 
kinase (CDK)4/6 activation and inhibition of the tumor suppressing retinoblastoma protein (pRB)(12–15). CCND1 
amplification and protein overexpression are correlated with decreased patient survival and increased 
progression in HNSCC(16–19). 
Current understanding of 11q13 amplification in mediating HNSCC progression is largely based on the study of 
protein products from amplified genes(20,21). However, the role of the noncoding regions of overexpressed 
mRNA transcripts from any 11q13 amplicon gene (e.g., 5’ and 3’-UTR regions) has not been evaluated. Non-
coding UTR regions are known to contribute to cancer progression(22,23). Such transcripts can function as 
ceRNAs that operate via several mechanisms(24–27). One mechanism is titration of miRNAs through 
competitive binding of miRNAs shared with different transcripts containing homologous MREs(26,28,29). Binding 
of miRNAs to transcripts results in transcript degradation, or blocks translation without substantial 
degradation(30,31). Both mechanisms reduce protein expression from shared MRE-containing transcripts. Many 
studies in cancer have shown oncogenic ceRNA effects by long non-coding (lnc) pseudogenes and non-
shortened 3’-UTR regions(16,29,32–36). Oncogenic ceRNAs thus sequester tumor-suppressive miRNAs at 
MREs shared with oncogenic target transcripts. This reduces the available levels of tumor-suppressive miRNAs, 
allowing transcripts normally degraded/blocked to persist and translate proteins(37). The ultimate result of such 
ceRNA activity is relief of tumor suppression that enhances neoplastic progression(29,38). 
Global ceRNA networks exist in HNSCC(39,40), where dysregulation of miRNA networks causes neoplastic 
gene expression(41–44). Such studies infer that the non-coding regions in 11q13 amplified transcripts may 
contribute to the aggressive advancement of HNSCC as ceRNAs. 11q13 genes can be amplified up to 80-fold 
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in HNSCC, increasing transcript levels 16-48 times above baseline(9,13,17,45). As such, highly overexpressed 
transcripts from the 11q13 amplicon may serve as ceRNAs in driving HNSCC. In this report we have evaluated 
the predicted MREs in the 3’-UTR regions of the most commonly overexpressed protein-coding genes from the 
11q13 amplicon. The CCND1 3’-UTR region was the only overexpressed transcript containing a higher number 
of tumor suppressive MREs. Patients with CCND1 3’-UTR overexpression have worse overall survival. The 
CCND1 3’-UTR localizes to the cytoplasm in 11q13 amplified HNSCC cells, allowing it to serve as a ceRNA. 
Correlation analysis of protein expression from transcripts with MREs shared with the CCND1 3’-UTR identified 
four proteins with a positive correlation in HPV-positive HNSCC (BID, RB1, PXN, and MACC1) and eight 
positively correlated in HPV-negative HNSCC (SERPINE1, TYMS, DVL3, ITGA2, BCL2L11, CCNB1, GATA3, 
and E2F1) in patients with CCND1 3’-UTR overexpression. Overexpression of several of these proteins is also 
positively correlated with CCND1 3’-UTR overexpression in other cancers with 11q13 amplification. This 
informatics-based approach provides new candidate protein and miRNA targets for further mechanistic 





Clinical and Survival Data 
Clinical and survival data were obtained from the 2016_01_28 TCGA head-neck squamous cell carcinoma 
(TCGA-HNSC) cohort, downloaded from Broad Genomic Data Analysis Center (GDAC) Firehose(46). Data were 
retrieved from the level 4 TCGA data file All_CDEs.txt and cBioPortal(47). TCGA-HNSC consists of a total of 
529 patients. However, only 263 patients had RNAseq data and were used for determining survival analyses. 
Patients were also evaluated for HPV in the All_CDEs.txt file, denoted by variable “hpv_status”, which was used 
to stratify the cohort into confirmed HPV-positive and HPV-negative subsets. Kaplan-Meier P-values were 
calculated using Mantel-Cox log-rank test with an alpha of 0.05. 
Determination of MiRNA Response Elements and Genetic Characteristics 
We used the University of California Santa Cruz (UCSC) Genome browser(48) and National Center for 
Biotechnology Information (NCBI) AceView(49) to determine lengths of open reading frames (ORFs), 3’-UTRs, 
exons, and introns. Predicted MREs for each gene were downloaded from TargetScan using the Conserved site 
context++ scores file(50). Genes from the 11q13 amplicon were extracted and individual miRNAs were 
categorized as tumor-suppressive, oncogenic, or indeterminate using OncomiRDB(51). Additional miRNAs were 
identified by manual evaluation of the literature.  
Copy Number and Expression Analysis of Genes, Exons, and Proteins 
CNAs were determined by Genomic Identification of Significant Targets in Cancer (GISTIC)2(52) analysis of 
TCGA 2016_01_28 level 4 data for 24,776 genes(46). Briefly, raw GISTIC2 values within all_data_by_genex.txt 
were used to categorize patients by amplification (more than two extra copies), gene gain (two extra copies), 
homozygous deletion, or heterozygous deletion. Expression levels for genes were obtained from TCGA-HNSC 
(N=263), TCGA bladder urothelial carcinoma (TCGA-BLCA) (N=56), TCGA breast invasive carcinoma (TCGA-
BRCA) (N=791), TCGA esophageal carcinoma (TCGA-ESCA) (N=185), and TCGA lung squamous cell 
carcinoma (TCGA-LUSC) (N=223) 2016_01_28 level 3 RNAseq gene expression datasets(46). Expression 
levels for exons were obtained from TCGA-HNSC 2016_01_28 level 3 RNAseq exon expression dataset(46). 
Gene and exon analyses were conducted using log2 fold change (log2FC) normalization calculated from reads 
per kilobase of transcript, per million reads (RPKM) in normal adjacent tissues as baseline. High and low 
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expression of each gene or exon was assessed by comparing the first quartile (lowest 25%) of expression to the 
fourth quartile (highest 25%). Changes in global mRNA expression were determined using the log2FC ratio 
between high and low CCND1 expression levels. Protein expression levels were obtained from TCGA-HNSC 
(N=179), TCGA-BLCA (N=50), TCGA-BRCA (N=630), TCGA-ESCA (N=126), and TCGA-LUSC (N=149) 
2016_01_28 level 3 RPPA AnnotateWithGene dataset(46). Protein expression analysis was conducted using 
the provided normalized values. Statistical significance was determined using Pearson correlation or one-way 
analysis of variance (ANOVA) and Tukey’s post-hoc with an alpha of 0.05. 
Western Blotting and Antibodies 
Western blotting was conducted as described(53) and visualized with autoradiography film (E3012, Denville 
Scientific) or captured by an Amersham Imager 600 (GE Healthcare Bio-Sciences). Antibodies used were anti-
cyclin D1 (sc-718, 1:1000; Santa Cruz Biotechnology) and anti-β-actin (#8457, 1:1000; Cell Signaling 
Technology). 
Cell Lines and Cell Culture 
Cell lines used were UMSCC19 and MSK921(54), MDA1586(55), UPCI:SCC040 and UPCI:SCC136(56) and 
HaCaT(57). UMSCC47(58) was purchased from the American Type Culture Collection (ATCC). All lines were 
propagated in Dulbecco's Modified Eagle Media (DMEM) supplemented with 10% fetal bovine serum and 1% 
penicillin-streptomycin.  
RNA In-Situ Hybridization 
RNA in-situ hybridization was performed as previously described(59). Briefly, custom Stellaris® FISH Probes 
were designed against CCND1 3'UTR by utilizing the Stellaris® RNA FISH Probe Designer (Biosearch 
Technologies, Inc., Petaluma, CA) available online at www.biosearchtech.com/stellarisdesigner (Version 2017). 
The CCND1 3'UTR were hybridized with Cy5. Stellaris RNA FISH Probe set labeled with (Biosearch 
Technologies, Inc.), following the manufacturer's instructions available online at 
www.biosearchtech.com/stellarisprotocolscells. Cells were grown on coverglass, permeabilized, and 
subsequently hybridized with a buffer containing custom fluorescent probes. Cells were then DAPI stained to 
visualize nuclei and mounted onto slides for microscopic analysis using a Nikon A1R confocal microscope. 
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Corrected total cell fluorescence was then calculated for each cell line. Statistical significance was determined 
one-way ANOVA and Tukey’s post-hoc with an alpha of 0.05.  
Determination of CCND1-targeting miRNAs 
To determine genes that share MREs for CCND1-targeting miRNAs to compare global and per-gene expression 
changes, the TargetScan Predicted Targets (default predictions) file was downloaded(50). CCND1 was extracted 
and miRNAs predicted to bind the 3’-UTR were used to find other genes with shared miRNA. Genes that are 
targeted by any shared miRNA are referred to as “targets”. Genes that are not targeted by any of the predicted 
CCND1-targeting miRNA are “controls.”  
Survival Analyses 
Survival was assessed using overall survival months and vital status supplied from TCGA-HNSC, TCGA-BLCA, 
TCGA-BRCA, TCGA-ESCA, and TCGA-LUSC clinical datasets. Data were stratified by applicable parameters 
and graphed with the Kaplan-Meier method. Statistical significance was determined using Mantel-Cox log-rank 





The 11q13 amplification is associated with overexpressed transcripts that harbor tumor-suppressing 
miRNA response elements 
Based on previously-defined subdivisions in breast cancer(20), the 11q13 amplicon was analyzed for 
amplification frequency found within TCGA-HNSC patients. The highest frequency of amplification was seen in 
core 2, with all genes being amplified in more than 20% of patients (Figure 1A). The protein-coding genes within 
this region were evaluated for 3'-UTR length and expression of the exon containing the 3'-UTR within TCGA-
HNSC patients. Several amplified genes contain long 3’-UTRs and displayed 3'-UTR overexpression. These 
include CCND1, ORAOV1, ANO1, FADD, PPFIA1, and CTTN in greater than 10% of patients (Figure 1B). To 
determine if these long 3'-UTRs harbored MREs for tumor-suppressing miRNAs, TargetScan Conserved site 
context++ scores were used to predict MREs and miRNA were classified as tumor-suppressive, oncogenic, or 
undetermined. Four 11q13 genes had over ten predicted tumor-suppressive MREs: CCND1 (N=50), ANO1 
(N=11), PPFIA1 (N=13), and SHANK2 (N=47) (Figure 1C). CCND1 was selected for further evaluation due to 
the unusually high amount of predicted tumor suppressive MREs in the 3’-UTR, its high tumor-suppressive 
miR:oncomiR ratio (Supplementary Figure S1), and because the 3'-UTR is overexpressed in HNSCC. Several 
well-known tumor-suppressive miRNAs are predicted to bind to the CCND1 3’-UTR, including miR-1-3p, miR-
16-5p, miR-17-5p, and let-7-5p (Figure 1D). The potential ability to bind and sequester a wide variety of tumor-
suppressing miRNAs could contribute to the poor survival seen in patients with genomic CCND1 amplification 
(Figure 1E). 
CCND1 3'-UTR is overexpressed in 11q13 the cytosol of amplified cells and is associated with poor 
patient survival 
The CCND1 transcript is encoded from five exons, with exon five containing the last 165nts of the ORF and the 
3,192nts 3'-UTR (Figure 2A). After normalizing exon RPKM expression values, all five exons are expressed in 
their entirety in HNSCC patients. After stratifying patients by amplification (two or more extra copies), gene gain 
(two extra copies), euploid (no extra copies), heterozygous deletion (loss of one copy), or homozygous deletion 
(loss of both copies), CCND1 expression is highest in amplified patients, where amplification and gene gain 
events exhibit elevated expression compared to euploid patients (Figure 2B). When comparing overall survival 
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for HNSCC patients with high exon 5 expression (highest quarter) to patients with low exon 5 expression (lowest 
quarter), patients with high exon 5 expression have decreased median (23.3 vs 90.6 months) and 5-year (32.7% 
vs 55.7%) overall survival (Figure 2C). 
Since nuclear export of the CCND1 transcript is required for oncogenic transformation(60), the ability of the 3’-
UTR to function as a ceRNA likely occurs in the cytoplasm. To determine the localization of the 3’-UTR in 11q13-
amplified HNSCC, we evaluated the expression level and subcellular localization of the CCND1 transcript in 
HNSCC cell lines. As expected, cyclin D1 protein overexpression was observed in HNSCC cell lines containing 
11q13 amplification compared to lines lacking amplification (Figure 3A). To measure CCND1 3'-UTR levels in 
these lines, we performed mRNA-ISH using probes homologous to sequences in the 3'-UTR. 11q13 amplified 
HNSCC lines contained 2-4-fold higher CCND1 3'-UTR levels compared to non-amplified cell lines (Figure 3B). 
Confocal microscopic evaluation of mRNA-ISH lines determined that the CCND1 3'-UTR is largely enriched in 
the cytosol of 11q13 amplified cells (Figure 3C), supporting a role for a cytoplasmic ceRNA function, as well as 
confirming that the 3’-UTR is not truncated when overexpressed in HNSCC. 
Target RNAs sharing CCND1 MREs are not globally altered by CCND1 3’-UTR overexpression  
To determine if CCND1 3’-UTR overexpression exerts a global ceRNA effect on mRNA expression, we utilized 
TargetScan predicted targets as well as TCGA mRNA gene expression data to separate gene expression into 
genes targeted by the same miRNA predicted to target CCND1 from miRNAs that are not predicted to bind the 
CCND1 3’-UTR (Figure 4A). 7,396 genes share MREs with CCND1 (‘targets”), while 6,230 do not (“controls”). 
When comparing gene expression normalized to log2FC, no differences were observed in the expression levels 
between these global gene groups in either HNSCC as a whole, or stratified by HPV-status (Figure 4B).  
Target transcript degradation and downregulation is not the only mechanism employed by ceRNA. Target 
proteins can be downregulated through inhibiting translation, sequestering transcripts, or direct degradation of 
the transcript through exonuclease activity(31,61). These alternative translation inhibitory mechanisms may not 
lead to accelerated degradation of target transcripts and would not be discernible in a global context (Figure 4C). 
Therefore, it is possible that target proteins can be downregulated due to CCND1 amplification and 
overexpression through one of these non-degradative mechanisms, and/or that the CCND1 3’UTR effect is only 
manifest against a small number of targets that would not be discernible by global evaluation (Figure 4D). 
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CCND1 3'-UTR overexpression correlates with a subset of overexpressed proteins protein expression 
in HNSCC and other 11q13-amplified cancers 
To evaluate alternative readouts of potential CCND1 3’-UTR ceRNA activity, TCGA RPPA data and correlated 
protein expression was correlated with increasing CCND1 3'-UTR expression (Figure 5A). Although the TCGA 
reverse phase protein lysate microarray (RPPA) dataset consists of only 160 different proteins, differences in 
protein expression were identified that correlated with CCND1 3’-UTR expression. In HPV-positive patients, eight 
proteins are negatively correlated significantly with increasing CCND1 3'-UTR expression. Of these, all but the 
transcripts of CDKN2A, C12ORF5, and CTNNA1 shared MREs with CCND1 (Figure 5D). We also observed four 
proteins (BID, RB1, PXN, and MACC1) that positively correlated significantly with increasing CCND1 3'-UTR 
expression and the transcripts of which share MREs with CCND1 (Figure 5B). In HPV-negative patients, nine 
proteins negatively correlated significantly with increasing CCND1 3'-UTR expression. Transcripts of PRKCA, 
MACC1, AKT1/2/3, and BAK1 share MREs with CCND1 (Figure 5C). In addition, 12 proteins positively correlate 
significantly with increasing CCND1 3'-UTR expression (Figure 5C). Of these, the transcripts of SERPINE1, 
TYMS, DVL3, ITGA2, BCL2L11, CCNB1, GATA3, and E2F1 share MREs with the CCND1 3’-UTR (Figure 5D).  
Evaluating mRNA expression for these target proteins revealed altered transcript expression when stratified by 
CCND1 3'-UTR expression levels. Expression levels of E2F1, SERPINE1, and TYMS were significantly different 
when stratified by CCND1 3'-UTR expression, suggesting that CCND1 expression is connected to target protein 
expression through control of translation or transcript degradation. The expression levels of the remaining 
transcripts were not significantly different when stratified by CCND1 3'-UTR expression levels, but may be 
regulated by a ceRNA mechanism that does not utilize target transcript degradation.  
In addition to HNSCC, several other cancer types have high levels of 11q13 amplification, including bladder(62), 
breast(63), esophageal squamous(64) and lung squamous cell carcinoma(65). To determine if the potential 
CCND1 3’-UTR ceRNA mechanism utilized in HNSCC is also present in these cancers, a parallel analysis was 
performed on TCGA-BLCA, TCGA-BRCA, TCGA-ESCA, and TCGA-LUSC. In TCGA-BLCA, while there were 
several significantly positively correlated proteins that also shared CCND1 MREs, no potential targets were 
shared with TCGA-HNSC. IGFBP2 and PARP1 are significantly negatively correlated and shared between 
TCGA-BLCA and TCGA-HNSC, but the transcripts do not share CCND1 MREs (Figure 6A). In TCGA-BRCA, 
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PARP1, CCNB1, ANXA1, DVL3, EIF4EBP1, PRKCA, and MYC were significantly negatively correlated similarly 
to TCGA-HNSC, but only the transcripts of CCNB1, DVL3, and PRKCA share CCND1 MREs. Interestingly, 
shared positive correlations include ITGA2 and GATA3, which do share CCND1 MREs in the transcripts and are 
also seen in TCGA-HNSC (Figure 6B). In TCGA-ESCA, LCK was significantly negatively correlated and was 
shared with TCGA-HNSC. Significantly positively correlated genes that were shared with TCGA-HNSC include 
both SERPINE1 and ITGA2, which transcripts share CCND1 MREs (Figure 6C). In TCGA-LUSC, ITGA2 was 
the only significantly positively correlated protein, with the transcript sharing CCND1 MREs present in TCGA-
HNSC (Figure 6D). Other shared proteins were discordantly regulated across cancer types (Figure 6E).  
When evaluating mRNA expression levels of proteins that are shared between CCND1 and TCGA-HNSC, the 
expression levels of ITGA2 and GATA3 in TCGA-BRCA and ITGA2 and SERPINE1 in TCGA-ESCA were all 
significantly different when stratified by CCND1 3'-UTR expression, suggesting that CCND1 3'-UTR expression 
levels has a role in regulating expression of these targets. In contrast, ITGA2 in TCGA-LUSC was not significantly 





In this study, we propose a ceRNA network involving a novel function of CCND1 3’-UTR that may compete for 
tumor-suppressing miRNA, leading to dysregulation of target transcripts and alteration of the expression of target 
proteins with tumor-promoting functions. We identified several proteins that had altered expression when 
stratified by high and low expression of the 3’-UTR exon of CCND1, including TYMS, SERPINE1, CCNB1, DVL3, 
ITGA2, GATA3, and E2F1. The 3’-UTR of CCND1 has been confirmed to bind and regulated by multiple miRNA, 
including miRs-15, 16, 17, and 20. In addition to miRNA, the transcript is also regulated post-transcriptionally by 
AU-rich element (ARE)-binding proteins (BPs) at seven putative sites that help regulate and stabilize the 
transcript(66). There is precedent for ceRNA networks in HNSCC as several ceRNA networks have already been 
described in HNSCC, but these do not include CCND1(39,67,68). The concept of amplification leading to the 
overexpression of transcripts that can serve as ceRNA has also been previously described. These include the 
lncRNA PVT1 that is amplified in gastrointestinal cancer(69), the frequently amplified oncogene CMYC(70), and 
MYEOV in lung cancer, which arises from the same amplification event as CCND1(71). The CCND1 3-’UTR also 
has a function in oncogenic transformation of cells by acting as scaffolding for eIF4E and subsequent assembly 
of ribonucleotides responsible for the modulation of cellular growth(60). The binding of any miRNA, ARE-BP, 
and other 3’-UTR-mediated functions, including any potential ceRNA-mediated function, requires the 3’-UTR to 
not undergo alternative cleavage and polyadenylation (APA) that is typically found in cancer cells(72). Recent 
studies have shown that this does not seem to occur for the CCND1 3’-UTR(73). These reports and our results 
allow for the potential for ceRNA-mediated function. 
This study has identified several proteins that have altered expression when stratified by high and low expression 
of CCND1 3’-UTR, including TYMS, SERPINE1, CCNB1, DVL3, ITGA2, GATA3, and E2F1. Most of these 
proteins have described roles in tumor progression. Thymidylate synthase (encoded by TYMS) has a role in 
DNA synthesis through the generation of thymidine deoxynucleotides, which is an important need of quickly 
dividing cells found in tumors(74,75). It has become a recent area of interest for targeting due to this role(76). 
Endothelial plasminogen activator inhibitor (encoded by SERPINE1) functions as the main inhibitor of tissue 
plasminogen activator and urokinase(77). However, a paradoxical role in cancer has been observed with 
overexpression of SERPINE1 being linked to tumor cell proliferation, migration, and invasion(77–80) and has 
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been interesting as of late for targeting with small molecule inhibitors(81). G2/mitotic-specific cyclin B1 (encoded 
by CCNB1) is a cell cycle regulatory protein that complexes with CDK1 to regulate early cell cycle events(82) 
such as condensation of chromosomes(83). CCNB1 is similar to CCND1 in that it regulates cell cycle and 
aberrant expression can lead to increased cell cycle and increased tumor progression(84–88). Segment polarity 
protein disheveled homolog DVL-3 (encoded by DVL3) functions in the regulation of cell proliferation(89) and 
overexpression of DVL3 has been linked to increased cellular proliferation and migration(90,91). Integrin alpha-
2 (ITGA2) makes up part of the α2β1 integrin duplex and is involved in cell adhesion and cell-surface-mediated 
signaling and has been implicated in tumor progression(92–96). GATA binding protein 3 (encoded by GATA3) 
is a transcription factor that binds GATA DNA sequences and functions in the development of tissues(97) and T 
helper cells(98), secretion of interleukins, and also induces maturation of breast epithelial cells(99). Its role in 
cancer is controversial, as it has been shown to have tumor-promoting(100) and tumor-suppressing roles(101), 
likely due to different transcriptional targets. E2F1 (encoded by E2F1) is a transcription factor involved in the 
CDK-pRB pathway that is responsible for regulating the transcription of S phase genes(102), including 
TYMS(103). Due to its function, overexpression of E2F1 has been implicated as a tumor-promoter in numerous 
cancer types(104–106) as well as a tumor-suppressor(107) depending on its transcriptional targets. 
Importantly, all identified target genes share confirmed MREs with CCND1. Perhaps the most well-known is its 
ability to bind hsa-miR-16(108) which is shared with ITGA2(109). CCND1 has also been shown to bind hsa-miR-
19(110), shared with BCL2L11(111). Both BCL2L11 and E2F1 share hsa-miR-17(111,112), hsa-miR-
20(111,112), hsa-miR-106(113,114), and hsa-miR-302(115,116) with CCND1(117,118). SERPINE1 shares hsa-
miR-34(119) and hsa-miR-449(120) binding with CCND1(121,122). TYMS shares hsa-miR-203 binding(123) 
with CCND1(124). The miRNA hsa-miR-372 is shared between ITGA2(125), E2F1(126), and CCND1(127). 
Lastly, DVL3 shares binding sites for hsa-let-7(128) with CCND1(121). Other microRNA, namely hsa-miR-142, 
that have been confirmed to bind CCND1(129) have not yet been confirmed to bind CCNB1 or GATA3 are only 
predicted by TargetScan at this time. 
This study also has implications in other cancer types with high 11q13 amplification rates. In esophageal 
squamous carcinoma, the expression levels of ITGA2 and SERPINE1 were altered when stratified by CCND1 
3’-UTR expression. SERPINE1 has been demonstrated as a prognostic marker in esophageal carcinoma with 
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overexpression being significantly higher in cancer patients and significantly correlates with smoking and patient 
age(130). Overexpression of SERPINE1 protein in esophageal squamous carcinoma has been linked to the 
promotion of invasion and migration through the activation of AKT and ERK signaling pathways(80). In lung 
cancer, ITGA2 is overexpressed in patients and is associated with clinical development of cancer(131), which is 
supportive of the findings in this study. In breast cancer, the expression levels of GATA3 and ITGA2 were 
significantly different when stratified by high and low CCND1 3’-UTR expression. Paradoxically, these proteins 
are reported to have both tumor-suppressive and tumor-promoting roles. Silencing of ITGA2 has been shown to 
promote cell migration(125), yet overexpression of ITGA2 can also lead to promoted cell proliferation(94). Loss 
of GATA3 is associated with invasive growth and poor prognosis(132), yet a stabilizing mutation found in GATA3 
can lead to a growth advantage in tumors(133,134)).  Overexpression of GATA3 through a ceRNA-mediated 
mechanism may mimic this stabilization effect. Stratification by CCND1 3’-UTR may elucidate the paradoxical 
roles of GATA3 and ITGA2 in breast cancer. Overall, this study underscores the importance of determining the 
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Figures and Tables 
 
Figure 1. The 11q13 amplicon contains genes with long 3’-UTRs that have tumor-suppressing MREs. A. 
The 11q13 amplified region displaying amplification frequency (grey) with defined cores of amplification (orange, 
red, green, blue). B. Genes within the core 2 region of the 11q13 amplicon with ORF length, 3’-UTR length, 
amplification frequency, and 3’-UTR exon overexpression frequency. C. Predicted tumor-suppressing MREs of 
genes within the 11q13 amplicon. D. Selection of tumor-suppressive miRNAs predicted to bind CCND1 3’-UTR. 
E. Overall survival Kaplan-Meier graph of CCND1 euploid patients (black) and CCND1 amplified patients (red). 




Figure 2. The 3’-UTR of CCND1 is expressed in patients and is associated with poor survival. A. 
Diagrammatic representation of CCND1 mRNA with UTRs (black), ORFs (yellow) and introns (magenta) 
locations and lengths. B. Exon-specific RNA expression values normalized to euploid patients (z-score). C. 
Overall survival Kaplan-Meier graph of low CCND1 exon 5 expression (black) and high CCND1 exon 5 
expression (red). Survival analysis was performed using Mantel-Cox log rank test with an alpha of 0.05. 
 
Figure 3. Cyclin D1 protein and mRNA is overexpressed in amplified cell lines and mRNA localizes to 
cytosol. A. Western blot of amplified and non-amplified HNSCC cell lines for cyclin D1 and beta-actin. B. 
Corrected total cell fluorescence (CTCF) of amplified and non-amplified cell lines for CCND1 3’-UTR mRNA-ISH. 
#: p<0.05 compared to HaCat; †: p<0.05 compared to MDA-1586; ‡: p<0.05 compared to UMSCC48. Statistical 
significance was determined using ANOVA and Tukey’s post-hoc with an alpha of 0.05. C. Representative 




Figure 4. Global mRNA expression is not altered by CCND1 3’-UTR overexpression. A. Project outline 
describing determination of CCND1 MRE sharing target mRNAs and determination of global mRNA expression. 
B. Global mRNA expression changes in High CCND1 3’-UTR expression:low CCND1 3’-UTR expression ratio 
(log2FC) between CCND1 MRE target genes (blue) and control genes (yellow) in TCGA-HNSC overall, HPP-
negative, and HPV-positive cohorts. C. Mechanisms of ceRNA-mediated regulation of cellular transcripts include 





Figure 5. Target protein regulation related to CCND1 3’-UTR expression in TCGA-HNSC. A. Project outline 
describing determination of CCND1 MRE sharing target mRNAs B-C. Pearson correlation between target protein 
RPPA value and CCND1 3’UTR log2FC in TCGA-HNSC HPV-positive (B) and HPV-negative (C) patients. Blue 
boxes represent significantly negatively correlated proteins and red boxes represent significantly positively 
correlated proteins. Proteins are labeled as non-significantly correlated (grey), significantly correlated (black), or 
significantly correlated and also sharing CCND1 MREs (red). D. Target protein transcript MREs shared with 
CCND1 in HPV-negative HNSCC. E. Target protein mRNA expression values (log2FC) stratified by high (blue) 
and low (yellow) CCND1 3’-UTR expression in HPV-positive (left) and HPV-negative (right) patients. Statistical 





Figure 6. Target protein regulation related to CCND1 3’-UTR expression in other 11q13-amplified cancers. 
A-D. Pearson correlation between target protein RPPA value and CCND1 3’UTR log2FC in TCGA-BLCA (A), 
TCGA-BRCA (B), TCGA-ESCA (C), and TCGA-LUSC (D) patients. Blue boxes represent significantly negatively 
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correlated proteins and red boxes represent significantly positively correlated proteins. Proteins are labeled as 
non-significantly correlated (grey), significantly correlated (black), significantly correlated and also sharing 
CCND1 MREs (red), significantly correlated and shared with TCGA-HNSC (green), or significantly correlated 
and shared with TCGA-HNSC and CCND1 (blue). E. Target protein transcript MREs shared with TCGA-HNSC. 
Alterations found in TCGA-HNSC are labeled in green and alterations in both TCGA-HNSC and CCND1 are 
labeled in blue. F. Target protein mRNA expression values (log2FC) stratified by high (blue) and low (yellow) 
CCND1 3’-UTR expression in TCGA-BRCA, TCGA-ESCA, and TCGA-LUSC patients. Statistical significance 
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Supplementary Figure S1. Predicted MREs of genes within the 11q13 amplicon. Predicted tumor-
suppressing MREs (blue) and oncomiRs (red) were evaluated for each gene within the 11q13 amplicon. 
Calculated tumor-suppressor:oncomiR ratio is displayed below each gene. 
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In Study 3, we have identified potential roles of CCND1 3’-UTR in the progression of HNSCC. However, patients 
that overexpress CCND1 Exon 5 also overexpress CCND1 Exon 1 (Figure 1, Study 3 Figure 2). In this addendum 
to Study 3, we aim to separate the effects of CCND1 ORF expression and CCND1 3’-UTR expression on patient 
survival as well as establish cellular mechanisms of CCND1 3’-UTR ceRNA-mediated effects on observed 




Cell Lines and Cell Culture 
Cell lines used were MDA1586(1) and UPCI:SCC040(2). All lines were propagated in Dulbecco's Modified Eagle 
Media (DMEM) supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin. Cell lines expressing 
engineered CCND1 constructs were selected using 10 µg/ml blasticidin (#A1113903, Gibco). Cell lines stably 
infected with pLKO.1-puro CCND1 shRNA or scramble control shRNA were generated by 20 µg/ml puromycin 
(#P9620, Sigma-Aldrich) selection following standard methods. 
Development of CCND1 Constructs 
A plasmid containing an HA-tag at the 3’ end of the CCND1 ORF (CCND1-HA) was purchased from Addgene 
(#9050). The ORF-HA sequences were PCR amplified to produce a 1,158 bp BamHI-SalI fragment that was 
then subsequently ligated into pLenti CMV Blast empty (w263-1) (#17486, Addgene) that was cut using the same 
restriction enzymes to produce the CCND1-ORF (ORF) construct. A 1,158 bp BamHI-XhoI fragment was made 
in parallel for ligation to a 3’-UTR fragment and then into pLenti CMV Blast empty. A CCND1 plasmid containing 
the 3’-UTR(3,4) provided by Kathy Borden (University of Montreal) was PCR amplified to produce a 3,212 bp 
XhoI-SalI fragment that was ligated to the 3’ end of the 1,158 bp BamHI-XhoI ORF fragment to create the 
CCND1-FL (FL) construct. The ORF was made refractory to two CCND1 shRNAs (TRCN0000295873 and 
TRCN0000295874) using a site-directed mutagenesis kit (#200523, Agilent), following manufacturer’s protocol 
to produce the final ORF and FL constructs. A frameshift mutation was generated by insertion of a guanine base 
immediately after the ATG start site in the +4 position to create the CCND1-FS (FS) construct. The pLenti CMV 
Blast empty served as the EV construct. 
Western Blotting and Antibodies 
Western blotting was conducted as described(5) and visualized with autoradiography film (E3012, Denville 
Scientific) or captured by an Amersham Imager 600 (GE Healthcare Bio-Sciences). Antibodies used were anti-
cyclin D1 (sc-718, 1:1000; Santa Cruz Biotechnology), anti-HA-Tag (#3724, 1:1000; Cell Signaling Technology), 






Total cellular RNA was extracted with Trizol Reagent (#15596026, Ambion) following manufacturer’s instructions. 
Eluted RNA was then treated with Turbo DNA-free kit (#AM1907, Invitrogen) to remove DNA. Concentrations of 
RNA were evaluated using a Nanodrop 2000 Spectrophotometer. 1 μg of total RNA was converted to cDNA 
using the iScript cDNA synthesis kit (#1708890, Bio-Rad). RT-qPCR was performed using the SsoAdvanced 
Universal SYBR Green Supermix (#1725271, Bio-Rad) and primers specific to the 3’-UTR of CCND1. Relative 
expression was calculated using the ΔΔCT method using GAPDH as a control endogenous gene.  
RNA In-Situ Hybridization 
RNA in-situ hybridization was performed as previously described(6). Briefly, custom Stellaris® FISH Probes were 
designed against CCND1 3'UTR by utilizing the Stellaris® RNA FISH Probe Designer (Biosearch Technologies, 
Inc., Petaluma, CA) available online at www.biosearchtech.com/stellarisdesigner (Version 2017). The CCND1 
3'UTR were conjugated to Cy5 for fluorescent visualization. Cells were grown on coverglass, permeabilized and 
hybridized with a buffer containing the labeled CCND1 probes following the manufacturer's instructions available 
online at www.biosearchtech.com/stellarisprotocolscells. Cells were counterstained with DAPI to visualize nuclei 
and mounted onto slides for microscopic analysis using a Nikon A1R confocal microscope. Corrected total cell 
fluorescence was calculated for each cell line. Statistical significance was determined one-way ANOVA and 
Tukey’s post-hoc with an alpha of 0.05.  
Cell Cycle Analysis 
MDA-1586 cells were grown to confluence and maintained for five days in order to induce contact-inhibition-
mediated cell synchronization. (https://www.future-science.com/doi/pdf/10.2144/01306rv01). UPCI:SCC040 
cells were synchronized using a double thymidine block as previously described 
(https://pubmed.ncbi.nlm.nih.gov/5165443/). Cells were then fixed and stained with propidium iodide (PI) as 
previously described(7,8) before flow cytometry analysis. Technical triplicates of both MDA-1586 and 
UPCI:SCC040, as well as biological triplicates of UPCI:SCC040 were assessed by flow cytometry. Flow 
cytometry experiments were performed in the West Virginia University Flow Cytometry & Single Cell Core 
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Facility, which is supported by the National Institute of Health grant U51 GM104942 (WV CTSI) and the 
Institutional Development Awards (IDeA) from the National Institute of General Medical Sciences of the National 
Institutes of Health grant numbers P30GM121322 (TME CoBRE) and P20GM103434 (INBRE). Data were 





Exogenous overexpression of CCND1 constructs in HNSCC cell lines 
To delineate effects of the CCND1 ORF and CCND1 3’-UTR on cancer progression, multiple CCND1 constructs 
were generated (Figure 2A). An empty vector (EV) control plasmid of pLenti Blast was used as a backbone for 
the cloning of CCND1 sequences and also serves as a control for downstream studies. A construct expressing 
green fluorescent protein (GFP) was generated by cloning GFP into EV to generate a control cell line  to serve 
as a control in downstream experimentation. The CCND1-HA ORF was mutated using site-directed mutagenesis 
to form a CCND1-HA ORF refractory against two different CCND1-targeting shRNAs designed to   knockdown 
of endogenous CCND1 protein expression. This CCND1-HA ORF was then cloned into EV to form the ORF 
construct in order to evaluate effects of CCND1-HA ORF alone. The full-length CCND1 3’-UTR was subsequently 
cloned into ORF to generate the full-length CCND1-HA sequence (FL). This construct was subsequently mutated 
at the +4 position by to introduce a frameshift that ablates expression of exogenous cyclin D1 protein (FS) to 
evaluate overexpression of CCND1 3’-UTR alone without loss of mRNA secondary structure that may be 
required for ceRNA effects. 
These constructs were introduced into the CCND1-diploid HNSCC cell line MDA-1586 using lentiviral infection 
to evaluate gain-of-function effects via CCND1 overexpression. Successful transduction and construction 
expression were evaluated by western blotting, RT-qPCR, and mRNA-FISH depending on produced protein 
and/or mRNA products. Western blot visualization displayed successful stable expression of CCND1 constructs 
with the presence of the HA epitope as a band of increased molecular weight reacting with to and anti-cyclin D1 
in the MDA-1586-ORF and MDA-1586-FL cell lines (Figure 2B). Since overexpression of 3’-UTR cannot be 
assessed by western blot due to lack of protein production, RT-qPCR was utilized to visualize expression of 
CCND1 3’-UTR in MDA-1586 cell lines. Both lines showed increased relative expression of CCND1 3’-UTR in 
MDA-1586-FL and MDA-1586-FS cell lines (Figure 2C). To further assess the expression of CCND1 constructs 
in MDA-1586 cells, mRNA-FISH was utilized which also allowed assessment of sub-cellular location of CCND1 
mRNA. Microscopic analysis indicated overexpression of CCND1 mRNA constructs in the cytosol of MDA-1586 
cell lines (Figure 2D).  
175 
 
To account for potential oncogene-addiction introduced through 11q13 amplification and subsequent enhanced 
endogenous CCND1 overexpression, the engineered CCND1 constructs were introduced into the 11q13-
amplified HNSCC cell line UPCI:SCC040. Visualization of protein expression by western blotting indicated 
successful overexpression of the ORF and FL CCND1 constructs (Figure 2E). To test the ability of these 
constructs to resist shRNA knockdown, UPCI:SCC040 cells expressing ORF, FL and ATG? were stably infected 
with an anti-CCND1 shRNA. Western blot visualization revealed successful knockdown of endogenous CCND1 
without impacting recombinant CCND1 overexpression (Figure 2F). 
Exogenous CCND1 3’-UTR overexpression does not appear to alter HNSCC cell cycle progression 
Due to the role of cyclin D1 in the progression of cell cycle, we sought to investigate the effects of overexpression 
of the CCND1 3’-UTR on cell cycle to assess 3’-UTR-mediated effects. Cell cycle was assessed using PI staining 
of synchronized HNSCC cell lines. MDA-1586 gain-of-function analysis displayed a modest increase of cells in 
the G2-M phase, suggesting increased proliferation of cells overexpressing the FL or FS constructs (Figure 3A). 
However, MDA-1586 cells were synchronized using a non-conventional method and the experimental results 
are only one run of analysis at only one time point (24 hours). Further analysis was conducted using the 
UPCISCC:040 cell, due to the aforementioned potential for oncogene addiction in the 11q13-amplified 
background that maybe necessary to visualize any changes in CCND1-amplified cells. Double thymidine block 
synchronization followed by biological triplicate (each repeat containing technical triplicates) revealed no 
differences in cell cycle at 6, 12, or 24 hours in transfected UPCISCC:040 cells (Figure 3B). This suggests that 
CCND1 3’-UTR overexpression does not impact HNSCC progression by modulating increase in cell proliferation 






In Study 3, we identified differentially expressed proteins that were correlated with CCND1 3’-UTR expression 
changes. In this Addendum, we show that CCND1 ceRNA-mediated effects on tumor progression do not act 
through increased cell cycle progression. However, the target proteins identified in Study 3 may function through 
other tumor-enhancing mechanisms, including increased proliferation, invasion, migration, apoptosis resistance, 
and DNA synthesis. Other assays such as BrdU incorporation or further optimized PI staining assays may be 
able to better evaluate potential changes on the cell cycle. These possibilities, coupled with the survival 
differences in patients with high CCND1 3’-UTR expression, underscore the need for further studies. The 
different CCND1 expression constructs provide useful tools for the evaluation of any ceRNA-mediated effects in 
HNSCC cell lines in future work. 
While TCGA offers a useful tool for evaluating global mRNA expression changes, evaluation using CCND1 
expression vectors is still vital for understanding CCND1 ceRNA-mediated effects on mRNA. For determining 
transcriptional changes specific to the CCND1 3’-UTR, isolated RNA from UPCISCC:040 parental and EV, FL, 
ORF and FS overexpressing cells will be DNAse and RiboZero treated before RNAseq in 2x150 format at 50M 
reads. Data will be evaluated for differential gene expression(9). Highly upregulated transcripts shared by FL 
and FS overexpressing cells compared with control and ORF lines will be considered novel candidates for 
CCND1 ceRNA activity. 3’-UTR regions from candidate targets will be evaluated by DIANA Tools, TargetScan 
and the literature for shared microRNA response elements (MREs) with the CCND1 3’-UTR. As TCGA results 
suggest, evaluation of target proteins may be more useful than purely transcriptomic analysis. To evaluate 
changes in protein expression, cells will be lysed with the EasyPrep Mini MS prep kit (Fisher) and subjected to 
label-free quadrupole Orbitrap liquid chromatography tandem mass spectroscopy (LC-MS/MS)(10) with the 
assistance of the WVU BioNano Research Facility. SIEVE, Compound and Proteome Discoverer will be used 
for peptide identification, protein assembly and quantification(11). Relative protein values will be compared for 
FL and FS overexpressing cells to control and ORF cells, with overexpressed proteins in FL and FS cells 
evaluated for MREs shared with the CCND1 3’-UTR. We anticipate multiple transcripts and proteins will be 
upregulated in the FS and FL cell lines compared to controls, including those identified in patient samples (Study 
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3 Fig. 5D). Upregulated proteins in FL cells may be due to cyclin D1 protein overexpression, rather than ceRNA 
by the 3’-UTR. These cases will be compared with the FS results. 
To test the ability of the CCND1 3’UTR as a ceRNA for putative target expression, the 3’-UTR regions for 
candidate and discovered ceRNA targets will be subcloned into a luciferase reporter vector and assayed(12). 
Constructs will be stably transfected into HNSCC CCND1 KD cells with overexpression of EV, ORF, FL and FS 
transcripts (Figure 2A). Target-driven luciferase activity will be measured. To determine if target overexpression 
is dependent on CCND1 ceRNA activity, the established seed region of MREs for miRNAs in each respective 
target 3’-UTR (Fig. 6D) will be mutated. Knockdown cells expressing miRNA-mutant constructs (MM) will be 
generated and the activity of the target 3’-UTR luciferase reporter compared to the CCND1 ORF, FL and FS 
control cells. These results will be validated using target site blocking (TSB) oligonucleotides (Qiagen miRCURY) 
against the 3’-UTR MREs for each target. TSBs will be transfected into control ORF, FL and FS cells, and target 
protein and mRNA expression will be measured. To control for specificity, TSBs will be transfected into MM cells 
and assayed for target expression. We predict overexpression of CCND1 FL and FS to increase candidate 
ceRNA target expression compared to ORF constructs due to 3’-UTR titration of shared miRNAs. TSB 
transfection is expected to block CCND1 and target transcript MREs, producing an inhibitory effect. 
Proliferation will be evaluated using CyQuant NF (Fisher) and Ki67 immunolabeling of fixed cells. Anchorage 
independent growth will be assayed for colony formation in soft agar as described(13). Apoptosis will be 
evaluated using annexin V staining and quantified by flow cytometry. HNSCC invasiveness will be evaluated 
with each cell line using an organotypic assay as described(14,15). Degree and extent of invasion will be 
quantified using a calculated index based on histologic imaging of H&E stained sections using Metamorph 
software as previously detailed(16). MM cell lines with known ceRNA effects for candidate targets will be 
evaluated in accordance with appropriate assays, with target expression monitored by western blotting and RT-
qPCR. FL and FS overexpression are anticipated to effect one or more hallmarks to a greater extent than ORF 
and EV. The FS construct may not enhance all of these processes in some cases due to lack of coincident cyclin 
D1 protein expression, but will provide additional evidence that the 3’-UTR contributes to one or more aspects 
of HNSCC progression. 
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11q13 amplification and CCND1 overexpression occurs in other tobacco-associated malignancies(17–20). 
Correlation analyses identify several shared overexpressed candidate CCND1 3’-UTR ceRNA targets (e.g., 
SERPINE1 and ITGA2) (Study 3 Figure 6), further underscoring the significance of the proposed work. The 
outcome of these future directions addressing regulation of the miRNA network by CCND1 transcript 
overexpression will provide unique insights into the consequence of 11q13 amplification and associated poor 
outcomes in HNSCC.   
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Figures and Tables 
 
Figure 1. Patient overall survival stratified by CCND1 exon expression. Survival analysis of patients with 
high CCND1 exon 1 (blue) or exon 5 (red) overexpression (N=65) or low exon 1 (green) exon 5 (black) expression 
(N=65) using the Broad HNSC Level 3 exon expression dataset. Z-scores were normalized to diploid values. 




Figure 2. Development of CCND1 constructs and expression in HNSCC cell lines. A. CCND1 expression 
constructs subcloned into pLenti-Blast CMV (Addgene). EV; empty vector control. GFP; GFP control. ORF; cyclin 
D1 open reading frame. FL; complete CCND1 transcript with ORF and 3’UTR. FS; point mutant frame-shifted at 
position +4 in the ORF.  B. Protein expression of CCND1 constructs. Western blotting of lysates from disomic 
MDA-1586 HNSCC cells transduced with the constructs in (A) and blotted as indicated. C. Ectopic expression 
of CCND1 3’-UTR regions. RNA from the indicated cells was amplified by RT-qPCR using primers targeting the 
CCND1 3’-UTR. Bars represent mean with SD error bars. Statistical significance was determined using ANOVA 
and Tukey’s post-hoc with an alpha of 0.05. ****: p<0.0001; **: p<0.01. D. Representative images of RNA-FISH 
for non-amplified MDA-1586 and amplified UPCI:SCC40 HNSCC lines. CCND1 transcripts display abundant 
cytoplasmic localization to serve as ceRNA. Bar = 20 μm. E. Protein expression of CCND1 constructs. Western 
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blotting of lysates from amplified UPCI:SCC040 HNSCC cells transduced with the constructs in (A) and blotted 
as indicated.  F. CCND1 knockdown and re-overexpression of HA-tagged ORF and FL constructs in 11q13 
amplified UPCI:SCC040. EV; empty vector sh Sramble control. 
 
Figure 3. Cell cycle analysis of CCND1 constructs in HNSCC cell lines. A. MDA-1586 and B. UPCISCC:040 
CCND1 overexpressing lines were synchronized, PI labeled and sorted by FACS. Analysis was conducted using 
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This dissertation describes studies that illuminate the relationship between Appalachian HNSCC survival, 
tobacco-induced DNA damage, and novel functions of the tumor progression driver cyclin D1. The first Study 
details how increased tobacco exposure in the Appalachian region can contribute to decreased survival of AJCC 
stage IV HNSCC patients with primary tumors within the HPV-associated oropharynx. The second Study 
establishes large-scale chromosomal damage that is correlated with increasing patient pack-year value and 
identifies several candidate genes of unknown or unappreciated function in HNSCC for future studies. The third 
Study outlines a potential ceRNA-driven mechanism of cyclin D1, a well-known tumor progression driver in 
HNSCC while the Addendum to Study 3 explores this potential mechanism in vitro. Together, these studies 
expand on the observed HNSCC disparity within Appalachia, correlate tobacco-use to 11q13 amplification and 
subsequent overexpression of a subset of genes, and link an 11q13 gene to novel functions (Figure 1). Results 
from this dissertation could impact patient treatment regimens and clinical trial stratification by solidifying 
tobacco-use and 11q13 gene, including CCND1, expression levels as important diagnostic criteria. 
 
 
Figure 1. Dissertation overview detailing three studies. 
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Although oral cavity and pharyngeal cancer incidence and mortality disparities in Appalachia have been 
documented in the past(1,2), the work outlined in Study 1 further describes these disparities by separating 
patients by AJCC stage, sex, race, and primary site. Thus, this approach utilizes a comprehensive methodology 
that includes cancer-specific survival data from the majority of Appalachian counties and the non-Appalachian 
counties within the same states. The results from this work are definitive descriptions of oral cavity and 
pharyngeal survival in the Appalachian region, pinpointing the observed disparity to AJCC-6 stage IV white males 
with tumors in the HPV-associated oropharynx. This suggests that these patients have a higher prevalence of 
HPV-negative cancer, which has been shown to have poorer survival(3–6), within classically defined HPV-
positive subsites. This difference is potentially driven by an increased use of smoking and smokeless tobacco 
amongst males in the region. The implication of these findings is that because tobacco remains the primary 
cause of HNSCC(7) and Appalachia harbors the highest tobacco-use rates in the country(8), accurate tobacco 
histories of patients is an important predictor of clinical outcome, regardless of the anatomical location of the 
tumor. This work also suggests that the recent discussion of treatment de-intensification of patients with HPV-
associated oropharyngeal cancers(9,10) should be revisited, and that tobacco-exposure needs to be included in 
this discussion as a treatment qualifier. Importantly, p16 immunohistochemistry (IHC) is one of the criteria used 
when determining treatment for HNSCC patients(11). This diagnostic indicator is well supported(12,13), yet not 
a perfect indicator of HPV positivity due to other chromosomal alterations that can occur to skew these results 
to lead to false positives and false negatives(14). CDKN2A is often deleted in HNSCC(3) which would lead to a 
false negative result even if the patient is HPV-positive. Conversely, CCND1 would elicit the same loss of p16 
negative-feedback loop by releasing more E2F transcription factor, which would also lead to an accumulation of 
p16 and could lead to be a false positive. These scenarios are detailed in Figure 2. 
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Since p16 IHC is currently paramount in determining the course of patient treatment, this could lead to disastrous 
results, even if this impacts a low number of patients. A better solution would be to perform CCND1, CDKN2A, 
and HPV PCR alongside p16 staining(15,16). Unfortunately, with the advent of AJCC 8th edition putting more 
emphasis on HPV status by downstaging patients if they are HPV-positive by p16 staining, we are beginning to 
see evidence of potential undertreatment and worse outcomes of patients due to the under-staging and less 
aggressive treatment proposed in the AJCC 8th edition(9). Overall, these studies, coupled with the results of 
Study 1, underscore the need for continued pursuit to fully understand molecular, behavioral, and geographical 
differences in the staging and treatment of HNSCC patients regardless of etiology. Future studies could track 
the effectiveness of smoking cessation campaigns in Appalachia, as well as effects of prophylactic HPV 
vaccination on HNSCC stage IV white male survival and how this effects patient survival over time. If the disparity 
does not normalize to national outcomes, it is imperative that continued government funding to the ARC, as well 
as continued education and smoking cessation campaigns will continue to be necessary for reducing HNSCC 
risk and improving survival in the Appalachian region. Such an approach can also be extrapolated to areas of 
disproportional smoking tobacco, smokeless tobacco(17), or betel-quid use(18). 
 
Figure 2. Possible outcomes of p16 IHC clinical test for prognosis. HPV virion adapted from The RCSB PDB 
"Molecule of the Month": Inspiring a Molecular View of Biology D.S. Goodsell, S. Dutta, C. Zardecki, M. Voigt, H.M. 
Berman, S.K. Burley (2015) PLoS Biol 13(5): e1002140. doi: 10.1371/journal.pbio.1002140 
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HNSCC is largely conceptualized by the field as being driven by genomic relief of tumor suppression(19). 
However, HNSCC also harbors many copy-number gains and amplifications, the most common of which is the 
11q13 amplicon. Chromosome 11q13 amplification is found in nearly one third of all patients and is associated 
with lower survival(3,20). Although it is believed 11q13 amplification and other CNAs in HNSCC are associated 
with DNA damage arising from carcinogenic insult due to cigarette smoking and associated DNA damage(7,21), 
the precise CNAs correlated with smoking have not been directly defined. The work outlined in Study 2 seeks to 
close this knowledge gap by correlating the copy number of 24,776 genes with the pack-year data of 509 patients 
from the well-annotated TCGA cohort to generate a smoking-associated copy number and expression landscape 
in HNSCC. This work resulted in identifying a smoking-associated expression signature (SAES) that mapped to 
four distinct chromosomal cytobands in known CNAs, including deletions of genes within 9p21.3 and 9p24.1 with 
the vast majority being amplifications of genes within 11q13.3 and 11q13.4. All underexpressed and 
overexpressed genes within the SAES reduced patient overall survival and were correlated with an increased 
relative risk of death. Interestingly, there is a near-linear positive correlation between probability of amplification 
of 11q13.3-q13.4 and smoking pack year as well as between overexpression of 11q13.3-q13.4 SAES genes. 
The correlation of these CNAs coupled with this predictive aspect with increased smoking tobacco usage 
underscores the importance of collecting complete tobacco use histories during patient consultation and 
diagnosis. This history is simple to collect from the patient and may be useful to both researchers and clinicians 
to predict probability of smoking-associated DNA damage and expression SAES genes which could better guide 
early treatment. In addition to the known drivers of HNSCC within these CNAs, such as CCND1 and 
CTTN(22,23), we have also identified candidate drivers of HNSCC where overexpression reduces patient 
survival. A subset of these candidate drivers also correlates with lymph node metastasis, which is an important 
prognostic indicator of patient outcome(24,25). These candidate genes include the mitochondrial ribosomal 
protein L21 (MRPL21), LAR protein tyrosine phosphatase-interacting protein alpha-1 (PPFIA1), fibroblast growth 
factor 19 (FGF19), two pore segment channel 2 (TPCN2), and E3 ubiquitin ligase RING finger protein 121 
(RNF121). MRPL21 encodes a large mitochondria ribosomal subunit, where proper stoichiometry is critical for 
mitoribosome assembly(26). There is no defined role for MRPL21 in tumor progression, but its cellular function 
suggests a role in regulating tumor cell metabolism. PPFIA1 encodes a LAR phosphatase-interacting protein 
that localizes to and regulates the disassembly of focal adhesions(27). Liprin-alpha1 has a roles in regulating 
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cell motility, invasion, and transmembrane signaling(28,29). FGF19 encodes a fibroblast growth factor that 
functions as a hormone in the regulation of bile acid synthesis, signaling through the fibroblast growth factor 
receptor 4 (FGFR4)(30) that is linked to tumor-promoting autocrine signaling(30). TPCN2 encodes a cation-
selective ion channel that releases calcium ions from lysosomal stores but does not have a defined role as a 
tumor promoter(31). RNF121 encodes an E3 polytopic membrane protein with five transmembrane regions 
thought to be part of the endoplasmic-reticulum-associated protein degradation response (ERAD) that 
downregulates several proteins in invertebrates(32). RNF121 does not have a well-defined role in tumor 
progression as it has been shown to be both a tumor promoter(33) and tumor suppressor(34), with a defined 
role in NF-κB activation(35). Future studies that expand our understanding of how 11q13 amplification and 
resultant gene overexpression of these poorly defined candidate genes contributes to poor patient outcome in 
smoking-associated HNSCC is further underscored by the increased resistance to chemotherapy and EGFR 
targeting in 11q13-amplified HNSCC(36–38). This highlights a persistent need for earlier and precise diagnosis 
for patients with SAES CNA and expression status to provide improved clinical management of tobacco-positive, 
HPV-negative HNSCC.  
The 11q13 amplicon contains several genes that have been linked to increased tumor progression, including 
CCND1(19), CTTN(39), FADD(40), and ORAOV1(41). These genes drive tumor progression through gene 
product protein-protein interactions. However, other functions of the mRNA transcript itself, independent of 
protein function, could drive tumor progression. In Study 3, we explored the potential competing endogenous 
effects of the RNA of these genes on altering expression of other cellular RNAs and ultimately altering cellular 
expression of proteins involved in either tumor-suppressive or tumor-promoting roles. We observed that the 
overexpression of the CCND1 3’-UTR is associated with reduced patient survival and also contains 31 MREs for 
tumor-suppressive microRNAs. When correlating expression of CCND1 3’-UTR from RNAseq analysis and 
protein expression from reverse phase protein lysate microarray RPPA analysis, we identified several proteins 
of interest with increased differential expression encoded by transcripts containing MREs shared with the CCND1 
3’-UTR. These proteins include TYMS, SERPINE1, CCNB1, DVL3, GATA3, E2F1, and ITGA2. All of these 
proteins have been linked to tumor progression, although their roles in HNSCC are only partially 
known(42,43,52–61,44,62,63,45–51). The added effect of these overexpressed tumor promoters creates an 
additional layer of complexity to the oncogenic role of overexpressed cyclin D1. Elucidating the full impact of 
190 
 
CCND1 mRNA overexpression, through 3’-UTR-mediated ceRNA sequestration or through cyclin D1 protein 
overexpression is imperative in understanding how to best stratify patients for treatment with CDK4/6 inhibitors 
that only impact CCND1 protein function. The amplification of 11q13 may not be enough in and of itself to justify 
stratification for CDK4/6 inhibitors. As shown in the PALOMA-1 clinical trial that stratified patients by CCND1 
amplification and the results did not support that stratification by CCND1 amplification improves patient 
outcome(64,65). Alternatively, there is evidence that stratification by CCND1 transcript expression is a poor 
predictor of response rates of other chemotherapy drugs(66). The results in this Study coupled with these 
stratification results suggest that CCND1 3’-UTR expression levels may be an important way to predict patient 
outcome from chemotherapeutic intervention. In the Addendum to Study 3, we created CCND1 expression 
vectors that overexpress different segments of the CCND1 transcript using in vitro assays to examine for the 
presence of a ceRNA-mediated effect on tumor progression. These constructs contained the ORF alone, full 
length CCND1, and a frameshift CCND1 mutant that does not produce cyclin D1 protein. Exogenous expression 
was confirmed using various in vitro assays including western blotting, RT-qPCR, and mRNA-FISH in both the 
non-11q13-amplified HNSCC cell line MDA-1586 and the 11q13-amplified HNSCC cell line UPCI:SCC040. Effect 
on cell cycle progression was also evaluated, with mixed results. For this reason, additional laboratory 
investigation is required to confirm that the suggested ceRNA effect is supported. Future experiments that 
examine effects of these proteins on tumor progression, such as transcriptome RNAseq or proteome mass 
spectrometry using the developed CCND1 constructs will be imperative for complete understanding of the 
dynamics at play. If the ceRNA effect is supported, there is potential to uncover new actionable targets that are 
deregulated due to the ceRNA effect. Additionally, confirming shared microRNA that interact with these target 
proteins will be an important first step to direct targeted anti-microRNA therapy approaches to mediate CCND1 
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Malregulation of the actin cytoskeleton enhances tumor
cell motility and invasion. The actin-binding protein
cortactin facilitates branched actin network formation
through activation of the actin-related protein (Arp) 2/3
complex. Increased cortactin expression due to gene
amplification is observed in head and neck squamous cell
carcinoma (HNSCC) and other cancers, corresponding
with elevated tumor progression and poor patient out-
come. Arp2/3 complex activation is responsible for driving
increased migration and extracellular matrix (ECM) deg-
radation by governing invadopodia formation and activ-
ity. Although cortactin-mediated activation of Arp2/3
complex and invadopodia regulation has been well estab-
lished, signaling pathways responsible for governing cor-
tactin binding to Arp2/3 are unknown and potentially
present a new avenue for anti-invasive therapeutic target-
ing. Here we identify casein kinase (CK) 2a phosphory-
lation of cortactin as a negative regulator of Arp2/3 bind-
ing. CK2a directly phosphorylates cortactin at a conserved
threonine (T24) adjacent to the canonical Arp2/3 binding
motif. Phosphorylation of cortactin T24 by CK2a impairs
the ability of cortactin to bind Arp2/3 and activate actin
nucleation. Decreased invadopodia activity is observed in
HNSCC cells with expression of CK2a phosphorylation-
null cortactin mutants, shRNA-mediated CK2a knock-
down, and with the CK2a inhibitor Silmitasertib. Silmi-
tasertib inhibits HNSCC collective invasion in tumor
spheroids and orthotopic tongue tumors in mice. Collec-
tively these data suggest that CK2a-mediated cortactin
phosphorylation at T24 is critical in regulating cortactin binding to Arp2/3 complex and pro-invasive activity, identifying
a potential targetable mechanism for impairing HNSCC invasion.
Implications: This study identifies a new signaling pathway that contributes to enhancing cancer cell invasion.
Visual Overview: http://mcr.aacrjournals.org/content/molcanres/17/4/987/F1.large.jpg.
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Introduction
Cell invasion from the primary tumor is responsible for initi-
ating the metastatic cascade and increasing cancer lethality (1, 2).
Invasion is initiated in part through the action of invadopodia,
actin-based membrane protrusions produced by tumor cells that
mediate dissemination by degrading restrictive extracellular
matrix (ECM) proteins through enzymatic matrix metalloprotei-
nase (MMP) activity (3). Invadopodia contain a central filamen-
tous (F-) actin core surrounded by an integrin-based adhesion
ring complex that anchors the structure to allow focal matrix
degradation and tumor cell protrusion through the basement
membrane (4). Cortactin and actin-related protein (Arp) 2/3
complex are essential protein components involved in invado-
podia precursor core formation required for subsequent MMP
recruitment and membrane protrusion (5, 6). Cortactin over-
expression is common in several cancer types including head and
neck squamous cell carcinoma (HNSCC), resulting in enhanced
motility, invasion, and invadopodia activity (7, 8). Cortactin
binding to Arp2/3 complex activates Arp2/3 actin nucleation
activity, enhancing cellular actin polymerization to form
branched F-actin networks (6, 8–10). Cortactin also directly binds
F-actin andbundles newly-formedfilaments, providing anoverall
stabilizing effect on the Arp2/3-F-actin network required for
invadopodia formation (5, 6, 11). Previous work has shown that
a DDW motif within the cortactin N-terminal acidic (NTA)
domain is central in mediating Arp2/3 activation and branched
actin network formation (7, 12–14). This region is similar
to the Arp2/3 binding motif found in the acidic region of
the Verprolin, Central, Acidic (VCA) domain of the Wiskott–
Aldrich Syndrome protein (WASp)-family of Arp2/3 nucleation
promotion factors (NPF). Although the cortactin DDWmotif is
well established as the region responsible for Arp2/3 binding,
posttranslational or other modifications of amino acids in the
NTA region that regulate binding have not been reported.
Tyrosine and serine phosphorylation of cortactin residues in
the carboxyl-terminal region are essential for invadopodia
formation, cellular invasion, and tumor metastasis through
multiple mechanisms ultimately involving activation of
WASp NPFs (6, 7, 15–18). In addition, comprehensive phos-
phorylation site mapping by mass spectroscopy has identified
NTA phosphorylation sites in close proximity to the DDW
motif (19). This raises the possibility that phosphorylation of
one or more of these residues may serve to govern Arp2/3
binding and invadopodia function in invasive cancer.
Casein kinase (CK) 2 is a ubiquitously expressed, constitutively
active serine/threonine kinase consisting of two catalytic subunits
(a or a') and two b regulatory subunits (20). Increased CK2
expression correlates with cell-cycle progression, apoptosis resis-
tance, and tumor cell motility in various cancers (20). Over-
expressed CK2 enhances HNSCC tumor cell motility (20). CK2
phosphorylates the cortactin homologue HS1 at an unidentified
site(s) in the NTA region (21), as well as residues near the DDW
region in the NPFs neuronal (N)-WASp and WAS protein family
member 2 (WASF2;WAVE2,WASp familyVerprolin-homologous
protein 2; refs. 22–25). Here we show that CK2 phosphorylation
of threonine (T) 24 in the cortactin NTA impairs binding to and
activation of Arp2/3 complex. Cortactin T24 andCK2 are required
for efficient invadopodia formation andECMdegradation activity
in HNSCC cell lines. Treatment of established and primary
HNSCC cells with the selective CK2 inhibitor Silmitasertib
impairs invadopodia function and regional HNSCC invasion.
These results identify a new mechanism of invadopodia regula-
tion that can be targeted to impair HNSCC invasion.
Materials and Methods
Cell culture, lentiviral infection and transfection, siRNA
HNSCC cell lines OSC19 and UMSCC1 were acquired and
maintained as described (26). MDA1586 cells were obtained in
March 2014 from Barbara Frederick (University of Colorado,
Denver, CO). All HNSCC lines were authenticated by STR
profiling at the University of Arizona Genetics Core in June
2017. PCR-based mycoplasma testing (13100-01; Southern Bio-
tech)was conductedonOSC19 andUMSCC1 lines inMarch2015
andwere free of contamination. TheMDA1586 linewas not tested
for mycoplasma. HEK293T/17 cells were obtained in April 2013
from Robert Wysolmerski (West Virginia University, Morgan-
town, WV). NIH3T3 cells were obtained in June 2017 from Ivan
Martinez (West Virginia University, Morgantown,WV) andmain-
tained for 10 passages. These lines were not authenticated or
tested for mycoplasma. Cells were propagated in DMEM supple-
mented with 10% FBS and 1% penicillin–streptomycin for
<6 months. OSC19 and UMSCC1 cells stably infected with
pLKO.1-puro cortactin shRNA or CK2a shRNA were generated
by clonal puromycin selection following standard methods
(CSNK2A1: TRCN0000380839, TRCN0000027627; CTTN:
TRCN0000040275).
UMSCC1 cells stably infected with pLU-Luc2 expressing lucif-
erase were generated following standard methods. Murine cor-
tactin rescue OSC19 and UMSCC1 cells containing cortactin
shRNA stably infected with pLenti CMV Hygro cortactin con-
structs were generated by subsequent clonal hygromycin selec-
tion. Complete cortactin knockdown in OSC19 and UMSCC1
cells was achieved by transfection of cortactin-targeting siRNA
(ON-TARGETplus SMARTpool L-010508-00-0020; Dharmacon)
using a Nucleofector I (Amaxa Biosystems).
Western blotting, antibodies, and immunoprecipitation
Western blotting was conducted as described (27) and visual-
ized with autoradiography film (E3012; Denville Scientific) or
captured by an Amersham Imager 600 (GE Healthcare Bio-
Sciences). Antibodies used were: anti-cortactin clone 4F11
(1 mg/mL; ref. 26), anti-pS473 AKT (#4060, 1:1,000; Cell Signal-
ing Technology), anti-panAKT (#2920, 1:1,000; Cell Signaling
Technology), anti-b-actin (#8457, 1:1,000; Cell Signaling Tech-
nology), anti-CK2a (#2656, 1:500; Cell Signaling Technology),
anti-DYKDDDK (FLAG) clone 2EL-1B11 (MAB3118, 1:500;
Millipore), and anti-Arp3 (#07-272, 1:500; EMD Millipore).
Immunoprecipitation was conducted from cells lysed in 50
mmol/L Tris Buffer pH 8.0 with 10 mmol/L EDTA and 1%
NP-40 (28). Clarified lysates (1 mg) were incubated with 50 mL
of FLAG M2 affinity resin (A2220; Sigma-Aldrich) for 2 hours at
4C. Immune complexeswere collected by centrifugation,washed
twice with Tris buffer, separated by SDS-PAGE, and Western
blotted with antibodies as described above.
Gelatin degradation assay, invadopodia characterization, and
microscopy
Cells were plated on Oregon Green 488-conjugated gelatin
(G13186; Invitrogen) coated coverslips (29). In cases of inhibitor
treatment, cells were allowed to attach for 1 hour, then incubated
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for 12 or 24 hours with Silmitasertib (S2248; Selleckchem) as
indicated. Cells were rinsed in PBS, fixed with 10% buffered
formalin (SF100-4; Fisher Scientific), and labeled as
described (29). Antibodies used were 4F11 (1:500) or anti-FLAG
(1:500). Primary antibodieswere visualized usingAlexa Fluor 647
conjugated goat anti-mouse secondary antibody (A21235, 1:500;
Invitrogen). F-actin was visualized with rhodamine-conjugated
phalloidin (R415, 1:1,000; Invitrogen). Coverslips weremounted
using ProLong Gold antifade with DAPI (P36935; Invitrogen).
Images for quantifying gelatin degradation and knockdown/
rescue expression were acquired with a Zeiss Axio Imager Z2
epifluorescentmicroscope equippedwith anAxioCamMRmCCD
camera and AxioVision software using LD Plan-Neofluar 40X/0.6
Corr and Plan-Apochromat 63X/1.4 oil objectives (Carl Zeiss
Microscopy). Acquisition parameters were held constant within
comparison groups. Confocal images were acquired using a
Zeiss Axio Imager Z1 LSM510 confocal microscope with EC
Plan-Neofluar 40X/1.30 and Plan-Apochromat 63X/1.4 oil objec-
tives and Zen2009 software (Carl Zeiss Microcopy). All represen-
tative images were level adjusted to enhance contrast and bright-
ness as needed and resized using Photoshop CC 2018 (Adobe
Systems). Gelatin images were corrected for uneven illumination
via bandpass filtering using ImageJ software (NIH). Degradation
and invadopodia formation was quantified as described previ-
ously (29), with n  70 lentiviral infected or 100 inhibitor-
treated cells evaluated for each condition. FLAG-stained control
images were thresholded against nonspecific staining using
ImageJ software. Cells above threshold values were considered
positive for rescue construct expression and used for quantitation.
For therapeutic treatments and RNAi stable cell lines, degra-
dation and cell areas were determined by Image J (NIH) on an
individual cell basis. Data represent the mean values normal-
ized to control degradation area per cell area from at least three
independent experiments. Invadopodia precursors were deter-
mined by colocalization of actin and cortactin at sites lacking
gelatin degradation. Active invadopodia were determined by
colocalization of actin, cortactin, and gelatin degradation. Data
represent the mean from at least three independent experiments.
Phase contrast images were acquired using a Zeiss Axiovert 200M
microscope equipped with an AxioCamMR CCD camera using a
Plan-Neofluar 10/0.30 objective and AxioVision software (Carl
Zeiss Microscopy).
CK2a kinase assay
In vitro kinase assays were performed as described (30). Briefly,
0.25, 0.5, or 1 mg of purified GST-wild-type (WT) or T24A cortactin
NTA fusion proteins were incubated with 8 ng CK2a (#14-445;
Millipore) and 10mCi 32Pg-ATP (#NEG002A500UC; PerkinElmer)
at 30C for 10 minutes. Reactions were terminated with hot SDS
sample loading buffer. Proteins were visualized by autoradiogra-
phy. PurifiedN-WASpGST-VCA (0.5 mg) andGST (1mg)were used
as respective positive and negative controls.
In vitro cortactin phosphorylation binding assay
Purified WT or T24A cortactin proteins (2.5 mg) were bound to
4F11-conjugated protein Gmagnetic beads (#10003D; Life Tech-
nologies). Immune complexes were incubated in the presence or
absence of activated CK2a (75 ng; #V4482; Promega) and ATP
(500 nmol, #BP413-25; Fisher Scientific) at 30C for 15 minutes.
Reactions were washed twice with 10 mmol/L Tris pH 7.4,
150 mmol/L NaCl, 0.5 mmol/L EDTA. Complexes were washed
once with 10 mmol/L Tris pH 7.4, 10 mmol/L EDTA, and
incubated with 50 ng Arp2/3 complex (#RP01-A; Cytoskeleton)
at 4C for 30 minutes. Following incubation, binding complexes
were washed once with 10 mmol/L Tris Buffer pH 7.4 with
25 mmol/L NaCl, 10 mmol/L EDTA, 1% NP-40, then boiled and
Western blotted with antibodies against cortactin and Arp3.
Actin polymerization assay
Actin polymerization experiments were conducted as described
previously (31). Reactions contained2mmol/L actin (10%pyrene-
labeled), 75 nmol/L Arp2/3 complex, 100 nmol/L cortactin, or
50 nmol/L GST-VCA (#VCG03; Cytoskeleton), and/or varying
amounts of CK2a (#14-445; Millipore) as indicated. For reactions
withCK2a,GST-VCA,or cortactinmutantswerepreincubatedwith
CK2a and500nmolATP for 15minutes at roomtemperatureprior
to addition to the actin polymerization reaction.
PDX-derived cell lines
Patient-derived xenograft (PDX) tumors and cell lines were
established as described (32). WVUSCC-AR2 and WVUSCC-AR5
were derived from surgical specimens of alveolar ridge HNSCC in
compliance with West Virginia University Institutional Review
Board approved protocol #1310105737A033. PDXs were devel-
oped in compliance with West Virginia University Institutional
Animal Care and Use Committee approved protocol #15-0302.6
by placing approximately 1 mm tumor fragments into subcuta-
neous pockets in the flanks of anesthetized 8- to 10-week-old
NOD/SCID-g (NSG)mice. Tumor fragments were overlayed with
Matrigel (354234; Corning) and incisions were closed using
wound clips.Micewereweighed andmonitored for tumor growth
on a weekly basis. PDX tumors were passed into new NSG mice
and/or used to generate cell lines once tumors reached 1 cm in
greatest dimension.
For cell line derivation, PDX tumors were minced and
digested in DMEM supplemented with 20% FBS and 1 mg/mL
collagenase IV (17104019; Gibco). Digested tissues were plated
onto NIH3T3 fibroblasts senesced with 4 mg/mL mitomycin C
(BP2531; Fisher Scientific) and cultured in DMEM:F12 1:1
supplemented with 10% FBS, 400 ng/mL hydrocortisone
(H0888; Sigma), 50 mg/mL gentamycin (15750060; Gibco),
5 mmol/L ROCK inhibitor (S1049; Selleckchem), 0.5 ng/mL
recombinant human EGF (PHG0311; Gibco), and 10 ng/mL
cholera toxin (C8062; Sigma). Both WVUSCC-AR2 and -AR5
were derived in August 2017 and maintained for 10 passages.
Derived lines were verified using cytokeratin 14 staining
(ab15462; Abcam). Neither STR profiling nor mycoplasma
detection was performed on these cell lines. Prior to utilization
in gelatin degradation or spheroid invasion assays,
PDX-derived cell lines were plated directly onto cell culture
dishes for one to two passages to remove the fibroblast pop-
ulation. Gelatin degradation and spheroid invasion assays were
performed in DMEM supplemented with 10% FBS.
In vitro tumor spheroid invasion
3D spheroid invasion assays were performed as previously
described (26). A total of 1104 (OSC19)or 2.5104 (UMSCC1
andWVUSCC-AR5) cells were plated into individual wells coated
with 1.5% noble agar for 24 hours (UMSCC1) or 48 hours
(OSC19 and WVUSCC-AR5) to form spheroids. For each line,
spheroids were collected, resuspended in 500 mL of 2 mg/mL rat
tail collagen I (354236; Corning), andplated into individualwells
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of a 24-well plate precoated with 400 mL solidified 2 mg/mL
collagen I. Plates were incubated for 1 hour at 37C, then over-
layed with 1 mL DMEM supplemented with 10% FBS and 1%
penicillin–streptomycin containing DMSO or 10 mmol/L
Silmitasertib. Spheroid invasion was visualized at the indicated
time points by phase contrast microscopy using a Zeiss Axiovert
200M microscope equipped with an AxioCamMR CCD camera
using a Plan-Neofluar 5X/0.15 objective and Axiovision software
(Carl Zeiss Microscopy). Maximal radial distances for invaded
cells were calculated using Axiovision software, with invasive
distance determined as the difference between the initial and
final maximum radius for each invaded spheroid.
Orthotopic tongue tumors and invasion analysis
Tongue tumor establishment was adapted from previous
work (33). A total of 2.5  104 luciferase expressing UMSCC1
cells were injected into the tongues of 8- to 10-week-oldNSGmice
(purchased from the West Virginia University Transgenic Animal
Core Facility). Mice were maintained using transgenic dough diet
(S3472; Bioserve) and weighed every 2 to 3 days. Tumor growth
was monitored by bioluminescent imaging using 150 mg/kg
D-luciferin (122796; Caliper Life Sciences) injected intraperito-
neally, followed by in vivo whole-body bioluminescence imaging
using an IVIS Lumina-II system and Living Image 4.0 software
(PerkinElmer). Tumors were allowed to establish for 1 week, then
mice were divided equally into two groups based on approximate
tumor size. Mice were given 50 mg/kg Silmitasertib in DMSO or
DMSO alone by oval gavage twice daily for 3 weeks. Mice were
subsequently euthanized, tongues excised, processed, and stained
for histologic analysis.
To quantify invasion parameters, whole tongue histologic
images were cropped to encompass the tumor invasive front and
analyzed using ImageJ. Images were processed with the colour
deconvolution 1.5 plugin using H&E or H&E2 presets. Resultant
colour_1 images were 25% contrast enhanced before conversion
into binary images. ROIs were selected for particles above 15,000
pixel units andmanually verifiedbyoverlayonto theoriginalH&E
image to remove artifacts. Invasive protrusions were defined as
projections at the leading edgeof the tumor surroundedby stroma
on three sides and identified on the binary image using the
polygon selection tool. Invasive distance was determined as the
difference between the farthest edge of the protrusion and the
protrusion base.
Statistical analysis
Differences in mean values between groups were evaluated
using Student or Welch t test. Significance was determined at
P < 0.05 utilizing GraphPad Prism 7 software. Error bars
represent  SEM.
Results
Cortactin threonine 24 is required for Arp2/3 complex binding
and activation
Phosphorylation of serine (S) 11, T13, and T24 in the murine
cortactin NTA domain has been reported (19). The proximity of
these residues to the canonical Arp2/3 binding motif consisting
of amino acids 20–22 (DDW) have the potential to regulate
Arp2/3 binding (Fig. 1A). To determine if these residues influence
cortactin binding to Arp2/3, FLAG-tagged murine cortactin con-
structswere generated that contained serine to alanine (S11A) and
threonine to alanine (T24A) phosphorylation-null mutations.
T13 was not evaluated because it is not conserved in human
cortactin. Co-immunoprecipitation studies indicate that S11A
cortactin bound endogenous Arp2/3 at levels similar to WT
cortactin, whereas T24A cortactin failed to effectively bind
Arp2/3 despite retaining the DDW binding motif (Fig. 1B). Thre-
onine to aspartic acid (T24D) phosphomimetic cortactin bound
Arp2/3 at reduced levels compared with WT (Fig. 1B). These data
demonstrate that both the DDW motif and T24 are required for
optimal Arp2/3 complex binding. Furthermore, reduced Arp2/3
binding resultant from the addition of negative charge at amino
acid 24 (T24D) suggests that phosphorylation may play a nega-
tive-regulatory role.
To assess the impact of T24 on Arp2/3 actin nucleation,
recombinant human WT, DDDW, and T24A cortactin proteins
were expressed in bacteria and purified (Fig. 1C). When evaluated
in pyrene-labeled actin assembly assays, WT cortactin displayed
slower polymerization kinetics compared with the N-WASp
VCA domain, whereas the DDDW mutant failed to activate
Arp2/3 as previously reported (Fig. 1D; refs. 16, 34, 35). T24A
cortactin demonstrated intermediate activity, with reduced
nucleation levels compared with WT cortactin and increased
nucleation compared with DDDW (Fig. 1D). Taken together these
data identify T24 in the cortactin NTA as a critical residue required
for optimal cortactin-mediated Arp2/3 binding and activation
regardless of phosphorylation status.
Cortactin T24 is required for invadopodia-mediated ECM
degradation
Cortactin is essential for initiating invadopodia formation,
maturation, and ECM degradation in part due to NTA-mediated
Arp2/3 binding (36, 37). To determine the role of cortactin T24 in
invadopodia function, a panel of cortactin knockdown-rescue cell
lines stably expressing FLAG-cortactin mutant constructs were
produced in invasive UMSCC1 (Fig. 2) and OSC19 (Supplemen-
tary Fig. S1) HNSCC cell lines. Both lines spontaneously produce
invadopodia and degrade ECM (26, 38). Although individual
cortactin siRNA (siCTTN) and shRNA (shCTTN) treatment
resulted in decreased cortactin expression andmatrix degradation
in each case (Fig. 2D; Supplementary Figs. S1B and S2), sequential
exposure to cortactin siRNA in stable shRNA cells resulted in
efficient and reliable cortactin knockdown (KD; Fig. 2; Supple-
mentary Figs. S1 and S2). Cortactin KD cells were used for
subsequent experimentation to minimize the possibility of resid-
ual endogenous cortactin masking the effects of re-expressed
FLAG-cortactin mutants. FLAG-WT cortactin expression in KD
cells partially restored the amount of active invadopodia forma-
tion in UMSCC1 cells (Fig. 2A–C) and fully restored ECM deg-
radation inUMSCC1 (Fig. 2A and B) andOSC19 (Supplementary
Fig. S1A–S1C) cell lines. FLAG-DDDW enhanced invadopodia
precursor formation but failed to rescue active invadopodia and
ECM degradation (Fig. 2A–C; Supplementary Fig. S1A–S1C).
Similarly, both FLAG-T24A and FLAG-T24D cortactin restored
invadopodia precursor formation while failing to induce inva-
dopodia maturation above KD levels, with active invadopodia
and ECM degradation levels for both mutants similar to that of
FLAG-DDDW cortactin (Fig. 2A–C; Supplementary Fig. S1A, S1C,
and S1D). These results suggest that Arp2/3 binding and activa-
tion facilitated by cortactin T24 is required for effective cortactin-
mediated invadopodia formation and ECM degradation in
HNSCC cells.
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CK2 phosphorylation of cortactin T24 regulates interaction
with Arp2/3 complex
The importance of T24 in Arp2/3 activation and invadopodia
function, along with prior identification of T24 as a cortactin
phosphorylation site, led us to identify the kinase(s) responsible
for phosphorylating T24. Computational analysis of the
sequences flanking T24 was performed by seven independent
predictive algorithms, six of which suggested that CK2a had the
highest probability of phosphorylating cortactin T24 (Supple-
mentary Table S1). To test this, kinase assays were conducted
using GST-tagged cortactin WT and T24A NTA fusion proteins
with purified active CK2a. The N-WASp VCA domain was used as
a positive control, because previous studies have shown this
region to be a CK2a substrate (23, 25). Increasing amounts of
GST-WT-NTA were efficiently phosphorylated by CK2a, whereas
no phosphorylation was evident in GST-T24A-NTA (Fig. 3A).
These data indicate that cortactin T24 can serve as a CK2a
substrate, and that T24 is the only residue targeted by CK2a in
the NTA region.
To determine if CK2a phosphorylation of cortactin T24
effects binding to Arp2/3 complex, recombinant human WT
or T24A cortactin proteins were pre-incubated with or without
Figure 1.
Cortactin T24 is required for binding
and activation of Arp2/3 complex.
A, Diagram representing cortactin
functional domains. NTA, N-terminal
acidic domain; R1-R6, repeats
regions with F-actin binding site
indicated; Helix, alpha helical
domain, PRR, proline rich region;
SH3, Src homology 3 domain. NTA
domain with position of S11 and
T24 in context of the DDW region is
shown. B, Immunoprecipitation
analysis of Arp2/3 binding to
cortactin NTAmutants. HEK293T/17
cells transfected with FLAG-empty
vector (EV), FLAG-wild-type
cortactin (WT) or the indicated
FLAG-cortactin mutants. Immune
complexes wereWestern blotted
with antibodies against cortactin
(top) and Arp3 (bottom). 1:10 diluted
total cell lysates wereWestern
blotted as indicated. C, Coomassie
blue staining of the indicated purified
recombinant human cortactin
proteins.D, Effect of cortactin T24A
on Arp2/3 complex activation.
Fluorometric evaluation of actin
polymerization over time with the
indicated cortactin mutants
incubated with Arp2/3 complex and
pyrene-labeled actin. Polymerization
curves: WT cortactin (blue), T24A
cortactin (dark green), and DDDW
cortactin (purple). N-WASp VCA
domain (black) was used as a
positive control; negative controls
include Arp2/3 complex plus actin
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CK2a, then mixed with purified Arp2/3. Phosphorylation of
WT cortactin by CK2a reduced binding of Arp2/3 complex to
background levels (beads alone) whereas no impact on T24A
was observed (Fig. 3B). To ascertain the impact of CK2a
phosphorylation on cortactin-mediated Arp2/3 activation,
actin assembly assays were conducted with CK2a-phosphory-
lated cortactin and N-WASp VCA domain. As previously deter-
mined, CK2a phosphorylation of N-WASp VCA results in a
modest reduction of Arp2/3 NPF activity (black vs.
grey, Fig. 3C; ref. 25). Similarly, WT cortactin incubated with
increasing amounts of CK2a prior to inclusion in polymeriza-
tion assays resulted in a dose-dependent suppression of actin
assembly, suggesting that CK2a phosphorylation impairs the
ability of cortactin to activate Arp2/3 complex (Fig. 3C).
Although Arp2/3 can be activated by direct phosphorylation
from multiple kinases (39–41), CK2a had no direct effect on
Arp2/3 activation (orange vs. pale green, Fig. 3C), suggesting
that the inhibitory effect on Arp2/3 activity is due to phos-
phorylated cortactin in these assays. To determine if the CK2a-
targeted T24 residue is responsible for the observed inhibitory
effect on Arp2/3 activity, polymerization assays were conducted
with WT and T24A cortactin proteins following incubation with
CK2a. Although CK2a inhibited the ability of WT cortactin to
activate Arp2/3 complex (blue vs. red, Fig. 3D), preincubation
of CK2awith T24A cortactin exhibited no additional inhibitory
effect on Arp2/3 nucleation activity (green vs. purple, Fig. 3D).
Collectively these data indicate that cortactin phosphorylation
at T24 by CK2a reduces the ability of cortactin to bind and
activate Arp2/3 complex-mediated branched actin network
formation.
CK2a is required for optimal HNSCC invadopodia function
To determine if CK2a impacts invadopodia function, CK2a
expression was stably knocked down in OSC19 and UMSCC1
cells using anti-CK2a shRNAs targeting two different regions in
the CK2a transcript. Both shRNAs reduced CK2a expression to
nondetectable levels in each cell line (Fig. 4A). Neither line
expressed the alternative CK2a' isoform in control or CK2a
knockdown cells (data not shown). CK2a knockdown in OSC19
cells reduced the level of active invadopodia by 71% to 88% and
ECM degradation by 63% to 73%, whereas knockdown in
UMSCC1 cells reduced active invadopodia formation by 68% to
92%andECMdegradation by 36% to 60%(Fig. 4B–D). Although
these data indicate that CK2a is a key mediator of invadopodia
Figure 2.
T24 is required for cortactin-
mediated invadopodia formation
and ECM degradation in HNSCC
cells. A, UMSCC1 cells with stable
shRNA scramble control (Ctl) or
anti-cortactin shRNA combined
with siRNA knockdown (KD) were
transduced with murine FLAG-WT,
-DDDW, -T24A, and -T24D
cortactin lentiviruses. Cells were
plated on Oregon Green (OG)-488
gelatin coated coverslips for 12
hours, fixed, and labeled with anti-
FLAG and rhodamine phalloidin
(Actin). Gelatin panels are pseudo-
colored white; degradation is
evident as black areas indicating
loss of fluorescence. Scale bar
represents 20 mm. B,Quantification
of gelatin matrix degradation for
control (Ctl), cortactin KD, and
FLAG-cortactin expressing UMSCC1
cells. C,Quantification of
invadopodia precursors (left) and
active invadopodia (right) numbers
from the lines assayed in B. Data
represents the meanþ SEM of n
100 cells for each line analyzed
from at least three independent
experiments. All gelatin
degradation conditions were
normalized to Ctl UMSCC1 cells.
n.s., not significant; , P < 0.05,
Welch's or Student t test vs. Ctl
(B, C); †, P < 0.05, Student t test vs.
wild type cortactin rescue (WT; C).
D, Total cell lysates from (A)
evaluated for endogenous and
FLAG-cortactin expression by
immunoblotting with antibodies
against cortactin (top) and b-actin
(bottom).
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maturation and function, neither invadopodia formation nor
matrix degradation was entirely abolished. This would indicate
that alternative signaling pathways impinging on cortactin and
other invadopodia proteins remain active in the absence of CK2a
expression.
The CK2a inhibitor Silmitasertib suppresses invadopodia
function in HNSCC cells
Silmitasertib (CX-4945) is an orally bioavailable small mole-
cule ATP-competitive inhibitor that targets CK2a kinase activity
and is currently undergoing clinical trials in multiple cancer types
Figure 3.
CK2a phosphorylation of cortactin
T24 inhibits Arp2/3 complex
binding and activation. A, Cortactin
T24 is a CK2a phosphorylation site.
Autoradiogram of active CK2a
incubated with the increasing
amounts (0, 0.25, 0.5, and 1 mg) of
GST-WT-NTA or GST-T24A-NTA
cortactin fusion proteins. GST (1 mg)
and the GST-VCA domain of
N-WASp (0.25 mg) were used as
respective negative and positive
phosphorylation controls. Positions
of autophosphorylated CK2a,
GST-VCA, and cortactin NTA
proteins are indicated on the left;
autoradiogram is representative of
three independent experiments.
B, CK2a phosphorylation at
cortactin T24 ablates binding to
Arp2/3 complex. Purified
recombinant humanWT and T24A
cortactin proteins (2.5 mg) were
bound with an anti-cortactin
antibody to protein G beads.
Immune complexes were
preincubated with or without 75 ng
active CK2a, washed and incubated
with 50 ng purified Arp2/3
complex. Co-immunoprecipitated
complexes wereWestern blotted
for cortactin (top) and Arp3
(bottom). 4F11-bound protein G
beads were used as a negative
control for nonspecific binding
(Beads). Arp2/3 complex (5 ng)
was used as positive control for
Arp3 immunoblotting. Blot is
representative of two independent
experiments. C, Cortactin
phosphorylation by CK2a inhibits
cortactin-mediated Arp2/3 actin
polymerization. WT human
cortactin or GST-VCA proteins
were preincubated with the
indicated amounts of active CK2a
and evaluated for effects on Arp2/3
activity. Polymerization curves are
representative from three
independent experiments.
D, Phosphorylation of T24 is
responsible for the inhibitory effect
of CK2a on cortactin-mediated
Arp2/3 activation. HumanWT and
T24A cortactin proteins were
preincubated with or without 30 ng
active CK2a and evaluated for
effects on Arp2/3-mediated actin
assembly. Polymerization curves
are representative from three
independent experiments.
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Figure 4.
CK2a is required for optimal HNSCC invadopodia function. A, Evaluation of CK2a expression in stable scramble control (Ctl) and CK2a shRNA HNSCC cells. Cells
were lysed andWestern blotted with antibodies against CK2a (top) and b-actin (bottom). B, Representative confocal images of OSC19 and UMSCC1 cells with Ctl
shRNA and with each anti-CK2a shRNA (shCK2a #1 and #2). Cells were plated on OG-488 gelatin coverslips for 12 hours then labeled with an anti-cortactin
antibody and rhodamine phalloidin (Actin). Gelatin is pseudo-colored white. Scale bar represents 20 mm. C, CK2a knockdown decreases invadopodia-mediated
ECM degradation. Quantification of matrix degradation area per cell area for Ctl and each anti-CK2a shRNA in the indicated cell lines. Degradation data were
normalized to Ctl condition for each cell line. D, CK2a knockdown decreases invadopodia numbers. Amount of invadopodia precursors (left) and active
invadopodia (right) per cell is shown for control and shCK2aOSC19 and UMSCC1 cells. Data in C and D represent the meanþ S.E.M. of n 100 cells analyzed from
at least three independent experiments. n.s., not significant;  , P < 0.05, Welch t test vs. Ctl.
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(NCT01199718, NCT02128282, NCT00891280; ref. 20). To
determine the impact of Silmitasertib on HNSCC tumor cell-
mediated invadopodia formation and ECM degradation, estab-
lishedHNSCC cell lines were treated with increasing Silmitasertib
concentrations and evaluated for effects on invadopodia activity
and ECM degradation. Dose-dependent decreases in ECM degra-
dation were observed at concentrations above 0.5 mmol/L in all
evaluated HNSCC lines (Fig. 5A and B). The greatest impairment
of gelatin degradation was seen at 10 mmol/L (Fig. 5A and B),
comparable to effective CK2-specific growth-inhibitory doses in
several cancer cell lines (20, 42). At this concentration, active
invadopodia formation was significantly diminished in OSC19
and UMSCC1 cells, whereas MDA1586 cells displayed nonsig-
nificant decreases (Fig. 5C). To determine if the invadopodia
inhibitory effect of Silmitasertib was directly due to altering
CK2a-mediated cortactin T24 phosphorylation, antibodies
against phosphorylated cortactin T24 peptides (pT24) were
designed and purified. Attempts by two different commercial
vendors failed to generate a pT24-specific antibody (not shown).
Therefore, we evaluated the phosphorylation status of S473
(pS473) in AKT following Silmitasertib treatment as a surrogate
marker for drug efficacy, as this site is known tobephosphorylated
by CK2a (20). MDA1586 cells treated with 1 or 10 mmol/L
Silmitasertib had decreased pS473 AKT after 24 hours, the same
timeframe used in ECM degradation assays (Supplementary
Fig. S3). OSC19 and UMSCC1 cells had decreased pS473 AKT
after treatment with 10 mmol/L Silmitasertib for 12 hours, the
time used for matrix degradation assays in these lines (Supple-
mentary Fig. S3).
The fact that CK2a phosphorylates multiple targets aside from
cortactin (20) raises the possibility that the inhibitory effect of
Silmitasertib may be due to impairing phosphorylation of addi-
tional proteins involved in invadopodia function. To determine
the extent of cortactin-specific CK2a phosphorylation in invado-
podia-mediated ECM degradation, UMSCC1 cells expressing
FLAG-WT, FLAG-T24A, and FLAG-T24D cortactin were treated
with 1 mmol/L Silmitasertib and evaluated for additional sup-
pressive effects on matrix degradation (Fig. 5D and E). Silmita-
sertib diminished ECM degradation in cells expressing FLAG-WT
cortactin by 51%, similar to the reduction observed in nontrans-
fected cells (Fig. 5D vs. B). Neither FLAG-T24A nor FLAG-T24D
expressing cells treated with Silmitasertib demonstrated reduc-
tions in ECM degradation levels from baseline vehicle-treated
controls (Fig. 5D and E). Although these results do not entirely
negate alternative CK2-dependent signaling pathways in invado-
podia regulation, it does suggest that cortactin T24 is the primary
CK2a target in governing HNSCC invadopodia function.
To evaluate the anti-invadopodia effect of Silmitasertib inmore
translationally-relevant models, PDXs were derived from a well-
and a moderately-differentiated HNSCC surgical sample. PDX
tumors maintained original patient tumor architecture, display-
ing collective invasion and keratin pearls characteristic of differ-
entiated HNSCC (Fig. 6A). Primary cell lines derived from these
PDX tumors form invadopodia and spontaneously degrade gel-
atin within 24 hours (Fig. 6B). Both lines exhibit tight colony
morphology under cell culture conditions consistent with
HNSCC lines derived from epithelial HNSCC (Fig. 6B; refs. 32,
43). Treatment of WVUSCC-AR2 and WVUSCC-AR5 with Silmi-
tasertib yielded similar results to those observed in established
lines, with gelatin degradation impaired 38% to 62% in
WVUSCC-AR2 cells and 56% to 66% in WVUSCC-AR5 cells at
and above 0.5 mmol/L (Fig. 6C and D). Similarly, 10 mmol/L
Silmitasertib treatment suppressed active invadopodia by 76% in
WVUSCC-AR2 and 91% in WVUSCC-AR5 (Fig. 6E). Collectively
these data indicate that CK2a kinase activity is essential for
maximal ECM degradation ability in HNSCC.
Silmitasertib inhibits HNSCC invasion
To determine if Silmitasertib impacts HNSCC invasion, we
initially utilized a 3D in vitro assay designed to model collective
invasion typically observed in differentiated HNSCC. Tumor
spheroids generated from OSC19, UMSCC1, and WVUSCC-AR5
PDX lineswere embedded between layers of collagen I.WVUSCC-
AR2 cells failed to form spheroids and could not be used in this
assay. Spheroids were treated with 10 mmol/L Silmitasertib or
vehicle (DMSO) for 48 hours (Fig. 7A and B). Silmitasertib
significantly reduced 3D collective invasion in all assayed lines
(Fig. 7B). We next evaluated the ability of Silmitasertib to control
invasion in the tongues of mice harboring orthotopic tumors.
Luciferase-expressing UMSCC1 cells injected into the tongues of
NSGmice formeddetectable tumorswithin 1week (Fig. 7C).Mice
were divided into two groups containing similar tumor size as
determined by in vivo bioluminescence, with one group treated
with vehicle andonewith Silmitasertib.Mice dosed twice daily for
3 weeks displayed a nonsignificant reduction in tumor growth
comparedwith controls, similar to previous single agent xenograft
studies (Fig. 7C; ref. 20). To negate potential bias due to unequal
tumor size, four equivalent tumors from each groupwere selected
for further assessment. In-depth evaluation of tumor margins
from tongues excised after 4weeks revealed alterations in invasive
characteristics of Silmitasertib-treatedmice (Fig. 7D–I). Tumors in
drug-treated mice had a less ragged appearance at the invasive
front, exhibiting shorter and smaller collective cell protrusions
into the tongue stroma compared with control mice (Fig. 7D–G).
In addition, tongues from Silmitasertib-treatedmice had reduced
perineural invasion of nerves adjacent to the invasive front
(Fig. 7H and I). No difference was seen in the size or invasive
distance of detached collective groups within the invasive front
(Supplementary Fig. S4). Collectively these data support a role for
CK2a signaling in driving several pro-invasive behaviors associ-
ated with poor patient outcome in HNSCC (2, 44).
Discussion
Proteolysis of restrictive tissue barriers is essential to all steps in
the metastatic cascade and increasing evidence indicates that the
proteolytic activity of invadopodia is required for invasive breach-
ing of ECM barriers (1). Signals that govern invadopodia are
dynamic and highly regulated, requiring coordinated activity of
several oncogenic pathways in parallel to achieve maximal effi-
ciency (1). Active assembly and turnover of cellular F-actin net-
works is required for initiating invadopodia formation and sub-
sequent maturation, involving recruitment and activation of
membrane-bound and secreted MMPs to mediate ECM proteol-
ysis (1). Breakdown of existing F-actin networks, in conjunction
with Arp2/3 activation in invadopodia, is responsible for actin
network turnover necessary for productive branched F-actin for-
mation that drives membrane protrusion. Early recruitment of
cortactin is necessary for invadopodia initiation,where phosphor-
ylation of C-terminal tyrosines 421, 470, and 486, along with
serines 405 and 418, occurs downstream of growth factor and
integrin signaling (45). These phosphorylation events create
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Figure 5.
Silmitasertib-mediated CK2 inhibition reduces invadopodia function in established HNSCC cell lines. A, Representative confocal images of MDA1586, OSC19,
and UMSCC1 cells plated on OG-488 gelatin coverslips for 1 hour before treatment with vehicle (DMSO) or 10 mmol/L Silmitasertib for 24 hours (MDA1586)
or 12 hours (OSC19 & UMSCC1; optimal ECM degradation times for each line). Cells were fixed and labeled with an anti-cortactin antibody and rhodamine
phalloidin (Actin). Gelatin is pseudo-colored white. Scale bar represents 20 mm. B, CK2a inhibition decreases invadopodia-mediated ECM degradation.
Quantification of gelatin matrix degradation area per cell area in HNSCC cell lines treated with the indicated Silmitasertib concentrations. C, CK2a inhibition
decreases invadopodia numbers. Amount of invadopodia precursors (left) and active invadopodia (right) per cell is shown for Silmitasertib-treated HNSCC
cell lines. Degradation data were normalized to DMSO-treated (0) cells for each cell line. Data in B and C represent the mean þ SEM of n  100 cells
analyzed from at least three independent experiments. n.s., not significant;  , P < 0.05, Welch or Student t test vs. DMSO for each cell line. D, Quantitation of
gelatin matrix degradation area per cell area for UMSCC1 cells expressing FLAG-WT, -T24A, or -T24D cortactin treated with DMSO or 1 mmol/L Silmitasertib.
Data represent the mean þ SEM of n  75 cells analyzed from at least three independent experiments. n.s., not significant;  , P < 0.05, Welch or Student t
test vs. DMSO for each condition. E, Representative confocal images of UMSCC1 cells expressing FLAG-WT, -T24A, or -T24D cortactin plated on OG-488
gelatin coverslips for 1 hour before treatment with vehicle (DMSO) or 1 mmol/L Silmitasertib for 12 hours. Cells were fixed and labeled with an anti-FLAG
antibody and rhodamine phalloidin (Actin). Gelatin is pseudo-colored white. Scale bar represents 20 mm.
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binding sites for scaffolding platforms that recruit N-WASp and
WAVE2, ensuring that activation of Arp2/3 is maintained
throughout the invadopodia cycle (6). Cortactin also recruits the
F-actin severing protein cofilin to invadopodia, providing
the necessary machinery for cyclic actin network breakdown
and regrowth during invadopod extension (16). In addition to
these important C-terminal functions, the ability of the NTA
region to directly bind Arp2/3 is also essential for invadopodia
formation and ECM degradation, presumably through direct
Arp2/3 activation and prolonged stabilization of Arp2/3-F-actin
networks (10, 16).
Regarding the ability of the cortactin NTA to bind Arp2/3,
this study reveals two distinct findings. First, that T24 is required
for Arp2/3 binding, because mutation of this residue ablates (A)
Figure 6.
Silmitasertib inhibits invadopodia function in HNSCC PDX cells. A, Establishment of HNSCC PDX tumors. Hematoxylin and eosin stained patient tumor tissue and
PDXs. Patient tumors were from the alveolar ridge (AR). Scale bar represents 200 mm. B, Invadopodia formation in HNSCC PDX cells. Representative confocal
images ofWVUSCC-AR2 (AR2) andWVUSCC-AR5 (AR5) PDX cell lines. Cells were plated on OG-488 gelatin coverslips for 24 hours and labeled with an anti-
cortactin antibody and rhodamine phalloidin (Actin). Gelatin is pseudo-colored white. Scale bar represents 20 mm. 10 representative phase contrast images
(Phase) of each line are shown on the right. Scale bar represents 100 mm. C, Confocal images ofWVUSCC-AR2 andWVUSCC-AR5 cells plated on OG-488 gelatin
coverslips, allowed to attach for 1 hour, then treated with vehicle (DMSO) or 10 mmol/L Silmitasertib for 24 hours. Cells were labeled with an anti-cortactin
antibody and rhodamine phalloidin (Actin). Gelatin is pseudo-colored white. Scale bar represents 20 mm. D, CK2a inhibition decreases invadopodia-mediated
ECM degradation in PDX-derived cell lines. Quantification of matrix degradation area per cell area for WVUSCC-AR2 andWVUSCC-AR5 PDX cell lines treated
with the indicated Silmitasertib concentrations. Degradation data were normalized to DMSO-treated cells for each cell line. E, CK2a inhibition decreases
invadopodia numbers in PDX-derived cell lines. Determination of amount of invadopodia precursors (left) and active invadopodia (right) in WVUSCC-AR2 and
WVUSCC-AR5 cells. Data represent the meanþ SEM. of n 100 cells analyzed from at least three independent experiments.  , P < 0.05, Welch t test vs. DMSO
for each cell line.
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or reduces (D) the association of cortactin with Arp2/3 in co-
immunoprecipitation assays. T24 is two residues C-terminal to
the well-defined DDWArp2/3 interaction motif that is conserved
in other Arp2/3 NPFs (6). This places T24 in close proximity to
contribute to Arp2/3 binding. Although the crystal structure of the
cortactin NTA bound to Arp2/3 complex has not been reported,
previous chemical crosslinking and three-dimensional recon-
struction studies indicate that the NTA region primarily binds
the Arp3 subunit in the complex, with the most N-terminal
residues spanning the Arp2–Arp3 interface to contact the Arp2
subunit (Visual Overview; refs. 9, 34). Thus, T24 may contribute
essential hydrogen bonding with recipient polar residues near the
basic side chains on Arp3 involved in electrostatic binding to the
acidic NTA residues. This concept is supported by the requirement
ofW22 in the DDWmotif for Arp2/3 binding, along with the lack
of an equivalent threonine in the VCA region of WASp pro-
teins (16, 34, 35). Although T24A cortactin appears incapable
of binding Arp2/3, it can activate Arp2/3 actin nucleation in
conditions where DDDW cortactin remains inactive (Fig. 1D).
This may be due to T24 having a lower affinity for Arp3 than the
DDW region and/or the high cortactin molar levels required to
stimulate NPF activity in vitro. Nonetheless, the requirement
for cortactin T24 in invadopodia-mediated ECM degradation
supports an essential biological role for this residue in a non-
phosphorylated context.
Second, our study shows that T24 phosphorylation serves to
negatively regulate cortactin binding to and activation of Arp2/3
complex (Fig. 3B–D). Addition of the phosphate group to T24
likely imparts a steric and electrostatic disruption, preventing the
DDW and other interacting residues in the NTA from initiating
and/or maintaining binding to Arp3. Steric interference may be
the predominant mechanism, since T24D cortactin can bind
Arp2/3 at reduced levels (Fig. 1B), indicating that negative charge
alone is insufficient to completely prevent Arp2/3 association.
Phosphorylation of T24 therefore serves to block the ability of
cortactin to bindArp2/3, similar to the regulation of the Arp2/3-F-
actin regulatory proteins coronin 1B and cofilin (46, 47).
Although we did not determine if phosphorylation of T24 serves
to release cortactin from existing Arp2/3-F-actin branchpoints,
phosphorylation of Arp2/3-bound cortactin T24 may be an
additional mechanism to dissociate cortactin from these regions.
Such a mechanism could function in facilitating breakdown and
recycling of invadopodia Arp2/3-F-actin networks.
The ability of CK2a to phosphorylate cortactin T24 supports a
wider role for this kinase in actin regulation. Previous work
identified T24 as a putative but unconfirmed CK2a phosphory-
lation site in the NTA region of myeloid-cell specific cortactin
homolog HS1 (21). In addition, CK2a phosphorylates two adja-
cent sites in theAdomainofWASp family proteins (22–25). These
studies report conflicting results on Arp2/3 activity, with phos-
phorylation of WASp enhancing and in N-WASp and WAVE2
inhibiting VCA-stimulated Arp2/3-mediated actin polymeriza-
tion. Our results with CK2a-phosphorylated N-WASp VCA
domain also shows an inhibitory effect on Arp2/3 activation
(Fig. 3C), suggesting that CK2a effects may be differential to
specific WASp family proteins.
Cortactin T24A and T24D expression in KD HNSCC lines
impairs active invadopodia formation and subsequent ECM
degradation (Fig. 2A–C; Supplementary Fig. S1A and S1C), sup-
porting in vitro evidence that T24 phosphorylation prevents
Arp2/3 binding and activation necessary for invadopodia activity.
The importance of CK2a-mediated cortactin T24 phosphoryla-
tion is further supported by the inability of Silmitasertib to further
suppress ECM degradation in cortactin T24A or T24D expressing
cells (Fig. 5D andE). CK2a-specific knockdownor pharmacologic
inhibition in cells would therefore be expected to reduce phos-
phorylation of cortactin and WASp family proteins, resulting in
net increased Arp2/3 activity as observed from in vitro studies. The
fact that CK2a knockdown or kinase blockade also impairs
invadopodia formation and function is paradoxical, but can be
explained by cyclic CK2a phosphorylation and dephosphoryla-
tion to regulate cortactin binding to and activation of Arp2/3 in
invadopodia during maturation and elongation. Dephosphory-
lation of cortactin T24 and WASp NPFs by unknown phospha-
tases would enable these NPFs to promote Arp2/3 activation,
actin polymerization, and invadopodia activity. Following net-
work breakdown during actin turnover, CK2a phosphorylation
would return NPFs to the inactive state to await the next cycle of
actin assembly. Although similar cyclic regulation of Src and
cofilin has been shown to be essential for invadopodia function
Figure 7.
Silmitasertib impairs collective invasion in HNSCC. A, Representative phase contrast microscopy images of OSC19, UMSCC1, andWVUSCC-AR5 tumor cell
spheroids embedded in collagen I (0 hour) then incubated in complete media containing 10 mmol/L Silmitasertib or vehicle (DMSO) for 48 hours. Red circles
indicate the maximum radial distance at indicated time points. Scale bar represents 100 mm. B,Quantitation of maximal collective invasive distance of each cell
line at 48 hours with vehicle (0) or Silmitasertib (10 mmol/L). Data represent the meanþ SEM of n 10 spheroids per cell line and condition analyzed from at least
three independent experiments.  , P < 0.05, Welch or Student t test vs. DMSO. C, Effect of Silmitasertib on HNSCC orthotopic tumor growth. Bioluminescent
monitoring of UMSCC1 cells orthotopically injected into tongues of NSGmice. Tumors were allowed to establish for 1 week prior to administration of Silmitasertib
or equal volume vehicle (DMSO). Data represent mean SEM from two independent experiments. DMSO, n¼ 9mice; Silmitasertib, n¼ 7 mice. n.s., not
significant; Student t test vs. DMSO. D, Silmitasertib inhibits orthotopic HNSCC invasion. Representative hematoxylin and eosin stained invasive front of
orthotopic UMSCC1 tongue tumors frommice receiving Silmitasertib or vehicle (DMSO) for 3 weeks. Black lines show tumor-encompassing RIO borders
determined by software analysis. Black box in DMSO tumor indicates the invasive protrusion shown in F. White box in DMSO tumor denotes region containing
perineural invasion (PNI) shown in I. Black arrow indicates direction of invasion toward tongue base. M, skeletal muscle; T, tumor. Scale bar represents 100 mm.
E, Invasive distance of tumor protrusions frommice treated with Silmitasertib or vehicle (DMSO). Data represent the meanþ SEM of two serial sections from
N¼ 4 tumors; n¼ 34 protrusions per condition.  , P < 0.05, Student t test vs. DMSO. F, Representative image of an invasive protrusion from vehicle-treated mice
shown in the black box inD. The protrusive region was traced in black to denote the tumor protrusion from surrounding muscle-containing stroma. M, skeletal
muscle; T, tumor protrusion. Scale bar represents 100 mm. G, Area of invasive protrusions frommice treated with Silmitasertib or vehicle (DMSO). Data represent
the meanþ SEM of two serial sections from N¼ 4 tumors; n¼ 34 protrusions per condition.  , P < 0.05, Welch t test vs. DMSO. H, Percentage of lingual nerves
displaying PNI in tumors frommice treated with Silmitasertib or vehicle (DMSO). Data represent the meanþ SEM of two serial sections from N¼ 4 tumors; n
60 nerves per condition.  , P < 0.05, Student t test vs. DMSO. I, Representative image of PNI shown in the white box in the DMSO-treated mouse in D. N, nerve;
T, tumor cells. Scale bar represents 50 mm.
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andprovides support for thismodel (38, 46), confirmation of T24
phosphorylation within invadopodia leading to altered actin
dynamics along with identification of the T24 phosphatase are
necessary to fully confirm this proposed mechanism.
Locoregional control of HNSCC dissemination is problematic,
where perineural invasion and invasive metastatic spread to
cervical lymph nodes accelerates patient decline (44, 48, 49).
Cortactin and CK2a expression are elevated in HNSCC and
individually correspond with poorer patient outcomes (7, 20).
CK2 knockdown and Silmitasertib treatment in HNSCC cells has
antiproliferative and antimetastatic properties in vitro and inmice,
providing support for the utility of Silmitasertib in HNSCC (20).
The anti-invasive effect of Silmitasertib shown here is likely due in
part to disruption of the invadopodia actin assembly through
combined inhibition of multiple Arp2/3 NPFs. We note that T24
cortactinmutants, CK2a knockdown, and Silmitasertib treatment
in HNSCC cells do not completely abolish invadopodia forma-
tion, degradation activity or invasion. Activation of invadopodial
Arp2/3 NPFs through alternative scaffolding or lipid-based sig-
naling pathways that can bypass CK2 inhibition can account for
this residual activity (1). However, our results indicate that CK2a
inhibition by a single agent does significantly impair collective
HNSCC invasion. Given the current paucity of treatment options
for invasive HNSCC, combining Silmitasertib with additional
drugs known to impair invadopodia function by blocking addi-
tional invadopodia and motility pathways (8) has the potential
to provide novel treatment options for controlling invasive
spread of late-stage HNSCC harboring elevated cortactin and/or
CK2 expression.
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When the Smoke Clears m6A from a Y Chromosome–
Linked lncRNA, Men Get an Increased Risk of Cancer
A. Rouf Banday1, Brenen W. Papenberg2, and Ludmila Prokunina-Olsson1
Long noncoding RNAs (lncRNA) have been implicated in
many diseases, including cancer. Although these disease-
associated effects have been mostly attributed to the ability of
lncRNAs to function as regulatory noncoding transcripts, there is
growing evidence that lncRNAs may also encode functional
micropeptides. In the current issue of Cancer Research, Wu and
colleagues report a micropeptide encoded by a Y chromosome–
linked lncRNA that may explain the higher incidence of esoph-
ageal cancer in male smokers. Furthermore, this report provides
broader insights related to the molecular epidemiology of male-
dominant and smoking-driven cancers and may also help explain
some cancer-related associations with mosaic Y chromosome
loss.
See related article by Wu et al., p. 2790
Long noncoding RNAs (lncRNA) are generally defined as long
(>200 nucleotides) transcripts that do not encode proteins. LncRNAs
include some well-known regulatory transcripts that affect cancer
initiation and progression, such as MALAT1 (metastasis-associated
lung adenocarcinoma transcript 1), HOTAIR (HOX transcript anti-
sense intergenic RNA), UCA1 (urothelial carcinoma associated 1),
BCYRN1 (brain cytoplasmic RNA 1), and HULC (highly upregulated
in liver cancer; ref. 1). Despite the “noncoding” designation, multiple
short open reading frames (ORF) for putative micropeptides can
usually be predicted within lncRNAs. An annotation of a 53-amino
acid peptide, HOX-AS3, which inhibits tumorigenesis in the colon by
metabolic reprogramming, provides one of a few examples demon-
strating functional properties of micropeptides rather than their
encoding lncRNAs (2). However, due to limited understanding of
their functions and lack of high-throughput methods for their anno-
tation, these putative lncRNA-encoded micropeptides are mostly
overlooked.
In the current issue of Cancer Research, Wu and colleagues (3)
present their discovery of a 21-amino acidmicropeptide (designated as
YY1BM) encoded by a Y chromosome-linked lncRNA, LINC00278.
They demonstrated the role of YY1BM in tumorigenesis and cancer
survival through its interaction with smoking exposure in male
esophageal squamous cell carcinoma (ESCC). ESCC is one of the
deadliest cancers in the world, with average 5-year survival rates
remaining under 20%. Tobacco smoking is considered a major envi-
ronmental risk factor for ESCC. Men are four times more likely to
develop ESCC than women, which might be partially explained by the
differences in smoking rates reported as 52.9% and 2.4% in Chinese
men and women, respectively (4), with comparable ratios in other
populations as well. Male-specific factors, both hormonal and genetic,
such as those encoded by the Y chromosome, might be contributing to
this complex disease, in interaction with environmental exposures.
This combination of risk factors is not specific to ESCC andmight also
be relevant to othermale-dominant and smoking-driven cancers, such
as of the head and neck, bladder, lung, and colon. However, molecular
mechanisms that can explain this gender bias in several common
cancers, especially in smokers, remain largely unclear. In their study,
Wu and colleagues hypothesized that some of these answers might be
literally encoded within the Y chromosome and chose to focus on
lncRNAs.
The authors found that the expression of three Y chromosome-
encoded lncRNAswas downregulated in esophageal tumors compared
to adjacent normal tissues; of those, only downregulation of
LINC00278 was validated in an additional set of samples. Next, they
experimentally demonstrated that one of the four ORFs predicted
within this lncRNAencoded a 21-amino acid (2.12 kDa)micropeptide.
Through rigorous in vitro and in vivo work, they demonstrated how
downregulation of LINC00278, and therefore the reduced production
of the corresponding micropeptide, could lead to ESCC in male
smokers. Specifically, they showed that the micropeptide could bind
the YY1 transcription factor, thereby blocking its interaction with the
androgen receptor (AR). On the basis of these findings, the micro-
peptide was designated as the YY1-binding micropeptide (YY1BM).
Low YY1BM expression resulted in reduced apoptosis in ESCC
xenografts and tissues by decreasing the AR-regulated eEF2K expres-
sion, which controls protein synthesis. This effect was particularly
noticeable under cellular stress conditions of severe nutrient depri-
vation, which might mimic the microenvironment of rapidly growing
tumor cells. Thus, YY1BM might be inhibiting tumorigenesis by
mediating cross-talk between pathways involving AR signaling, pro-
tein synthesis, and cell metabolism. These findings could also justify
using AR-targeted therapies for men with ESCC and other cancers to
be identified affected by decreased YY1BM expression.
Smoking is the major environmental risk factor for many cancer
types, but themolecularmechanisms of smoking exposure are still only
partially understood. It is also unclear whether smoking has different
cancer-related effects in men and women, and if so, why? Wu and
colleagues provide the most unexpected answer to this question.
Dynamic regulation of transcriptional outcomes through the N6-
methyladenosine (m6A) posttranscriptional RNA modification
emerged as a mechanism of cellular adaptation to physiological and
environmental conditions (5). This process is regulated by a combi-
nation of proteins with specific functions to add/write (methyltrans-
ferases), erase (demethylases), or read m6A on various transcripts. By
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exposing cells to cigarette smoke condensate, the authors identified a
complex of METTL3/14 andWATP as a writer, ALKBH5 as an eraser
and YTHDF1 as a reader, all affecting translation of LINC00278 into
YY1BM.Of these proteins critical form6A function, only expression of
ALKBH5 (an eraser) was increased by smoking exposure, through its
promoter hypomethylation. Thus, it appears that smoking exposure
facilitates m6A clearance from LINC00278 by activating the expression
of ALKBH5 (m6A eraser), resulting in decreased production of
YY1BM, thereby contributing to tumorigenesis. Because YY1BM can
be produced only in men, women with equal smoking exposure would
not have the same cancer-related molecular consequences of smoking.
The authors also linked the reduced expression of LINC00278 with
decreased survival of men with ESCC, particularly in smokers. It was
assumed that this association is related to the decreased production of
YY1BM, given its antitumorigenic properties. However, thismight not
be entirely attributable to the expression or the functional effects of this
lncRNA, considering several competing or overlapping mechanisms.
First of all, LINC00278 is adjacent to the ZFY gene, which is one of the
genes affected by the extreme downregulation of chromosome Y gene
expression (EDY), a phenomenon associated with age and smoking in
men (6). Because ZFY was affected by EDY in multiple nontumor as
well as tumor tissues, mRNA expression of LINC00278 (not tested by
that study) might also be affected by EDY in general and not
specifically in ESCC. Focusing on lncRNAs, Wu and colleagues did
not analyze any mRNA expression, including that of ZFY. Thus, it is
difficult to disentangle whether LINC00278 expression is the sole
reason for the reported association with decreased survival, given that
other genes in this region may be equally downregulated.
Downregulation of LINC00278 might also be a molecular mani-
festation of the age- and smoking-dependent mosaic loss of Y chro-
mosome (mLOY), which affects a fraction of somatic cells already in
normal tissues and is further enhanced in tumors (7, 8). Although both
mLOY and EDY could serve as informative biomarkers, molecular
mechanisms underlying cancer-related consequences of these events
are still unclear. Downregulation of ZFY has been suggested to have
some cancer-related functional significance, but with limited exper-
imental evidence. On the basis of the results presented by Wu and
colleagues, downregulation or loss of LINC00278 expression might
offer at least a partial explanation of why mLOY and EDY are likely to
be associated with cancer, especially in smokers. First, both these
mechanisms would result in a decrease of LINC00278 expression, and
thus, of YY1BM. Second, smoking-mediated clearance of m6A from
LINC00278would further prevent the translation of this micropeptide
from LINC00278, whichmight already be decreased throughmLOYor
EDY. In other words, by affecting m6A-dependent translation of
YY1BM, smoking would likely increase cancer risk even without
mLOY. However, the risk might be stronger in smokers with mLOY,
due to downregulation of YY1BM by two different mechanisms.
Wu and colleagues also demonstrated that intratumoral treatment
with recombinant YY1BM significantly reduced tumor growth and
improved the ESCC survival inmale xenograftmousemodels. A recent
study showed that another lncRNA-encoded micropeptide inhibited
triple-negative breast cancer progression (9).Micropeptides are attrac-
tive as therapeutic agents due to their high specificity, potency, and low
toxicity. Insulin is a well-studied example of a natural 51-amino acid
minipeptide encoding an essential hormone, which is used as themain
drug to treat type I diabetes. On the basis of cell membrane penetration
and solubility, mini- and micropeptides might be more optimal than
large proteins encoded by the bona fide protein-coding genes. Numer-
ous micropeptides encoded by noncoding RNAs, including lncRNAs,
might offer treasure troves of natural small-molecule–type peptides of
possible biological significance. A recent genome-wide functional
study has given a broad look at the translation of ORFs outside of
canonical coding sequences (10). Among those, about 100 lncRNA-
encoded micropeptides were found to regulate cell growth, highlight-
ing their potential importance in cancer and other diseases. While
these studies need extensive validation, we might expect some new
cancer drugs to be found among naturally existing lncRNA-encoded
micropeptides.
Of multiple findings from this study of significance across several
fields, we will reiterate several main points: micropeptides encoded
by short lncRNA-encoded ORFs might have major cancer-related
functions; these functions may be modified by environmental risk
factors such as smoking and contribute to gender bias; micropep-
tides could be the source of naturally existing small molecules and
potential anticancer therapeutic agents. The molecular mechanism
presented by Wu and colleagues offers a plausible explanation for
the higher risk of ESCC in men than women, and smoking men,
specifically. This study should inspire follow-up analyses in other
smoking-driven cancers affecting both sexes, but with a dispropor-
tional male:female ratio.
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